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Abstract 
 
 
The diagnosis of BAD is often missed or misdiagnosed for IBS-D as these 
conditions present similarly with chronic diarrhoea. The principal hindrance 
to diagnosis of BAD is limited access to the diagnostic SeHCAT scan. 
Mechanisms of aetiology underlying BAD have not been fully elucidated and 
to date, an alternative biomarker for BAD that is more accessible and 
patient preferable, has yet to make its way into clinical practice.  
 
One of the greatest scientific challenges this decade has been 
understanding the relationship between the gut microbiome, its functionality 
and role in human health. BAs are metabolised by the gut microbiota, 
therefore their role as signalling molecules in regulating intestinal 
homeostasis is influenced primarily by the gut commensals. 
 
This thesis is the first study to profile the gut microbiome in BAD and 
investigate the mechanisms of how bacterial metabolic products may 
influence the development of disease. This was achieved by conducting 
16S ribosomal RNA gene analysis, the most important target of study in 
bacterial ecology. Bacterial metabolites (SCFAs and VOCs) and BAs were 
measured using gas and liquid chromatography, mass and ion mobility 
spectrometry.  
 
The results indicate intestinal dysbiosis with reduced bacterial diversity in 
patients with BAD. A statistically significantly greater total concentration of 
SCFAs with increases in the concentrations of acetate and propionate were 
observed in BAD compared to IBS-D. A statistically significant increase in 
the concentrations of faecal primary BAs and serum CDCA was observed in 
BAD compared to IBS-D. Separation of VOC profiles was evident between 
the BAD, IBS-D and HC groups but greatest discrimination was between the 
IBS-D and HC cohorts. 
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In conclusion, intestinal dysbiosis with altered fermentation and resultant BA 
dysmetabolism were observed. The metabolic output of the microbiota 
rather than abundance of specific bacterial taxa appears to be more 
important in the aetiology of BAD.!
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1. Introduction 
 
Diarrhoea is defined as the abnormal passage of loose or liquid stools more 
than three times daily and/or a daily stool weight more than 200g/day. It is 
considered chronic if symptoms have persisted for greater than 4 weeks(1). 
Chronic diarrhoea is prevalent in 4-5% of the Western population and is a 
common problem encountered in primary care accounting for nearly 1 in 20 
referrals to gastroenterology in secondary care(2, 3).  
 
Diarrhoea-predominant irritable bowel syndrome (IBS-D) is a common 
cause of chronic diarrhoea. Bile acid diarrhoea (BAD) has found to affect a 
third of patients previously diagnosed with IBS-D and is often overlooked in 
the differential diagnosis of chronic diarrhoea(2). This is of great clinical 
significance given that IBS patients form the largest group of patients seen 
in a general gastroenterology clinic(4). The diagnostic algorithm for 
investigating chronic diarrhoea outlined by the British Society of 
Gastroenterology in 2003 places the consideration of investigating BAD at 
the bottom of the pathway, once all other organic causes of diarrhoea have 
been excluded(5). This highlights how BAD is often regarded as a rare 
phenomenon, even among specialists, with frequently missed opportunities 
for diagnosis, giving rise to a large undiagnosed population. Consequently, 
the boundaries between IBS-D and BAD become blurred with little 
separation of these two distinct disease entities.   
 
 
1.1 Bile Acid Diarrhoea (BAD) 
 
1.1.1 What is BAD? 
BAD is a common cause of chronic diarrhoea and occurs as sequelae of a 
defect in the enterohepatic circulation of bile acids (BAs), which is discussed 
in section 1.1.2.  
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Three types of BAD are classically recognised and categorized according to 
their underlying aetiology. In 1967, Alan Hofmann first described the 
syndrome ‘Cholerheic Enteropathy’, in patients who had undergone an 
ileocaecal resection and suffered with diarrhoea due to excessive BAs in the 
colon(6). Descriptions in the late 1960s and early 70s of patients who 
experienced diarrhoea with ileal disease of less than 100cms in length and 
responded to treatment with Cholestyramine, a bile acid binder, further 
supported this occurrence. Patients with ileal disease in excess of 100cms, 
experienced greater steatorrhea, secondary to BA deficiency with impaired 
micelle formation and fat digestion(7, 8). This is now known as Type 1 BAD, 
which is secondary to ileal disease or resection and is typically a result of 
Crohn’s disease or radiation ileitis. In one study, the prevalence of BAD in 
patients who had undergone ileal resection for Crohn’s disease and were in 
clinical remission was 97%. 54% of patients with unoperated Crohn’s 
disease in clinical remission were also found to have BAD(2).    
 
Type 2 (primary or idiopathic) is the most common cause of BAD and is 
demonstrated in the absence of intestinal disease as well as being 
associated with a histologically normal ileum(9). More recently, a new 
mechanism for type 2 has been proposed where malabsorption of BAs does 
not occur in these patients. The discovery of Fibroblast Growth Factor-19 
(FGF-19), an ileal bile acid-farnesoid X receptor (FXR) dependent hormone, 
in suppressing BA biosynthesis, generated further interest in its role in 
BAD(10). This resulted in the discovery of reduced levels of FGF-19 in 
patients with BAD(11). Consequently, in patients with reduced levels of 
FGF-19, hepatocytes are unable to downregulate BA synthesis, resulting in 
a large BA pool with incomplete BA reabsorption and increased delivery of 
BAs to the colon, triggering diarrhoea. Other potential mechanisms involved 
in the development of primary BAD are genetic variants in the Klotho β 
(KLB) and Fibroblast growth factor receptor 4 (FGFR4) genes as well as 
upregulation of the membrane bound BA receptor, G protein-coupled BA 
receptor 1 (GPBAR1)(12). The KLB and FGFR4 genes are involved in 
feedback regulation of BA synthesis and have been associated with faecal 
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BA excretion and colonic transit in patients with IBS-D(13). Genetic variation 
in GPBAR1 has also demonstrated quantitative changes in colonic transit 
and BA secretion(14). 
 
Type 3 BAD comprises of causes which are not included with types 1 and 2 
that may interfere with normal recycling of BAs, small bowel motility, 
reduced storage capacity and saturation of uptake mechanisms. Causes 
include post cholecystectomy, small bowel bacterial overgrowth, diabetes 
mellitus, pancreatitis and coeliac disease(15). 
 
A study of 373 patients diagnosed with BAD demonstrated a significantly 
greater proportion of patients who had undergone a cholecystectomy 
(27.4% with BAD vs 13.3% without BAD), terminal ileal resection or right 
hemicolectomy for Crohn’s disease (18.4% vs 1.6%), or terminal ileal 
resection or right hemicolectomy for other reasons (7.4% vs 1.6%). In those 
with severe BAD, there were significantly more patients who had a previous 
right hemicolectomy or terminal ileal resection for Crohn’s disease or for 
other reasons. Types 2 and 3 BAD were found to predominate in patients 
with mild BAD, whilst type 2 was more prevalent in moderate BAD and type 
1 in severe BAD(16). 
 
1.1.2 Bile Acids and Pathophysiology of BAD 
BAs constitute 50% of the organic components of bile and are saturated, 
hydroxylated C24 cyclopentanophenanthrene sterols(17, 18). They are 
water-soluble detergent molecules, which facilitate dietary lipid absorption in 
the small intestine through solubilizing fatty acids and monoglycerides, the 
lipolysis products of triglycerides, and transport them as mixed micelles. In 
the micelles, the polar BAs can present the hydrophobic fat molecules to the 
brush border membrane of the intestine, where they diffuse down their 
concentration gradients into the intestinal epithelial cells, to enable digestion 
and absorption(19). The majority of fat absorption takes place in the 
proximal 100cms of the jejunum(20). The BAs then remain in the intestinal 
lumen until they are absorbed in the terminal ileum. 
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Enterohepatic Circulation of Bile Acids 
The liver synthesizes the two primary BAs: cholic acid (CA) and 
chenodeoxycholic acid (CDCA). In liver peroxisomes, BAs are further 
metabolized by conjugation (N-acyl amidation) to glycine or taurine to 
produce the amphipathic structure that encompasses both hydrophobic 
(lipid-soluble) and polar (hydrophilic) regions. The amino acid conjugate is 
polar and hydrophilic while the cholesterol portion of the BA is 
hydrophobic(21). This conjugation step allows for BAs to remain ionised 
within the duodenum as ionization renders BAs impermeable to cell 
membranes through increasing their solubility. This property permits 
spontaneous formation of micelles by allowing a high concentration of BAs 
to reach the critical micellar concentration(19).  
The BAs are then actively secreted across the canalicular membrane into 
bile and carried to the gallbladder where they are stored(22). Ingestion of a 
meal results in the secretion of secretin and cholecystokinin (CCK) by 
chyme. To increase the volume of bile, biliary duct cells are stimulated by 
secretin to secrete bicarbonate and water. CCK stimulates gallbladder 
contraction resulting in bile flowing into the duodenum(17).  
The primary BAs activate the farnesoid X receptor (FXR) in the liver, 
stimulating expression of small heterodimer partner (SHP) to inhibit the 
action of the homolog-1 liver receptor, which controls the upregulation of 
Cytochrome P450 family 7 subfamily a member 1 (CYP7A1) - the rate-
limiting BA synthesis enzyme(23, 24). Through intestinal FXR activity, BA 
synthesis is also inhibited via stimulation of the expression of FGF19. To 
impede BA synthesis, FGF19 binds hepatic fibrobast growth factor-4 (FGF4) 
and activates c-Jun N-terminal kinase 1/2 (JNK1/2) and extracellular signal-
regulated kinase 1/2 (ERK1/2)(25). BAs are actively reabsorbed from the 
ileum and circulated back to the liver via the hepatic portal vein and this 
process is known as the enterohepatic circulation. This ensures recycling of 
the majority of synthesized BAs to maintain a functional BA pool. In adults, 
the BA pool is 2-3 grams in size. With each meal, this pool cycles several 
times, resulting in the BA secretion of 4-6 grams per meal or 12-18 grams 
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per day. 0.3 grams of BAs are synthesized each day therefore digestion of 
lipids occurs predominantly through the use of recycled BAs(26). 
Only 1-2% of BAs escape the enterohepatic circulation and undergo 
biotransformation by the gut microbiota in the large bowel to form the 
secondary BAs, deoxycholic acid (DCA), and lithocholic acid (LCA)(22). 
These are then excreted in the faeces (0.3-0.5 grams per day)(27). 
Transformations by the intestinal microbiota include deconjugation (removal 
of the amino acid side chain), epimerization (of 3-, 7-, and 12-hydroxy 
groups), oxidation (removal of H2), dehydroxylation (replacement of a 
hydroxyl group with a hydrogen), and hydroxylation (replacement of a 
hydrogen with a hydroxyl group)(17). This microbial transformation is a key 
step and is outlined in further detail below: 
Deconjugation: Bile salt hydrolases (BSHs) are enzymes, which catalyse 
the hydrolysis of the C24 N-acyl amide bond of conjugated BAs. BSH 
enzymes have been purified from various bacteria, including Bacteroides 
fragilis, Bacteroides vulgatus, Clostridium perfringens, Listeria 
monocytogenes, as well as several species of Lactobacillus and 
Bifidobacterium(18, 28). With regards to the ecological importance of 
microbial BSH activity, there are three main hypotheses. Firstly, the 
liberated amino acids arising from the deconjugation reaction may 
potentially be used as carbon, nitrogen, and energy sources. Glycine may 
be metabolized to ammonia and carbon dioxide and taurine to ammonia, 
carbon dioxide, and sulphate, all of which could then be integrated into 
bacterial metabolites(17). Secondly, the tensile strength of the membranes 
may increase or a change in membrane fluidity may affect sensitivity to 훼-
defensins and other host defense molecules through BSHs facilitating 
incorporation of cholesterol or bile into bacterial membranes 
(29, 30). Thirdly, BSHs may play a role in bile tolerance and play a 
detoxification role, allowing for microbial survival in the gastrointestinal tract 
in the presence of bile salts(17).  
 
Oxidation and Epimerisation: Oxidation and epimerization of the 3-, 7-, and 
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12-hydroxy groups of BAs in the gastrointestinal tract are catalyzed by 
homoserine dehydrogenase (HSDHs) enzymes, which are expressed by 
intestinal bacteria. Epimerization of BA hydroxyl groups generates a stable 
oxo-bile acid intermediate, necessitates the actions of two stereochemically 
distinct HSDHs and can be performed by a single species containing both 
α- and β- HSDHs or by two species, one possessing an α-HSDH and the 
other a β-HSDH. 3-α and 3-β HSDH enzymes have been discovered in 
several bacteria belonging to the Firmicutes phylum whereas bacteria 
capable of intraspecies 3-hydroxy epimerization include Peptostreptococcus 
productus, C. perfringens, and Eggerthella lenta. 7훼-HSDHs have been 
identified among members of the Clostridium, Eubacterium, Bacteroides, or 
Escherichia genera. Intraspecies 7-hydroxy epimerization has been 
observed in species of the Clostridium, Eubacterium, and Ruminococcus 
genera of bacteria(17).  
Dehydroxylation: The 7α-dehydroxylation reaction of primary BAs results in 
the production of the secondary BAs, which predominate in human faeces. 
Therefore, this is the most quantitatively significant microbial bile salt 
transformation. Species of the Firmicutes phylum (Clostridium and 
Eubacterium) retain 7α-dehydroxylation activity(17). 7 α/β -dehydroxylation 
is restricted to free BAs, therefore a precondition for this to occur is the 
removal of glycine/taurine BA conjugates via BSH enzymes(31, 32).  
1.1.3 Symptoms 
Through stimulating colonic secretion and motility, the secretomotor effects 
of BAs in the colon manifest clinically as the symptoms of BAD. This 
comprises of water diarrhoea, bloating, faecal urgency and faecal 
incontinence. These symptoms impact considerably on a patient’s lifestyle 
by affecting activities of daily living and limiting travel or the ability to leave 
the house(11). Abdominal pain, discomfort and bloating have been found to 
be more common in patients with mild BAD(16). 
The mechanisms of action include activation of intracellular secretory 
processes, increasing mucosal permeability through the detergent effects of 
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the BAs, inhibiting Cl-/OH- exchange via Ca2+ and PI3 kinase dependent 
pathways, as well as stimulating mucus secretion(33, 34). Typically, BA 
concentrations above 3 mmol/L will initiate colonic water secretion by 
activating adenylate cyclase(35, 36). The colonic secretory effects of water 
and electrolytes have been shown to be structure-specific and are 
secondary to the presence of two α hydroxyl groups at the 3, 7 (CDCA) or 
the 3, 12 (DCA) positions in the BA molecule(33). These effects have not 
been demonstrated with CA(37). Sulfation of BAs by intestinal bacteria has 
appeared to abolish the secretory activity of CDCA and convert it to a non-
secretory form(38). Furthermore, BAs in the colon are capable of inducing 
high amplitude, propulsive contractions, thereby contributing to disordered 
defecation in these patients(19). 
1.1.4 Prevalence  
BAD is often recognised as a rare phenomenon and misdiagnosed for IBS-
D which is reflected in a recent systematic review stating that in excess of 
28% of patients meeting accepted Rome I, II or III criteria for IBS-D have 
SeHCAT (tauroselcholic [75selenium] acid nuclear medicine scan – this is 
described in section 1.1.5) results consistent with BAD. This effect was 
observed in all countries where the studies originated from(39). In 2009, 18 
studies containing 1223 patients with chronic diarrhoea were systematically 
reviewed to evaluate the prevalence of BAD. This demonstrated that 32% of 
patients had BAD as defined by a SeHCAT retention of <10%. Interestingly, 
the data gathered from these studies collected over a 22-year period (from 
as early as 1985) found that the trends in the prevalence of undiagnosed 
patients remained fairly static over time. Variation in the prevalence of the 
severity of BAD was observed with a 4-13% prevalence range for a 
SeHCAT retention <5%, 12-65% for retention <10% and 18-53% for 
retention <15%. With regards to the types of BAD being diagnosed in the 
UK, 61% of patients have type 1 BAD, 22% have type 2 and 15% have type 
3(40). 
It has been estimated that 1% of the Western population suffer with 
BAD(41). Half a million adults in the UK alone who are currently being 
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treated for IBS-D are expected to have BAD(15). In the UK, 5 new 
diagnoses of BAD per gastroenterologist per year (1% of new patients) are 
made. Limited diagnosis of BAD is evident in secondary, specialist care with 
22% of gastroenterologists rarely testing for BAD or not at all in patients 
presenting with chronic diarrhoea(40). Failure or a delay in diagnosis 
manifests in social embarrassment, loss of employment opportunities and 
recurrent unnecessary investigations for patients(42). 
There are several factors, which may influence why BAD is under-
diagnosed. One is that it is frequently not considered in the differential 
diagnosis of chronic diarrhoea as a functional diagnosis is often made in the 
absence of alarm symptoms and in the presence of normal blood and 
endoscopic test results. Even when the diagnosis is considered, many 
patients may not be referred for a definitive diagnostic test (SeHCAT 
scan)(43). Only 6% of British gastroenterologists were found to investigate 
for BAD as first line in patients with chronic diarrhoea and only a third used 
a definitive diagnostic test to do so(40). There is also national variation in 
the referral for a definitive diagnostic test with 50% of SeHCAT scan 
requests originating from only 10 hospitals(40). Other clinician independent 
factors that may hinder making a diagnosis of BAD include the cost of 
diagnosis, the therapeutic trial of Colestyramine not tolerated by all patients 
which some physicians use as a definitive diagnostic test and access to 
diagnostic facilities(15). The latter is observed in several UK hospitals where 
fewer than 80 of the 250 departments that are equipped to perform a 
SeHCAT scan ever do so(40).  
 
1.1.5 Diagnosis 
A definitive diagnosis of BAD is desirable to assess severity of disease and 
tailor treatment appropriately. The 2008 UK NICE Clinical Practice 
Guidance on the diagnosis and management of IBS does not mention BAD 
or propose any guidance on appropriate diagnostic techniques (NICE). In 
the UK, the SeHCAT test is licensed for use in the investigation of BAD and 
measurement of BA pool loss(44). The NICE scope, which assesses the 
use of the SeHCAT scan in investigating BAD, mentions that although there 
! 32!
is no direct comparator for SeHCAT, there remains insufficient evidence to 
determine whether SeHCAT is a cost-effective diagnostic option(45).  
 
SeHCAT is not widely used in clinical practice and in the US, unlike most of 
Europe, the SeHCAT scan is unavailable and clinicians depend on reaching 
a diagnosis of BAD by performing a therapeutic trial of BA sequestrants 
(BAS)(46). In fact, the American Gastroenterology Association medical 
position statement on IBS (2002) advises on a trial of Colestyramine for 
suspected BAD in patients with post-infective and post-cholecystectomy 
diarrhoea(47). This is inadequate as patients may be non-compliant with 
BAS due to reports of poor palatability and experience of side effects such 
as abdominal pain, flatulence and borborygmi thereby halting the attempt at 
diagnosing BAD(15). Symptoms may also only improve with higher doses of 
a BAS, which patients may have discontinued prematurely and so the 
diagnosis of BAD may be missed. 
 
The various diagnostic methods for BAD are outlined below. The SeHCAT 
scan has superseded other diagnostic approaches in being the test of 
choice in clinical practice. A recent systematic review identified the SeHCAT 
scan with the greatest diagnostic yield in identifying BAD in patients with 
functional bowel disorder (FBD) with diarrhoea. Approximately 31% of 
patients with FBD with diarrhoea had BAD based on a SeHCAT scan result 
compared to an average of 23% diagnosed by other diagnostic tests, 
including serum C4, serum FGF19 and total faecal BA excretion(48). 
 
14C-glycocholate (14C-BA) breath and stool test 
This is a method to determine bacterial-dependent deconjugation due to 
bacterial overgrowth in the small intestine. 14C-glycine is released from the 
BA, absorbed into the portal circulation, rapidly metabolized in the liver and 
the end product is then exhaled into the breath where is it measured as an 
early peak of 14CO2(12). If the 14C-BA enters the colon and is not 
reabsorbed in the terminal ileum, it will be deconjugated by colonic bacteria. 
A smaller proportion will remain intact to be excreted in stool therefore stool 
collection after the breath test can identify BAD(49). A disadvantage to this 
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test is that positive breath exhalation at 2-4 hours will not differentiate 
between BAD and small bowel bacterial overgrowth. As well as concerns 
over radiation exposure, there is the labour intensity and complexity of the 
test, which limits its use in clinical practice(49). 
 
75Selenium Homotaurocholic Acid Test (75SeHCAT) 
This test was introduced to the UK in 1981 and measures BA pool loss 
through calculating the retention of radiolabelled (75Se) synthetic 
homocholic acid conjugated with taurine 7 days after ingestion(50). 
[75Se]Tauroselcholic acid is a BA analogue, which demonstrates identical 
physiological behaviour to natural BA conjugates(51). It is resistant to 
passive diffusion and bacterial degradation and therefore can enter the 
enterohepatic circulation through reabsorption via the terminal ileum or pass 
through the colon unaltered to be excreted in the stool(49). 97-100% of 
[75Se]Tauroselcholic acid is excreted with a biological half-life of 2.6 days 
and 3% is eliminated with a mean half-time of 62 days(44). Retention rates 
are expressed as a percentage of the original value of compound retained 
and are used to grade severity of BAD with cut-offs of 5%, 10% and 15% 
demonstrating mild, moderate and severe disease respectively. However, 
these thresholds are not standardized or validated(50). 
 
The patient ingests a capsule of 75selenium homotaurocholic acid (gamma 
radiolabeled BA) and after one hour, by which time the 75selenium has 
distributed in the gut, a baseline scan is taken and represents 100% 
retention. A follow up scan is conducted on day 7 where the percentage of 
remaining 75selenium homotaurocholic acid in the body is calculated. This is 
achieved by dividing the amount of radioactivity from 75selenium on 
subsequent scans by the baseline scan on day 1(49).  
The advantage to this test is that gamma emission, with a short half-life and 
decreased radiation to extra-abdominal organs is used(49). The main 
disadvantage is the limited availability of this test and the requirement for 
multiple visits. 
! 34!
Quantifying severity of disease with the SeHCAT scan has been found to 
help predict response to BAS with a decreased response noted as severity 
is reduced(52). In a systematic review of 20 studies considered for the 
assessment of the value of the SeHCAT test in predicting response from 
BAS, a positive test in patients with chronic diarrhoea established average 
response rates of 85%, 73% and 72% for cut-offs at 5%, 10% and 15% 
respectively. For patients with chronic diarrhoea and a negative SeHCAT 
test, the response rate was 14% at a cut-off at 5% and 0% at a cut-off of 
15%. The test demonstrated greater response rates in those patients with 
underlying Crohn’s disease and a positive SeHCAT test with response rates 
being 95% at a cut-off of 5% and 86-89% at a cut-off of 15%(44).  
 
A sensitivity of 94% and specificity of 100% have been reported for the use 
of this test(53). The highest specificity from the SeHCAT test is reported in 
patients with severe BAD with cut-off levels of <5%-<8%. A higher 
sensitivity with decreasing specificity is seen in patients with both moderate 
and severe BAD at the cut-off level of <15%(15). 
 
Despite being the accepted gold standard to diagnose BAD, the SeHCAT 
scan is underutilized in the UK due to lack of guidance on its role as a 
diagnostic tool, the prohibitive cost of approximately £210 per patient and 
the variation amongst clinicians in diagnosing BAD with some performing a 
diagnostic trial of BAS(54). There is significant heterogeneity amongst UK 
hospitals in the interpretation on SeHCAT results with lack of consistency in 
centres utilising differing criteria for defining an abnormal SeHCAT result, 
impacting on subsequent patient management. Patients with BAD type 1 
were found to demonstrate the highest proportion of centre-defined 
abnormal SeHCAT results(50).  
 
Serum 7 α-hydroxy-4-cholesten-3-one (C4)  
Serum C4 is a simple blood test measuring BA synthesis and is a 
downstream product of CYP7A1. 90% of BA synthesis is regulated by the 
enzyme CYP7A1(12). Standardised specimen collection is required due to 
diurnal variability in C4 with peak concentrations occurring postprandially at 
! 35!
13:00 and 21:00, lasting for 1.5-3 hours(55). Typically, blood is drawn after 
an overnight fast and C4 is isolated using liquid chromatography-tandem 
mass spectrometry. An elevated serum C4 concentration has been defined 
as being >60.7ng/mL(49). 
 
When compared to the SeHCAT test, the C4 assay has a lower 
performance with sensitivity of 90%, specificity of 79%, negative predictive 
value of 98% and positive predictive value of 74% in diagnosing BAD(49). 
The test is limited in its use as it remains unknown whether factors such as 
shift work, age and emotional states may affect the circadian rhythm and 
therefore the synthesis of BAs(49). Disadvantages to the test include the 
possibility of a false positive result in patients with liver disease or those 
who are being treated with statins(12). 
 
Faecal BAs 
Functional diarrhoea and IBS-D have increased secretory BAs (CA, CDCA, 
DCA) and the measurement of these have proven to be technically 
challenging(56). Due to diurnal variation in BA synthesis, multiple stool 
collections over 3-5 days are required to quantify faecal BAs and diagnose 
BAD(57, 58). The performance of this test is unknown. 
 
Enzymatic and chromatographic approaches are used to measure faecal 
BAs. An enzymatic 3α-steroid dehydrogenase assay quantifies faecal BAs 
indirectly to oxidise deconjugated BAs and produce reduced nicotinamide 
adenine dinucleotide (NADH) which is then measured biochemically(12). 
Chromatographic approaches include the use of GC-MS, liquid 
chromatography-tandem mass spectrometry, or HPLC-mass 
spectrometry(49).  
 
Serum FGF-19 
Fasting serum levels of the biomarker FGF-19 have found to correlate with 
SeHCAT retention and inversely with C4 concentrations(59). FGF-19 is 
synthesized in the ileum and is involved in the negative feedback of BA 
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synthesis by acting in the liver to inhibit the crucial BA synthetic enzyme 
CYP7A1(60). The median FGF-19 serum value has been found to be 65% 
of the median in the control group of a study that presented with similar 
symptoms and had normal SeHCAT retention. Lower FGF-19 levels were 
also found in patients with severe BAD (SeHCAT retention value 0-5%) as 
well as in the obese patients with primary BAD(11). The microRNA miR-34a 
is found to be increased in obesity and has demonstrated a role in FGF-19 
responses via regulation of β-Klotho expression(61). Significant 
heterogeneity was evident in FGF-19 levels in patients with BAD and a 
possible mechanism for this may be defective hepatic responsiveness to 
FGF-19(59). Therefore, this complex interplay of mechanisms may 
contribute to the pathogenesis of BAD. 
 
To detect a SeHCAT cut-off of <10%, a fasting FGF-19 level of 145 pg/ml 
has demonstrated a 61% positive predictive value and a 82% negative 
predictive value(11). 
 
Urine Volatile Organic Compounds (VOCs) 
This test involves detection of VOCs in urine samples, utilising the 
technology of an electronic nose in combination with a Field Assymetric Ion 
Mobility Spectrometer (FAIMS) as well as a Gas Chromatography Mass 
Spectrometry (GC-MS). VOC signatures are the resultant products of 
fermentation by the intestinal microbiome and this is covered in further detail 
in section 1.3.1. Linear discriminant analysis has been able to separate out 
the VOC profiles of patients with BAD from both healthy controls and 
patients with ulcerative colitis with achievement of statistical differences 
between the groups. In this study, GC-MS suggested the presence of two 
chemical compounds in patients with BAD, 2-propanol and acetamide, 
produced by the cleavage of BAs by gut bacteria, may account for the 
differences found(54). Advantages to the utility of VOCs as biomarkers in 
the diagnosis of BAD are that they are non-invasive, portable and relatively 
inexpensive.   
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1.1.6 Management of BAD 
The mainstay of treatment is a low fat diet coupled with anion exchange 
resins -  bile acid sequestrants (BAS). Patients may also utilize conventional 
anti-diarrhoeals such as Loperamide, which have the advantages of being 
relatively inexpensive, available in tablet form, have no effect on the 
bioavailability of co-administered medications and being better tolerated 
than BAS(27). They are prescribed by a quarter of British 
Gastroenterologists for the treatment of BAD(40). 
 
In underlying causes of BAD (e.g. Crohn’s), therapy should be targeted 
towards the specific condition, although in many patients, there are no 
particular aetiologies that are identified (such as in primary BAD) or are 
treatable (e.g. post cholecystectomy). Despite BAD being a prevalent 
condition, there is currently a lack of national guidance available on the 
appropriate management of patients who may benefit from targeted 
therapeutic intervention. NICE have recognised this and recommend that 
further research into the efficacy and tolerability of treatment for BAD is 
required(27). 
 
 
Low Fat Diet 
The use of low fat diets (<30-40g fat/day) is not well described. Ingestion of 
dietary fat has demonstrated an increase in faecal BA excretion rate(62). In 
patients with mild BAD, a low fat diet may be considered with or without the 
addition of medium-chain triglycerides, as a calorific supplement, which do 
not require BAs for solubilsation(46). 
 
A study of patients with BAD secondary to pelvic irradiation therapy for 
malignant gynaecological tumours, demonstrated that a low fat diet of 
<40g/day for 3-6 months resulted in a decrease in a faecal extraction of BAs 
with relief of symptoms(63). A more recent, larger study agreed with these 
results. Dietary intervention of providing 20% of energy from fat was 
undertaken, reducing the daily mean fat intake by a third. This led to a 
significant improvement in clinically important symptoms including bowel 
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frequency, urgency, lack of control, flatulence, abdominal pain, steatorrhea, 
borborygmi and bloating(64). Formal dietetic assessment is required and 
compliance may be low due to poor taste(27). 
 
Bile Acid Sequestrants (BAS) 
BAS are positively charged, non-digestible resins, with high affinity in 
binding to BAs in the intestine to form insoluble complexes, which are then 
excreted in the faeces. Before the advent of statins, these medications were 
used in patients with raised cholesterol, as by reducing the enterohepatic 
circulation of BAs, cholesterol is converted to BAs in the liver. This results in 
a reduced hepatic cholesterol content, which in turn, increases expression 
of the LDL-receptor, thereby lowering the serum LDL-cholesterol 
concentration(65).  
 
There are currently three commercially available BAS: Colestyramine, 
Colestipol and more recently, Colesevelam. Colesevelam is unlicensed for 
the use in BAD and coupled with the fact it is more expensive compared to 
the other BAS, it is rarely used in clinical practice.  Both Colestyramine and 
Colestipol have been used in the management of cholestatic pruritus, 
particularly in Primary Sclerosing Cholangitis(66). The emerging role of BAS 
in patients with type 2 diabetes mellitus, metabolic syndrome and insulin 
resistance is also being recognised(67, 68). 
 
BAS are also capable of binding other compounds therefore can impair 
absorption of fat-soluble vitamins (A,D, E and K) and medications including 
diuretics, digoxin, warfarin and beta-blockers(69). This effect may be 
overcome by administering BAS either 1 hour after or 4-6 hours before other 
drugs and monitoring levels of fat-soluble vitamins periodically. 
Colesevelem has the potential benefit of not affecting the bioavailability of 
other drugs and vitamins71. This is due to its individual structure (compared 
with the other BAS) of a polyallylamine crosslinked with epichlorohydrin and 
alkylated groups, causing an ‘open’ structure with side chains that maximize 
binding with BAs and reduce interactions with other medications(65).  
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Despite having a high safety profile and being cheap, BAS are limited in 
their use through poor compliance due to the gastrointestinal side effects 
they may incur in patients. These include abdominal pain, constipation, 
bloating, nausea and flatulence, which may lead to discontinuation of 
treatment in 40-70% of patients(70). They also have poor palatability given 
they only exist in powder/granule forms, which need to be dissolved into a 
paste. Colesevelam is better tolerated due to its more gelatinous 
consistency(71).  
 
A recent systematic review of the management of BAD, the largest to date, 
found Colestyramine treatment to be effective in 70% of patients (range 
63%-100%) who maintained good clinical response at follow up. An 
association between response and severity of BAD was not evident(27). In 
a randomized controlled trial, Colesevelam was investigated as first line 
therapy which found that it was associated with firmer stool consistency, a 
moderate increase in the 24-hour colonic transit time and ‘greater ease of 
stool passage’(72). The use of Colesevelam as first- and second-line 
therapy (after failure of Colestyramine) has been investigated with 87% of 
patients declaring success after reporting an improvement in symptoms and 
continuing long-term treatment. As second-line therapy, Colesevelam was 
deemed successful in 57% of patients who maintained good clinical 
response at follow-up(73). Treatment with Colesevelam has been 
significantly associated with the severity of BAD, based on serum 7αC4 
levels(72).  
 
FXR Agonists 
A proof-of-concept study investigating the utility of obeticholic acid in 
patients with BAD was recently undertaken(74). Obeticholic acid is an FXR 
agonist that is 100 times more potent than CDCA, a natural FXR 
agonist(75). In patients with primary BAD, where reduced levels of FGF-19 
have been demonstrated, the use of an FXR agonist was hypothesized to 
stimulate FGF-19 production in the ileum. CDCA has been shown to induce 
FGF-19 transcript expression in human ileum explants(76). In patients with 
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primary BAD, the study exhibited an increase in the baseline fasting median 
FGF-19 level after treatment with obeticholic acid with levels being similar to 
those found in healthy controls. 90% of patients had a median increase of 
71% over baseline FGF-19 levels. Fasting C4 and BA values were reduced 
after treatment with obeticholic acid in patients with primary BAD. Stool 
frequency and consistency improved with treatment in patients with primary 
BAD and those with secondary BAD resulting from shorter ileal resections 
(<45cms). An improvement was noted in the symptoms of urgency in 
patients with both primary and secondary BAD and pain in patients with 
secondary BAD(74). 
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1.2 Diarrhoea predominant - Irritable Bowel Syndrome (IBS-
D) 
 
1.2.1 Irritable Bowel Syndrome (IBS) and Burden of Disease 
IBS is a multifactorial, chronic functional bowel disorder that is the most 
commonly diagnosed gastrointestinal condition. There is an absence of a 
physiological or a demonstrable structural abnormality to explain the 
symptoms of IBS sufferers(77). The diagnosis of IBS is usually confirmed 
once organic (pathological) disease has been excluded and after a negative 
diagnostic evaluation, a patient being diagnosed with IBS has a less than 
5% risk of receiving an alternative organic diagnosis in the future(78). IBS 
accounts for a significant proportion of referrals to secondary care. Referrals 
for IBS in Northern England were responsible for 36% of all new patient 
appointments with each patient requiring an average of two visits(79). 
Despite IBS having the ability to be diagnosed and managed within primary 
care, 30% of patients in the UK are referred to secondary care; two thirds to 
a physician and a third to the surgeons(80). This may either be to exclude 
other potential diagnoses or for further management. A UK study 
demonstrated that three months after seeing a Gastroenterologist for IBS, 
patients only experienced a small and not statistically significant 
improvement in quality of life, which was not maintained(81). 
 
The condition can be debilitating in some patients whereas others may only 
experience mild or moderate symptoms(82). It is a disease based on 
symptoms, characterised by the presence of abdominal pain or discomfort 
accompanied by altered stool form or frequency(83). The subtypes of IBS 
are categorized by the Rome IV criteria (discussed in section 1.2.4), 
according to the predominant symptom and include: IBS with constipation 
(IBS-C), IBS with diarrhoea (IBS-D), mixed IBS (IBS-M) and unsubtyped 
IBS (IBS-U)(84). Somatic co-morbidities are often associated with IBS, 
including somatic pain disorders (chronic fatigue syndrome, fibromyalgia 
and chronic pelvic pain) psychiatric conditions (anxiety, major depression) 
and other function gastrointestinal disorders (dyspepsia, gastroesophageal 
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reflux disease)(85, 86). Several of these co-existing functional conditions 
occur in approximately half of all patients with IBS and exist almost twice as 
often as in the general population(87-89). IBS patients with these somatic 
disorders report symptoms that are more severe than those in patients with 
IBS alone(88, 90). 
 
IBS is a chronic, relapsing condition, representing a considerable burden to 
individuals, society and healthcare systems. Patients utilize more healthcare 
resources than those without IBS beyond the first year following diagnosis 
for gastrointestinal symptoms and non-gastroenterology related care(91). 
IBS generates a significant economic burden secondary to the costs of 
consultations, investigations, prescribed and over-the-counter medications, 
and sickness absence from work(92-94). In the United States, the total 
direct and indirect expenditures exceed $20 billion with an estimated direct 
cost per patient being between $742 and $7547(91, 95). 12% of patients 
stop work due to their IBS(96). Reductions in other dimensions affecting 
quality of life in patients with IBS may also occur with one study reporting 
68% of sufferers missing out on an activity or social event each week(97). 
The severity of bowel and psychological symptoms produces the most 
significant effect on reducing quality of life in patients with IBS(98). 
 
The natural history and symptoms of IBS vary over time and patients may 
migrate between different IBS subtypes(99). Usually, transition is from IBS-
C or IBS-D to IBS-M whereas switching between IBS-C and IBS-D occurs 
less commonly(100). Although IBS assumes no attributable mortality, it still 
bears significantly on quality of life(101, 102). A systematic review 
demonstrated that during long-term follow-up of clinic-based IBS patients, 
30%-50% remained unchanged, 12%-38% improved and 2%-18% 
worsened. Worse outcomes were predicted by various factors including 
longer duration of disease, higher somatic scores, previous surgery and co-
existing anxiety and depression(78).  
 
The global prevalence of IBS is 11%(77). The lowest prevalence of IBS is 
found in Southeast Asia (7%) with the highest occurring in South America 
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(21%)(77). In Western populations, the prevalence of IBS is up to 20% with 
an incidence of 1-2% in community samples(77, 103). Data from the United 
States report that 30% of patients with symptoms will consult, with 80% of 
these patients having IBS-D(104). In a meta-analysis examining the 
prevalence of IBS according to each of the 4 subtypes, even distribution 
was demonstrated. 22% of patients had IBS-C, 23% had IBS-D, 24% had 
IBS-M and 22% had IBS-U. The prevalence of IBS was also found to be 
higher in females (14%) compared to males (8.9%). With regards to 
socioeconomic status, there was no significant difference in the prevalence 
of IBS found in patients of higher socioeconomic status compared to those 
of medium or lower socioeconomic statuses(77). 
 
1.2.2 Risk Factors for IBS 
The greatest documented risk factor for IBS is female gender with an odds 
ratio of 1.67. Women were more likely to exhibit IBS-C and less likely to 
meet criteria for IBS-D than men(105). Reasons underlying the excess of 
IBS seen in women may include differences in gender health seeking 
behaviour, gender differences in access to health care and biological 
functions (e.g. hormonal regulation of gut function)(82). Women with IBS are 
more likely to have suffered sexual, verbal or physical abuse, which may 
contribute to the development of IBS through dysfunction of the brain-gut 
axis and mucosal immune system(106). 
 
Clustering of IBS within families has been reported and is driven by social 
learning, shared household environmental exposure and genetics(107, 
108). Individuals with a biological relative with IBS have a twice as high 
relative risk of developing IBS(109). Twin studies have demonstrated that 
having a mother or father with IBS is a stronger predictor for an individual 
having IBS than having a twin with the condition(110). 
 
IBS occurs in patients across all age groups, with no difference observed in 
the frequency of subtypes by age(111). With advancing age (>50 years), the 
incidence of IBS decreases but is similar in children and adolescents 
compared with adults and does not necessarily transition from childhood to 
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adult life(77, 112). Recurrent abdominal pain in childhood may reflect 
learned illness behaviours in some IBS patients, initiating persistent 
changes in the brain-gut axis which leads to the unconscious perception of 
interoceptive input from the gastrointestinal tract(113, 114). Patients above 
the age of 50 years report milder pain however their quality of life is deemed 
worse(111). Patients above the age of 65 years are likely to have symptoms 
for at least one year before they consult whereas younger patients under 
the age of 65 years report a significantly shorter history of symptoms(115). 
 
An association between preceding gastrointestinal infection and IBS has 
been demonstrated with a reported prevalence of 10%(116). Female sex, 
younger age, premorbid psychological conditions and the severity of the 
initial infection are risk factors for developing post-infectious IBS(82). Unlike 
typical IBS, post-infectious IBS spontaneously resolves in approximately 
half of patients within 6-8 years of the index infection(117). 
 
Personal, psychological, social and somatic factors have all found to be 
associated with an increased risk of patients developing IBS and are 
outlined in table 1. Less well recognized factors are marked (*) and are 
based on single studies(82). 
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Table 1: Factors associated with risk of developing IBS 
PERSONAL    
Female sex Age >50 years Birth cohort* Breast feeding 
(<6 months)* 
Herbivore pet in 
childhood* 
Low birth weight* Low body mass 
index* 
 
 
PSYCHOLOGICAL    
Illness behaviour Low quality of life Acute 
psychological 
stress 
Stressful life 
events 
Sexual/physical 
abuse history 
Anxiety/depression/ 
somatisation 
Intimate 
partner 
violence* 
Addictive 
behaviour* 
 
SOMATIC    
Gastrointestinal 
infection 
Somatic symptoms 
(e.g. joint pain, 
migraine) 
Endometriosis Abdominal 
obesity 
Left-sided 
diverticular disease 
Antibiotic use Abdominal 
surgery 
Spicy food 
consumption* 
Sleep problems* Low exercise level*   
 
SOCIAL    
Childhood 
socioeconomic 
status 
Family history of 
substance abuse 
Family history 
of mental 
illness 
Insufficient 
autonomy at 
the workplace* 
Shift work* Marital status 
(never married)* 
Increasing 
number of 
family 
members* 
Childhood war 
exposure* 
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1.2.3 Pathophysiology of IBS-D 
The pathophysiology of IBS-D is heterogenous and some of the key factors 
contributing to the aetiology are outlined below: 
 
Diet 
The relationship between diet and IBS is ill defined and diet may trigger IBS 
symptoms and/or induce alterations in gut microbiota, permeability and pro-
inflammatory responses(85, 118). Osmotically active, short-chain 
carbohydrates (including lactose, fructose, sugar alcohols, fructans and 
galactans) may result in increased fermentation in the bowel, exacerbating 
symptoms in patients with IBS who have underlying abnormalities in gut 
sensation and function(119). Postprandial exacerbations of symptoms either 
as an immediate or deferred reaction have been reported in 50% of patients 
with IBS(120). Many patients associate one or more foods with the onset of 
symptoms and the most implicated food items include wheat, milk, caffeine, 
fructose, alcohol, certain meats, spicy and fatty foods, dairy products and 
grains(121). A high fat intake in IBS patients is associated with a heightened 
colonic motor response to eating and increased visceral sensitivity(122). A 
relationship between IgG antibodies and IBS symptoms has been reported 
in patients with IBS-D where exclusion of specific IgG-associated foods 
resulted in a significant decline in the symptoms of abdominal distension, 
pain and bloating(123). 
 
An exaggerated postprandial serotonin response may account for the 
symptoms of urgency and diarrhoea seen in IBS-D as serotonin stimulates 
receptors responsible for intestinal secretion and peristalsis(121, 124). This 
occurs as elevated levels of postprandial serotonin have been demonstrated 
in patients with IBS with decreased serotonin reuptake resulting from 
diminished affinity for the reuptake transporter protein(124, 125). 
Accelerated colonic transit where an increased number of brief (<15 
seconds) colonic contractions, alterations in small intestinal motor function 
(e.g. increased frequency of duodenal and jejunal contractions, migrating 
motor complexes and ileal distension) have been reported in patients with 
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IBS-D, however, whether this is secondary to a disruption in serotonin 
signaling or other mechanisms remains unclear(126-128). 
 
The influence of dietary factors on the immunological phenomena of the gut 
microbiota in IBS is observed by the impact of probiotic administration and 
will be discussed in section 1.3.4. The overproduction of hydrogen by 
intestinal microbes has been associated with IBS symptoms, especially 
flatulence and abdominal pain(129). Methanogenic Archae, which efficiently 
remove hydrogen gas in the intestine, have demonstrated decreased levels 
in patients with IBS-D(130). A low FODMAPs (fermentable, oligo-, di-, 
monosaccharides and polyols) diet, which may be used to improve 
symptoms in patients with IBS-D, has been found to reduce absolute counts 
and total abundance of intestinal bacteria but not relative abundance of 
specific bacterial groups. Lower relative abundances of butyrate-producing 
bacteria and A. muciniphila, and a significantly higher abundance of R. 
torque have been reported in the low-FODMAP diet in comparison to a high-
FODMAP diet(131).  
 
Apart from investigating the impact of the FODMAPs diet on the intestinal 
microbiota, there is a lack of data examining the functionality effect of this 
diet and other dietary interventions on the gut microbiome in patients with 
IBS(122). Animal studies have illustrated alterations in diet have a 
considerable influence on intestinal microbial composition, function, and 
effect. Mice fed a high fat diet were found to have impaired intestinal 
mucosal barrier integrity secondary to modification of the BA profile with an 
increase in the concentration of DCA and decrease in the proportion of a 
potentially cytoprotective tertiary BA, ursodeoxycholic acid (UDCA). The 
decrease in UCDA was associated with disruption of the intestinal barrier 
most likely due to the increased ability of cytotoxic BAs like DCA to induce 
barrier dysfunction. DCA has been recognised to disrupt lipid bilayers while 
the hydrophilic BA UCDA stabilizes them and protects mitochondria against 
DCA-induced reactive oxygen species production(132). Another mouse 
study found that consumption of a high saturated fat diet stimulated the 
expansion of the sulphite-reducing microorganism, Bilophila wadsworthia. 
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This was related to a proinflammatory T helper type 1 immune response 
with an increased incidence of colitis in genetically susceptible mice that 
lacked IL-10(133).  
Epithelial Barrier 
Disruption of the intestinal epithelial barrier permits increased antigenic 
invasion resulting in the activation of the mucosal immune systems, which 
may progress to IBS-D(134, 135). The inflammatory infiltrate is composed of 
increasing numbers of activated mast cells and mast cell products (mainly 
neurotransmitters and inflammatory mediators), which have been located in 
the terminal ileum, and the proximal and distal colon of IBS patients(136-
139). Mast cells are involved in the regulation of visceral sensitivity, 
intestinal motility and epithelial and mucosal gut barrier function(140). Acute 
and chronic stress promotes mast cell activation and the presence of 
chronic stress in patients with IBS-D has been found to significantly 
contribute to symptom intensity and duration of these symptoms(141-143). 
In IBS-D patients, activation of mast cells, measured by expression of 
tryptase mRNA, exhibited correlation with stool frequency and consistency. 
Poor correlation was seen with absolute numbers of mast cells, implying 
that mast cell activation rather than numbers influence bowel habit(144).  
 
Tryptase, one of the mediators released by mast cells, can cause 
morphological changes in the epithelial gut barrier by activating protease-
activated receptor 2 on epithelial cells, resulting in modulation of tight 
junction (TJ) proteins and increases in permeability through paracellular 
pathways(145). The jejunal mucosa of IBS-D patients has demonstrated 
structural abnormalities at the intercellular apical junction complex (AJC) 
with perijunctional cytoskeletal condensation and enlarged apical 
intercellular distance. This was associated with molecular and gene 
alterations, which identify mechanisms regulating AJC function. An increase 
in the expression of the CLDN2 protein and decreased expression of 
CLDN3 and CLDN4 has been observed(146). CLDNs (claudins) and OCLN 
(occludins) are TJ transmembrane proteins, which form the structural core 
of the TJ and are associated with the perijunctional cytoskeleton 
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(predominantly actin and myosin), which is vital for the regulation of 
paracellular permeability(135). CLDN2 has been associated with cation-
selective channel activity and increased intestinal permeability, whereas 
CLDNs 3 and 4 reduce permeability through the paracellular space, 
strengthening the epithelial wall barrier(147, 148). The net modification 
observed in the expression of the components of the CLDN protein family 
would result in an increase in the permeability of the intestinal wall 
barrier(146). 
The phosphorylation status of OCLN is related to its distribution in epithelial 
cells(149). OCLN has been located in the cytoplasm of jejunal enterocytes, 
suggesting redistribution of the protein with internalization seen whereas in 
healthy subjects, it was predominantly observed in the TJ(146). 
Internalisation and phosphorylation of OCLN has demonstrated a disruption 
in the integrity of the AJC, resulting in increased intestinal permeability(150). 
Increased myosin light chain (MLC) phosphorylation has been observed in 
IBS-D patients, which has been linked to AJC disassembly and disruption of 
the epithelial wall barrier(146, 151, 152). 
Lastly, the presence of HLA-DQ2 or DQ8 genotype appears to render IBS-D 
patients with increased susceptibility to gluten altering mRNA expression of 
TJ proteins and increased small bowel permeability(153). 
Bile Acids 
BAs are regarded as endogenous laxatives that stimulate colonic motility, 
increase mucosal permeability, reduce net fluid and electrolyte absorption 
and encourage net secretion across colonic epithelial cells(37, 154, 155). 
 
Increased colonic exposure to BAs in patients with predominantly IBS-D and 
IBS-M, influences colonic transit time and bowel habit. A subset of patients 
with IBS who had an abnormal SeHCAT retention value and/or increased 
C4 levels, indicating increased BA exposure to the colon, were observed to 
have increased bowel frequency, accelerated colonic transit time and rectal 
hyposensitivity(156). This is supported by another study demonstrating 
increased faecal primary BAs in patients with IBS-D compared to healthy 
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controls. This correlated with increased stool frequency and reduced stool 
consistency(157).  
 
Microbiome 
The role of the gut microbiome in IBS is discussed in section 1.3.4. 
 
Brain-Gut-Immune Axis 
The gut, brain, intestinal microbiota and immune systems demonstrate 
reciprocal associations in health and disease(82). A combination of 
hormonal, neuronal and immunological pathways allows the brain to 
modulate the sensory, motor, secretory and autonomic functions of the 
gastrointestinal (GI) tract and this communication of the brain with the GI 
tract is bidirectional(158). Through the autonomic nervous system and 
hypothalamus-pituitary-axis (HPA), the brain can influence various 
mechanisms, which have been reported to be dysregulated in IBS. These 
include intestinal epithelial permeability, immune function, intestinal motility 
and fluid secretion and composition of the intestinal microbiome(159-161).  
 
The enteric nervous system (ENS) and central nervous system (CNS) 
influence many gastrointestinal functions via communication along the vagal 
and autonomic pathways(158). Increased parasympathetic tone and 
adrenergic dysfunction have been demonstrated in patients with IBS-D 
when compared to those with IBS-C, which may influence colonic motor 
activity and IBS subtype(162). 
 
Functional signaling between immune cells and nerves predominantly 
occurs in between the epithelial and submucosal layers of the intestinal wall 
where there is a high concentration of immune cells – mainly, mast cells, T 
lymphocytes and macrophages. Cytokines and mediators released by these 
immune cells interact with extrinsic nerves, enteric nerves and glial 
cells(82). Mucosal mediators from patients with IBS evoke increased 
activation of somatic pain and visceral pathways when applied to intestinal 
preparations isolated from rodents compared with healthy controls(163, 
164). Mucosal mediators derived from patients with IBS and visceral 
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hypersensitivity activated spinal nociceptors acutely when given to animal 
models but this observation did not occur in normosensitive patients with 
IBS(165). Furthermore, chronic exposure to soluble mediators from colonic 
biopsies from patients with IBS-D has demonstrated sensitization of 
nociceptive neurons(166). 
 
The hypothalamic-pituitary-adrenal (HPA) axis can be activated in response 
to environmental stress by the key activating hormone, corticotrophin-
releasing factor (CRF), secreted from endocrine cells in the paraventricular 
nucleus of the hypothalamus(158, 167). Animal studies have demonstrated 
stress induced release of CRF stimulates colonic secretion, intestinal 
motility and visceral sensitivity(167). CRF stimulates the anterior pituitary to 
release adrenocorticotropic hormone (ACTH), which in turn, induces 
secretion of cortisol from the adrenal cortex. Cortisol has an anti-
inflammatory role on the GI immune and systemic system. Reduced cortisol 
levels and response and heightened vagal activation have been observed in 
patients with IBS-D(168). 
 
1.2.4 Diagnosis and Symptoms of IBS 
 
Variations in form and frequency of bowel habits, along with having 3 or 
more different stool forms per week have been shown to discriminate IBS-D 
from other organic gastrointestinal disease(169). Other symptoms, although 
non-specific, support the diagnosis of IBS and include abnormal stool 
frequency (>3 per day or <3 per week), abnormal stool passage (urgency, 
feeling of incomplete evacuation, straining), abnormal stool form 
(loose/watery stool or hard/lumpy), bloating/abdominal distension and 
passage of mucus(170). A post-prandial exacerbation of symptoms is 
common in IBS but not exclusive to the diagnosis(171).  
 
Symptoms of IBS-D may mimic other organic gastrointestinal diseases and 
therefore it is important to screen for them. Patients with IBS symptoms 
have a 4-fold increased likelihood of biopsy proven coeliac disease and 
therefore routine screening in these patients particularly those with IBS-D, 
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should be undertaken with IgA TtG +/- quantitative IgA(172, 173). A small 
subset of patients with suspected IBS-D may have microscopic colitis 
therefore when colonoscopy is performed, random colonic biopsies should 
be carried out(173). As mentioned earlier, a third of patients with IBS-D 
symptoms have BAD therefore testing for this condition with a SeHCAT 
scan or any other diagnostic tool that is available is advised. Lastly, it is 
important to consider inflammatory bowel disease (IBD) in the differential 
diagnosis of patients with IBS-D symptoms. Studies suggest that the Rome 
criteria for IBS may be fulfilled in more than a third of patients with IBD(174). 
Therefore, the use of faecal calprotectin, which has been found to be cost-
effective in identifying IBD, is advisable(175). A recent meta-analysis 
demonstrated that a CRP of ≤0.5 and faecal calprotectin of ≤40, excludes 
IBD in patients with symptoms of IBS and that the addition of these two 
biomarkers, along with symptom-based criteria, may further support the 
diagnosis of IBS(176). 
 
A recent systematic review of the accuracy in diagnosing IBS with 
diagnostic criteria, biomarkers and/or psychological markers demonstrated 
that performing a combination of these tools was a more effective way in 
diagnosing IBS compared with using diagnostic criteria alone. The 
combination in achieving the best positive likelihood ratio was faecal 
calprotectin, intestinal permeability and Rome I criteria(177). 
 
Diagnostic Criteria 
The diagnosis of IBS relies on the exclusion of organic pathology and the 
presence of symptoms in alliance with diagnostic criteria, the latest version 
being the Rome IV criteria, which is the current international gold standard. 
These criteria include abdominal pain or discomfort associated with altered 
bowel habit. Stool consistency may be assessed with the Bristol Stool Form 
Scale, which is a validated tool in reporting of stool appearance from a 
score of 1 (hard and lumpy stool) to 7 (entirely liquid)(178). There is 
currently no valid biomarker for IBS and although patients often undergo a 
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series of investigations to exclude organic disease, the current 
recommendation is to base diagnosis on symptoms(82).  
 
The first attempt at diagnostic criteria for IBS was the Manning criteria, 
published in 1978(179). The experience gained from the Manning criteria 
aided the development of the Rome Foundation criteria, which have been 
found to be 69-96% sensitive and 72-85% specific for the diagnosis of 
IBS(180). All these criteria require symptoms to be chronic and recurring 
and occur for ≥3 days per month (now ≥1 day per week in the new Rome IV 
criteria) in the past ≥3 months with symptom onset ≥6 months before the 
diagnosis (Rome III and IV criteria)(82). The Rome III criteria have only 
been validated in one study(181). In addition, the Rome III criteria have 
been criticized for separating out those with IBS-D from patients with 
functional diarrhoea with overlap of the two conditions occurring in one in 
four patients. Those with IBS-D were found to have differing characteristics 
to those with functional diarrhoea: IBS-D patients were of a significantly 
younger age, more were female, of a lower BMI, more often reported 
bloating, had a higher rate of education to university or post-graduate level 
and demonstrated higher levels of anxiety and somatization. Frequency of 
diarrhoeal symptoms was no different between the two groups of 
patients(182).  
 
Since publication of the Rome III criteria in 2006, there have been several 
changes to the Rome IV diagnostic criteria for IBS, which are as 
follows(183): 
 
1. Removal of the term ‘discomfort’ from the criteria and use of only the term 
‘pain’. 
 
2. Increased minimum frequency threshold of abdominal pain from 3 
days/month in Rome III to 1 day/week in Rome IV. 
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3. Relief of abdominal pain/discomfort after defecation was previously 
required in Rome III, which is no longer required in Rome IV and has now 
been replaced to pain related to defecation. 
 
4. Stool consistency and change no longer require starting at the ‘onset’ of 
abdominal pain/discomfort. Demonstration of an association between the 
symptoms in Rome IV is now required. 
 
5. A change in identifying the IBS subtypes where previously, Rome III 
criteria required the proportion of total stools using the Bristol Stool Chart 
Scale to classify IBS. As patients may have greater duration of normal stool 
frequency, a majority was being classified as IBS-U compared to the other 
subtypes. Rome IV now relate the diagnostic criteria to the proportion of 
days with symptomatic stools (i.e. loose/watery) rather than all stools 
(including normal ones). This has resulted in the IBS-U group being reduced 
significantly. 
 
The Rome III and IV criteria are demonstrated in table 2. 
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Table 2: Rome III and IV criteria in diagnosing IBS 
Rome Criteria Rome III (2006)(83) Rome IV (2016) 
Symptoms Recurrent abdominal pain or 
discomfort at least 3 
days/month in the last 3 
months, associated with ≥2 
of the following: 
 
1. Improvement with 
defecation 
 
2. Onset associated with 
change in stool frequency 
 
3. Onset associated with 
change in stool form 
(appearance) 
Recurrent abdominal pain, 
on average, at least 1 day 
per week in the last 3 
months, associated with ≥2 
of the following: 
 
1. Related to defecation 
 
2. Associated with change in 
stool frequency 
 
3. Associated with change in 
stool form (appearance) 
Duration of Symptoms Criteria should be fulfilled for at least 3 months with 
symptom onset ≥6 months prior to diagnosis. 
 
 
Biomarkers 
As discussed earlier, diagnostic criteria alone perform only modestly in 
predicting the diagnosis of IBS and therefore, further research is being 
conducted into developing novel biomarkers, which may aid in the 
diagnostic work-up of IBS.  
 
Serum biomarkers 
In 2009, ten serum biomarkers were incorporated into a diagnostic algorithm 
and assessed in differentiating IBS from non-IBS. These include Interleukin-
1β (IL-1β), Growth-related oncogene-α (GRO-α), Brain-derived neurotrophic 
factor (BDNF), Anti-Saccharomyces cerevisiae antibody (ASCA IgA), 
Antibody against CBir1 (Anti-CBir1), Antihuman tissue transglutaminase 
(tTG), Tumour necrosis factor (TNF)-like weak inducer of apoptosis 
(TWEAK), Antineutrophil cytoplasmic antibody (ANCA), Tissue inhibitor of 
metalloproteinase-1 (TIMP-1) and Neutrophil gelatinase-associated lipocalin 
(NGAL). The sensitivity and specificity of this algorithm was 50% and 88% 
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respectively(184).  
 
More recently, 34 gene expression and serology markers (including the 10 
biomarkers utilized in 2009) were combined with 4 psychological measures 
to differentiate IBS from health and between subtypes of IBS. The other 
biomarkers included in this study were histamine, prostaglandin E2 (PGE2), 
serotonin, tryptase, substance P, interleukins 6, 8, 10 and 12 as well as a 
host of gene expression markers. This panel had a sensitivity and specificity 
of 81% and 64%, respectively in differentiating between IBS and health. A 
subset of four biomarkers (anti- tTG, histamine, ZNF326 and RNF26) 
contributed to the majority of the performance. With regards to IBS 
subtypes, the best differentiation was observed between IBS-D and IBS-C 
(AUC = 0.92). The addition of the psychological markers did not improve 
discrimination further between the IBS subtypes but did yield an incremental 
discrimination in IBS from health(185). None of these biomarkers mentioned 
are currently used in clinical practice. 
 
Volatile Organic Compounds (VOCs) 
This is discussed in section 1.5.3. 
 
Granins 
Secretogranins (Sg) and chromatogranins (Cg) are proteins located in 
secretory cells of the endocrine, enteric and immune systems, which are 
thought to reflect their activity. Faecal levels of SgII, SgIII, CgA and CgB 
have been investigated in patients with IBS and healthy controls. Higher 
faecal levels of SgII, SgIII and CgA with lower levels of CgB were seen in 
IBS patients and this reached statistical significance. SgII demonstrated the 
greatest discriminatory performance in positively identifying IBS 
patients(186). Granins are not specific to IBS as they can be observed in 
other gastrointestinal conditions such as coeliac disease and lymphocytic 
colitis(187). 
 
Epithelial Gap Density 
Disrupted intestinal permeability may compromise intestinal barrier function, 
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which is maintained by epithelial cells with tight junctions between the 
cells(188). An increased epithelial gap density in the terminal ileum in IBS 
patients has been demonstrated using confocal laser endomicroscopy. A 
trend towards higher gap density in female and younger patients was 
observed. A cut-off value of 30 gaps per 1,000 cells was used to define 
abnormal cell gap density and revealed a sensitivity and specificity of 62% 
and 89%, respectively(189). This is not exclusive to IBS as patients with IBD 
have also demonstrated an increased epithelial gap density(190). 
Furthermore, the diagnostic accuracy of this test is likely to depend on the 
operator’s skill set and experience and the test may only be limited to 
particular endoscopy units.  
 
Colonic Mucosal Markers 
Immune activation may contribute towards the pathogenesis of IBS. Using 
quantitative immunohistochemistry on mucosal biopsies, IBS patients have 
shown a significant 72% increase in colonic immunocytes compared to 
controls, with increased numbers of CD3+, CD4+ and CD8+ T cells and 
mast cells. 50% of IBS patients have demonstrated increased immune cells, 
however this test is limited as a significant immune infiltrate has also been 
observed in other gastrointestinal diseases, including microscopic colitis and 
ulcerative colitis(191). 
 
1.2.5 Pharmacological Management of IBS-D 
Management of IBS involves a holisitic, integrated approach based on 
reassurance, education, dietary alterations, pharmacotherapy and 
behavioural and psychological treatment, given the fact that 50-70% of IBS 
patients report somatic and psychological symptoms(192, 193). In 2009, the 
American College of Gastroenterology IBS Task force announced that the 
three classes of medications with the strongest evidence (grade 1B – 
moderate to high evidence) for efficacy in IBS-D were tricyclic 
antidepressants (TCAs), antibiotics (i.e. Rifaxamin) and the 5HT3 antagonist 
Alosetron(194, 195). 
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a) Anti-motility Agents 
Loperamide, a µ-opioid receptor agonist, is frequently used as a first-line 
agent in IBS-D. Its main benefit is to improve stool consistency, reduce stool 
frequency and defecation urgency but has less impact on the symptoms of 
abdominal pain and bloating(194, 196). It works by reducing peristalsis, 
increasing intestinal transit time and reducing loss of fluid and 
electrolytes(118). Central adverse effects are avoided as Loperamide does 
not cross the blood-brain barrier(82). It has shown to be well tolerated, with 
the only adverse effects reported including constipation, swollen fingers, 
trouble with sleeping and oral blisters(197-199). Despite Loperamide being 
an effective antidiarrhoeal drug, there is no evidence to support its use in 
relieving global IBS symptoms(194). 
 
Eluxadoline, a mixed µ-opioid receptor agonist and δ–opioid receptor 
anatagonist, reduces contractility and secretion in the gastrointestinal tract 
and was approved for use in IBS-D patients in the USA in 2015(200). In two 
phase 3 trials, 23-33% of patients on 75mg and 100mg of Eluxaoline, 
compared to 16-20% of the placebo group, demonstrated a decrease in 
abdominal pain and an improvement in stool consistency on the same day 
for at least 50% of the days for 26 weeks. The most common adverse 
events observed were nausea, constipation and abdominal pain. The safety 
concerns of the drug were secondary to the excess rates of 
pancreatitis(201). 
 
b) Serotonergic Agents (5-HT3 receptor antagonists) 
These include Alosetron, Ramosetron and Ondansetron and their 
mechanism of action is considered to occur through inhibition of the 
ascending excitatory component of the peristaltic reflex and of the high 
amplitude propagating contractions within the gastrointestinal tract(202). 5-
HT3 receptors have shown an important role in visceral pain, and 5HT3 
antagonists reduce painful sensations from the intestine and slow intestinal 
transit(203, 204). Randomised, placebo-controlled trials of Alosetron have 
demonstrated an improvement in stool consistency, stool frequency and 
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overall IBS symptoms in females, however the effects were limited by a 
rapid reduction with treatment cessation(205-210). In males, a study 
observed treatment with Alosetron resulted in improved stool consistency, 
relief of abdominal pain and discomfort but a lack of effect on stool 
frequency, bloating, urgency and incomplete evacuation(211). The concerns 
surrounding Alosetron are based on reports of ischaemic colitis, occurring in 
approximately 0.1% of patients(212). Ramosetron, is of benefit in both men 
and women with IBS-D, demonstrating ‘a global assessment of relief of IBS 
symptoms’ and been found to be safe(213, 214). Out of the 5-HT3 
antagonists, Alosetron is currently the only medication, which has been 
recommended for use in females with IBS-D(194).  
 
c) Antidepressants 
Selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants 
(TCAs) improve global IBS symptoms and reduce abdominal pain in IBS 
patients (NNT = 4)(194). In low doses, TCAs are effective in relieving pain 
of visceral origin, increasing pain thresholds, relieving concomitant 
depression and altering intestinal transit times(47, 194, 215). As TCAs 
prolong intestinal transit time, they are preferentially used over SSRIs for 
patients with IBS-D(195). 
 
Table 3 demonstrates three controlled trials investigating TCAs and SSRIs 
in patients with IBS-D(216-218). 
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Table 3: Trials investigating TCAs and SSRIs in IBS-D 
Study Treatment Study 
Duration 
Population Results 
Vahedi et al, 
2008(216) 
Amitriptylline 
10mg 
2 months All patients 
with IBS-D 
(based on 
Rome II 
criteria) 
Significant reduction in 
stool frequency and 
feeling of incomplete 
evacuation. Improved 
complete response (loss 
of all symptoms).  
Greenbaum et 
al, 1987(217) 
Desipramine 
50-150mg 
Crossover 
study with 
Atropine 
and placebo 
(3 x 6-week 
test 
periods) 
28 IBS 
patients (19 
with IBS-D, 9 
with IBS-C) 
IBS-D patients: Decreased 
stool frequency, diarrhoea, 
abdominal pain, 
depression and slow 
rectosigmoid contractions. 
13/19 IBS-D patients 
improved ‘globally’. 
Talley NJ et 
al, 2008(218) 
Imipramine 
50mg and 
Citalopram 
40mg (double-
blind, placebo-
controlled, 
parallel group) 
12 weeks 51 IBS 
patients (37 
with IBS-D) – 
based on 
Rome II 
criteria 
Imipramine: improvements 
in bowel symptom severity 
rating for interference, 
distress and depression 
score. 
 
Citalopram not superior to 
placebo. 
(Adapted from Olden KW. Targeted therapies for diarrhoea-predominant irritable bowel 
syndrome. Clin Exp Gastroenterol, 2012) 
 
With TCAs, adverse effects include constipation, dry mouth, dizziness and 
drowsiness(118). Adverse effects of SSRIs include diarrhoea, nausea and 
vomiting. As these side effects are common, they may limit patient 
tolerability(194). 
 
d) Dietary Modification 
Patients with IBS readily specify particular food products that precipitate 
symptoms however only 11-27% of those are accurately identified when 
confirmed in formal, blinded food challenge studies(219). Wheat, fruit and 
vegetables appear to be particularly offending food products and the low 
FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides 
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and polyols) diet aims to address this(82). FODMAPs are osmotically active 
and are poorly absorbed by the small intestine, resulting in the net secretion 
of fluid into the small intestine, causing distension and abdominal symptoms 
with increased water delivery to the colon. FODMAPs are also rapidly 
fermented by the intestinal microbiota, resulting in gas production which 
gives rise to colonic distension, pain and bloating(220). Two randomized 
controlled trials have demonstrated an improvement in IBS symptoms with a 
low FODMAPS diet. One trial specifically showed an improvement in the 
IBS symptoms of bloating, pain and passage of wind but greater satisfaction 
was observed in IBS-D patients in particular, where altered faecal frequency 
and consistency occurred(221). 
 
A very low carbohydrate diet (20g carbohydrate/day) has been observed to 
improve abdominal pain, quality of life, stool frequency and consistency in 
IBS-D sufferers(222). A gluten free diet has also been shown to reduce 
stool frequency in IBS-D patients, the effects being more pronounced in 
patients with HLA-DQ2 or DQ8 genotype(153). 
 
e) Probiotics 
Probiotics have been defined as ‘live microorganisms which when 
administered in adequate amounts, confer a health benefit on the host(223). 
There are three randomized controlled trials (RCTs), which have 
investigated the effects of probiotics in patients with IBS-D and are outlined 
in table 4(224). 
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Table 4: RCTs of probiotics in IBS-D 
Study Probiotic strains (brand name), 
dose/duration 
Population Results P 
value 
Kim HJ et 
al, 
2003(225) 
B. longum, B. longum subsp. infantis, 
B. breve, L. acidophilus, L. paracasei 
subsp. paracasei, L. delbrueckii 
subsp. bulgaricus, L. plantarum, 
Streptococcus salivarius subsp. 
thermophilus (VSL#3)  
1 sachet (225 billion lyophilised 
bacteria) BD for 8 weeks 
IBS-D 
(Rome II) 
Reduced 
abdominal 
bloating. 
 
No changes 
in colonic 
transit 
0.046 
Ki Cha B et 
al, 
2012(226) 
Lactobacillus acidophilus, 
Lactobacillus plantarum, 
Lactobacillus rhamnosus, 
Bifidobacterium breve, 
Bifidobacterium lactis, 
Bifidobacterium longum, 
Streptococcus thermophiles 
 
1 capsule BD (1 x 1010 cells/day) for 
8 weeks 
IBS-D 
(Rome III) 
Increased 
proportion of 
patients with 
adequate 
relief of 
overall IBS 
symptoms 
0.01 
Zeng J et 
al, 
2008(227) 
Streptococcus thermophilus, 
Lactobacillus bulgaricus, 
Lactobacillus acidophilus, 
Bifidobacterium Longum 
 
Fermented milk, 200g BD for 4 
weeks (each ml contained at least 
1.3 x 108 CFU total) 
IBS-D 
(Rome II) 
Decreased 
small bowel 
permeability 
 
Primary end 
points not GI 
symptoms. 
 
 
 
 
 
- 
(Adapted from Hungin AP. Systematic review: probiotics in the management of lower 
gastrointestinal symptoms in clinical practice - an evidence-based international guide. 
Aliment Pharmacol Ther 2013(224)) 
 
Given this data, probiotics may be used in IBS to improve global symptoms, 
bloating and flatulence however recommendations with regards to specific 
preparations are unable to be made due to insufficient evidence(194). 
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f) Non-absorbable Antibiotics (Rifaximin) 
Modifying the intestinal microbiota is a growing area of interest in the 
management of IBS. The role of antibiotics in IBS has already demonstrated 
encouraging results. Eradication of small intestine bacterial overgrowth in 
IBS patients with antibiotics was shown to improve symptoms of abdominal 
pain and diarrhoea and eliminate IBS in approximately 50% of 
patients(228). Normalisation of the lactulose breath test in IBS patients with 
Neomycin has resulted in correction of bowel habit in 35% of patients(229).  
 
Rifaximin is derived from Rifampin through the addition of a pyridimazole 
ring to minimize systemic absorption and is a semi-synthetic antibiotic(230). 
It acts by inhibiting synthesis of bacterial ribonucleic acid (RNA), through 
binding to the β subunit of the bacterial deoxyribonucleic acid dependent 
RNA polymerase(231). The anti-bacterial effects include activity against 
gastrointestinal aerobic and anaerobic Gram-positive and gram-negative 
bacteria, while imposing a relatively low risk of bacterial resistance(232-
234). Rifaximin may also alter the function of the intestinal microbiota 
through a number of mechanisms. Modification of bacterial adherence may 
occur through preventing mucosal inflammation in reducing mucosal 
bacterial colonization and infection. Bacterial metabolism may also be 
altered as well as down-regulation of bacterial virulence(235). 
 
Due to limited evidence for its use, Rifaximin is only indicated in IBS-D and 
in not other IBS subtypes(156). The TARGET study group have 
demonstrated in two phase 3, double-blind, placebo-controlled trials 
(TARGET 1 and TARGET 2) that patients with IBS without constipation, 
treatment with 550mg Rifaximin for two weeks provided significant relief of 
global IBS symptoms, including abdominal pain, bloating and loose or 
watery stools(236). The TARGET 3 study, which is currently only published 
in abstract form, showed that in patients with IBS-D who initially responded 
to Rifaximin and then had symptom recurrence, were then given a repeat 
course of Rifaximin. This resulted in significant improvements in IBS related 
abdominal pain and stool consistency compared with patients receiving a 
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placebo(235). 
 
g) Faecal Microbiota Transplant (FMT) 
This involves administering healthy donor stool into the colon of 
symptomatic patients. FMT has already demonstrated therapeutic potential 
in Clostridium difficile infection and inflammatory bowel disease (IBD)(237). 
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Fermentation: Short chain fatty acids, the gut microbiome 
and volatile organic compounds 
 
Our research group has coined the term ‘fermentome’ to express the 
complex relationship between diet (resulting in the production of short chain 
fatty acids), the intestinal microbiota and volatile gases. It has been 
proposed that the gas products of fermentation serve as biotransmitters and 
are important for intestinal homeostasis through intestinal microbiota 
chemical signaling(238). 
 
The human right colon is well suited as its role as a fermentation chamber, 
with its ordered inlet in the form of the ileo-caecal valve and no 
corresponding valve at the outlet (i.e. the hepatic flexure). The hepatic 
flexure is acutely angled, connected to the diaphragm via the colophrenic 
ligament and partially rotated. Contraction of the teniae coli (the longitudinal 
strap muscles across the hepatic flexure) augments the ‘kink’, which creates 
a closed chamber for fermentation to occur. Relaxation of the teniae coli 
allows for the chamber to open and its contents to transit through the 
colon(238).  !!!!!!!!!!!!!!
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1.3 Short Chain Fatty Acids (SCFAs) 
 
1.3.1 Overview of SCFAs 
SCFAs are the end products of metabolism by anaerobic microbes in the 
colon and have been proposed to be the link between microbiota and host 
tissues(239). Faeces consist predominantly of water (80-90%) with its 
fibrous residue being mainly in the form of non-starch polysaccharides 
(NSP)(238). NSPs are the main substrates for fermentation by resident 
intestinal bacterial digestive enzymes, resulting in the principal SCFAs of 
acetate, propionate and butyrate, which contribute to normal bowel function 
and are an energy source for the colonocytes, as well as yielding 
metabolisable energy for microbial growth(238, 240). If the capacity of the 
colonic microbiota to metabolise the polysaccharides is exceeded, the result 
may be an osmotic diarrhoea(241). The minor branch chained SCFAs (iso-
butyric, iso-valeric and n-valeric acid) found in small amounts in faeces are 
derived from bacterial fermentation of proteins. Mucus, sloughed cells and 
gastrointestinal secretions may also contribute to the production of 
SCFAs(241).  
 
SCFAs are weak organic fatty acids, categorized by the number of their 
carbons. They refer to carboxylic acids with aliphatic tails of 1 to 6 carbons, 
including acetate (C2), propionate (C3), butyrate (C4), valerate (C5) and 
hexanoate (C6)(241, 242). The proportions of SCFA in the lumen are 
approximately 60% acetate, 25% propionate and 15% butyrate with the 
normal concentration range of these SCFAs being 70-100mM 
(241, 243). Rodent studies demonstrate that the production of propionate 
and butyrate are inversely related. Sources of fibre (such as oat bran) 
enhance steroid excretion, which lowers plasma cholesterol and increases 
the contribution of propionate relative to butyrate, whereas wheat bran has 
the opposite effect(244).  
 
An estimated 100-200 mM of SCFAs are produced daily, 95-99% of which, 
are absorbed by the colon(241, 245). This absorption is associated with 
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increased sodium absorption and bicarbonate secretion. The equilibrium of 
ionised and protonated SCFAs and their transport across cell membranes 
are dependent on pH. The transport of other solutes and electrolytes in the 
colon is altered by absorption of SCFAs. This may occur through formation 
of isolated pH compartments in the crypts, modifying transfer of weak 
electrolytes and acid-base transport(241). In rodent distal colons, SCFAs 
have demonstrated inhibition of cAMP-mediated Cl- secretion(246). 
Therefore, SCFAs possess both anti-secretory and pro-absorptive 
properties(241). Following a right hemicolectomy, the effect of SCFAs 
stimulating sodium and water absorption is maintained through adaptation 
of the remaining left hemicolon. However, after a total or subtotal colectomy, 
the effect is lost and diarrhoea occurs secondary to impaired 
fermentation(246).  
 
Fermentable carbohydrates are able to modify the microbial ecology either 
by supplying SCFAs or acting as substrates. The principal products of 
fermentation in the adult human are heat, gases (CO2, CH4, H2) and 
SCFAs(240). There are three bacterial reactions consuming a large 
proportion of the gas volume in the colon. Firstly, methanogenic bacteria, 
accounting for 50% of the population, reduce CO2 to CH4 and consume H2 
in the process. Secondly, sulphate-reducing bacteria that reduce SO4 to 
sulphides, including H2S. Thirdly, acetogenic bacteria consume variable 
amounts of H2 and reduce CO2 to acetic acid(241).  
 
Fermentation predominantly occurs in the proximal large bowel and SCFAs 
are transported in the faecal stream to distal regions with a higher 
concentration and a progressive decline of SCFAs being observed along the 
bowel (figure 1)(240). This is supported by levels of SCFA excretion being 
greater with transverse colostomy compared to sigmoid colostomy with 
concentrations of levels in sigmoid colostomy fluid being 40-50% of those 
with a transverse colostomy(247). Depending on diet, the proximal colon 
assumes a total concentration of SCFAs of 70-140 mM, reducing to 20-
70mM in the distal colon. The total SCFA concentration or the individual 
acids observed in the distal colon is not predictive of those found proximally. 
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Numbers of indigenous bacteria are also greatest in the proximal 
colon(240). The luminal pH in the proximal colon is lower due to the 
increasing concentration of acidic fermentation products(243). This reduced 
pH encourages the formation of butyrate through the acidic pH allowing the 
butyrate-producing bacteria to compete with Gram-negative carbohydrate-
utilising bacteria, such as Bacteroides spp(248). In addition, in vitro studies 
have observed that lower pH values (and increased concentrations of 
SCFAs) are recognised to prevent the overgrowth of pH-sensitive 
pathogenic bacteria(249).  
 
Figure 1: Fermentation in the colon 
 
 
The rate of transit of colonic contents, as well as the type of fibre determines 
the rate and degree of fermentation(240, 241). Water-soluble fibre such as 
pectin is virtually completely fermented by bacteria whereas only 5-20% of 
cellulose and lignin undergo anaerobic fermentation in the colon. Diets high 
in resistant starches, fibre and complex carbohydrates result in increased 
production of SCFAs(241). Foods with greater quantities of soluble NSP 
undergo the greatest losses on transit and this is accompanied by increased 
bacterial faecal excretion(250, 251). At whole gut transit times of greater 
than 50 hours, butyrate cannot be detected and this is likely due to colonic 
uptake(240). A significant difference in the total SCFA concentration as well 
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as concentrations of the individual acids (acetic, propionate and butyrate) 
between men and women is observed with higher concentrations being 
evident in men. Concentrations of the minor acids are similar between the 
sexes(252).  
 
1.3.2 SCFAs and Intestinal Health 
Once absorbed by the colonocyte, SCFAs are used locally as fuel for the 
colonic epithelial cells with butyrate being the preferred fuel resulting in 70-
90% being metabolized by the colonocyte. SCFAs provide 5-10% of human 
basal energy requirements(239). Butyrate is favorably used over propionate 
and acetate in a ratio of 90: 30: 50(241). Propionate is a substrate for 
hepatic gluconeogenesis and inhibits cholesterol synthesis in the liver(241, 
253). Acetate is used in the production of long chain fatty acids, glutamate, 
glutamine and beta-hydroxybutyrate(253). SCFAs also modulate secretion 
of the satiety hormones, including leptin and peptide YY(254, 255). 
 
Gram-positive anaerobic bacteria have the ability to produce butyrate with 
the two main producers being Eubacterium rectale/Roseburia spp of 
Clostridial cluster XIVa of the Firmicutes and Faecalibacterium prausnitzii, of 
the Clostridial cluster IV cluster(256). The pH of the colon may be lowered 
by the production of SCFAs. This is of significance due to the varied 
tolerance of a reduced pH for different species within the Firmicutes phylum 
with the butyrate-producing associated Clostridium cluster IV growth rates 
being considerably reduced while the Clostridium cluster XIVa group 
demonstrated the smallest reduction in growth rate(257). 
 
Pro-absorptive/Anti-secretory Effects 
SCFAs, in particular butyrate, exert regulatory pro-absorptive/anti-secretory 
effects on the transepithelial ion transport and this occurs through various 
mechanisms. Stimulation of NaCl absorption occurs via two coupled 
transport systems (Cl-/HCO3- and Na+/H+ and Cl-/butyrate and Na+/H+) on 
the colonic brush border. Cl- secretion inhibition occurs through blockage of 
Na-K-2Cl, a cotransporter on the enterocyte basolateral membrane(243). 
Butyrate therapy, in the form of resistant starch (a precursor of butyrate) has 
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demonstrated an improvement in stool volume and recovery time in children 
with cholera diarrhoea(258, 259).  
 
Trophic Effects 
Muscular atrophy of the colon may occur in diets lacking fibre. DNA 
synthesis and content as well as mucosal weight increase with fibre and this 
effect is mediated by SCFAs, which is considered to have a trophic effect on 
normal colonic mucosa(245). Rodent studies where subjects were fed a 
fibre-free diet but intracolonically infused with either a combination of 
SCFAs or a butyrate solution demonstrated significant colonic growth as 
reflected by increased protein, mucosal mass, RNA and DNA(260). SCFAs 
have also been observed to mediate colonotrophism locally in stimulating 
cell proliferation in the basal 60% of the crypts(261). This may be due to 
increases in visceral blood flow, aerobic oxidation of SCFAs for energy, 
stimulation of the enteric nervous system and increased production of 
enterotrophic hormones(262). SCFAs have been shown to increase blood 
flow in the rectum(263). Rectal infusion of SCFAs into surgical patients 
demonstrated a 1.5-5 fold increase in splanchnic blood flow(264). This is 
thought to be secondary to chemoreceptors, local neural networks as well 
as direct effects on smooth muscle cells. It is assumed that greater blood 
flow improves tissue oxygenation and transport of absorbed nutrients(240).  
 
Anti-carcinogenic Effects 
The anticarcinogenic effects of butyrate have been well studied. Dietary 
fibre is well documented in several epidemiological studies in protecting 
against colorectal cancer(265-268). In vitro, the addition of butyrate to 
carcinoma cell lines resulted in induction of apoptosis, inhibition of 
proliferation and differentiation of tumour cells(269-271). Apoptosis is 
enhanced by butyrate and not by the p53 gene, which controls programmed 
cell death and is often seen in tumours(272, 273). Propionate and acetate 
are also capable of inducing apoptosis but to a lesser extent than butyrate 
and require higher concentrations to do so (≥40mM)(274). At concentrations 
of 1-5 mmol/L, butyrate can switch the phenotype of cancer cells to being 
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more consistent with normal cells and restoration of the cytoskeleton and 
composition of the glycosylated cell surface components. At the molecular 
level, butyrate has been observed to modify oncogene expression 
(downregulation of N-ras) and induce hyperacetylation of histones(275, 
276).  
 
Immunity Effects 
SCFAs have been acknowledged as potential mediators involved in the 
effects of the intestinal microbiota on intestinal immune function through 
acting on endothelial cells and leucocytes by two mechanisms. These are 
inhibition of histone deacetylase and activation of G-protein-coupled 
receptors - GPCRs (GPR41 and GPR43). They regulate various leucocyte 
functions including production of eicosanoids, cytokines (TNF-∝, IL-2, IL-6 
and IL-10) and chemokines (MCP-1 and CINC-2). SCFAs also affect the 
ability of leucocytes to migrate to the foci of inflammation and destroy 
microbial pathogens(239). 
 
Biological Effects 
SCFAs play an important role in the maintenance of a functioning 
gastrointestinal system by slowing the passage of food in the upper 
gastrointestinal tract to improve nutrient digestion(240). After a rectal 
infusion of SCFA or ingestion of lactulose (fermentable carbohydrate), a 
reduction in gastric tone, giving an expansion of volume was observed. The 
mechanism of action is the activation of the ileocolonic brake in a dose-
dependent fashion(277).  
 
The biological effects of SCFAs on the colon have been implicated in 
intestinal disease, including diversion colitis and ulcerative colitis. It was 
hypothesised that diversion colitis arose from a deficiency in SCFAs and 
instillation of a SCFA solution resulted in an improvement in the endoscopic 
score, resolving the inflammation(278). However, this finding was 
contradicted by another study, which did not identify an improvement in 
either endoscopic or histological appearance in these patients when given a 
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butyrate enema(279). Impairment in butyrate oxidation in isolated 
colonocytes in patients with both active and quiescent ulcerative colitis has 
been observed(280). Oxidative stress plays a role in inflammation and the 
initiation and progression of carcinogenesis(281, 282).  
 
Butyrate regulates the colonic defense barrier, where intestinal permeability 
is decreased with a reduction in its concentration(283, 284). Butyrate 
participates in the assembly of tight junctions via AMP-activated protein 
kinase, which affects the intestinal wall permeability(285). In colonocytes, 
butyrate has been observed to increase expression of the MUC2 gene, 
inducing mucin synthesis, which can affect the mucous layer resulting in 
improved protection against luminal agents(286, 287).  
 
A rodent study has exhibited the ability of SCFAs in regulating the ENS and 
colonic motility. Rats given a resistant starch diet demonstrated increased 
colonic transit with butyrate increasing the cholinergic-mediated colonic 
circular muscle contractile response ex vivo(288). Butyrate may affect 
colonic visceral perception as administration of butyrate enemas in healthy 
volunteers revealed an increase in colonic compliance and decrease in 
pain, urge and discomfort measured with a rectal barostat procedure(289).  
 
 
1.3.3 SCFAs in IBS and BAD 
There are very few studies, which examine the role of SCFAs in IBS and 
none to date in BAD. An association between the gut microbiome and IBS 
has been observed in several studies with inconsistent results in 
characterising the microbiota in IBS. It is crucial to consider that the function 
of the microbiota may be as important as the phylotype in the maintenance 
of health and genesis of disease. Function may be measured as microbial 
metabolites in the form of SCFAs.  
 
Studies have demonstrated conflicting evidence with one study reporting 
reduced SCFAs in IBS-C and increased SCFAs in IBS-D(290). Another 
study observed reduced SCFAs in IBS-D(291). The production of SCFAs is 
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able to lower the pH of the colon(257). A study observed a reduction in the 
proportion of Bacteroides in patients with IBS and Bacteroidetes are 
recognised to be inhibited in acidic conditions(257, 292). The same study 
reported an increase in Bifidobacterium adolescentis in IBS although this 
species has not been found to have a reduction in its growth rate in acidic 
conditions(292, 293). Members of the Bacteroides genus are saccharolytic 
commensals and produce acetic, succinic, lactic and propionic acids(294). 
Bifidobacteria produce acetic and lactic acids with smaller quantities of 
formic acid and ethanol(295). Depending on the dysbiosis observed, one 
would expect varying concentrations of the different SCFAs produced.  
 
In the quest to demonstrate altered gut microbiota with a relationship 
between IBS symptoms and an unbalanced organic acid (SCFAs) profile, a 
study revealed significantly higher counts of Lactobacillus and Veillonella in 
patients with IBS. Compared to healthy controls, these patients also 
expressed significantly increased levels of acetic acid, propionic acid and 
total organic acids. Although the quantity of bowel gas between the two 
patient cohorts did not reach a statistical difference, significantly worse 
gastrointestinal symptoms, quality of life and negative emotions were 
observed in IBS patients with high acetic or propionic acid levels(296). The 
association observed between organic acids and visceral IBS symptoms is 
reflected in a rodent study where rats who were treated with an intracolonic 
infusion of acetic acid demonstrated higher sensitivity to colorectal 
distension than those infused with saline(297). The heterofermentative 
species of Lactobacillus metabolises lactic and acetic acid from fructose or 
glucose(298). Veillonella is able to produce acetic and propionic acid from 
lactic acid therefore the altered gut microbiota profile observed appears to 
be associated with higher levels of organic acids in IBS patients(299). This 
notion is further supported by a study of patients with small bowel bacterial 
overgrowth who had a 4-fold increase in the total concentration of SCFAs in 
their jejunal secretions compared to their healthy counterparts. These 
patients display a colon-like microbiota in the small intestine with the 
modified microbial composition accounting for most of the SCFAs in the 
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jejunal secretions(300).  In addition, the use of antibiotics has demonstrated 
a reduction in the total concentration of SCFAs in faecal excrement(301).  
 
As well as the disease itself, treatment for the condition may further alter the 
intestinal microbiota and production of SCFAs. IBS-D and IBS-M patients 
who were put on a low FODMAPs diet (LFD) demonstrated a reduction in 
Clostridium, Megasphaera, Pediococcus, Actinobacteria, Bifidobacterium, 
and Faecalibacterium prausnitzii bacteria as well as a concentration of total 
SCFAs and n-butyric acid. Interestingly, after ten days of supplementation 
with a high-fructo-oligosaccharides (FOS) diet, the levels of these bacteria 
increased but the SCFAs remained unchanged. Clostridium, Megasphaera, 
Pediococcus and Faecalibacterium prausnitzii are members of the 
Fimicutes phylum, which is known to contain several fermenting 
bacteria(302). Faecalibacterium prausnitzii in particular, is a major butyrate 
producing commensal and has been referred to as a biomarker of intestinal 
health in adults(303). Therefore, a reduction in SCFA production is to be 
expected, especially if other bacteria increase in numbers and occupy their 
metabolic niches(302). Diminished levels of Bifidobacterium and 
Faecalibacterium prausnitzii with a LFD are likely secondary to the reduced 
availability of galacto-oligosaccharides and prebiotic fructans (including 
FOS)(304). This belief is supported by the fact the study reported a rapid 
diet-induced reversal of the gut microbiota with FOS supplementation.  
A recent study reported that the difference between faecal propionic and 
butyric acid (mmol/l) was the best diagnostic biomarker for all subgroups in 
IBS, with a cut-off value >0.015 mmol/l indicating IBS(305).  
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1.4 The Gut Microbiome 
 
There are three terms used when studying the intestine as a habitat. The 
first term is ‘microbiota’ which describes the microorganisms present in a 
defined ecosystem in the body(306). The second is ‘metagenome’, 
reflecting the assembly of genes and genomes of the microbiota, providing 
sequence information. Lastly, the term ‘microbiome’ defines the habitat with 
its microbial population, their genes and genomes and the interactions 
between themselves and with the host. 
 
1.4.1 Overview of the Gut Microbiome  
The gastrointestinal tract harbors a diverse community of approximately 
1014 microorganisms comprising of 500 to 1000 distinct bacterial species 
and is the most heavily colonized organ in the human body(18). There is 10 
times the quantity of commensal bacteria and fungi inhabiting the human 
body compared to human cells(307). The intestinal microbiota are not 
homogenous and are distributed along the length of the whole 
gastrointestinal tract, with the diversity and density increasing from the 
stomach to the colon(307). A continuum arises from 101 to 103 
bacteria/gram of contents in the stomach and duodenum to 104 to 107 
bacteria/gram in the jejunum and ileum, culminating in 1011 to 1012 
bacteria/gram in the colon(308). Firmicutes and Actinobacteria of the Bacilli 
class enrich the small intestine whereas anaerobic bacteria constitute the 
majority of the colonic gut microbiota and are predominantly represented by 
Bacteroidetes and the Firmicutes, with Proteobacteria, Verrucomicrobia, 
Actinobacteria, Fusobacteria and Cyanobacteria being present in minimal 
proportions(309, 310).  
As well as the longitudinal variation exhibited by the intestinal microbiota, 
there is also the presence of latitudinal heterogeneity in the composition of 
the microbiota. The intestinal lumen is separated from the epithelium by a 
thick, complex mucus layer. The communities of microbes present in the 
intestinal lumen which are either dispersed in liquid faecal matter or bound 
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to food particles, vary significantly from the mucosa-associated microbiota 
embedded and attached to this mucus layer, as well as the microbiota that 
appear in immediate proximity of the epithelium(311). The gastrointestinal 
tract is constituted mainly by the luminal bacteria, which are important in 
intestinal homeostasis, with the toxins and metabolites of these bacteria 
modulating the host immune system(312, 313). Several bacterial species, 
including Bacteroides, Bifidobacterium, Streptococcus, members of 
Enterobacteriacea, Enterococcus, Clostridium, Lactobacillus, and 
Ruminococcus have been observed in faeces but did not access the mucus 
layer and epithelial crypts, where Clostridium, Lactobacillus, and 
Enterococcus have been found in the small bowel(314).  
Over a lifetime, the composition of the gut microbiome changes significantly 
and age-specific alterations imply the microbiome-mediated effects on 
health of the host. Initial colonization of the gastrointestinal tract may occur 
even prior to birth with the detection of bacteria in the placenta, amniotic 
fluid, cord blood and foetal membranes suggesting that the presence of 
these microorganisms may not necessarily indicate a sterile in utero 
environment or pathological state(315). Vaginal microbial abundance and 
diversity are reduced in pregnancy, with the dominance of Lactobacillus 
species being observed(316). Given the vagina’s close proximity to the 
foetus, it would be assumed as the primary source of inoculum however, the 
placental microbiome has been demonstrated to be more akin to the human 
oral microbiome, composed of nonpathogenic commensal microbiota, 
including the Firmicutes and Tenericutes phyla(317). Bacteria commonly 
enter the circulation through ulcerated gingival crevicular tissue surrounding 
the teeth and this is considered to be the source of bacterial translocation 
for physiological and pathological bacteria from the oral cavity, which then 
colonise the placenta and are exposed to the foetus. This is reflected in the 
fact of preterm birth being associated with both periodontal disease and 
intrauterine infection(315, 318). Throughout childhood and adolescence, the 
maturation of the intestinal microbiota appears to parallel the physiological 
development central nervous system and gastrointestinal tract(319, 320). 
Once established, the intestinal microbiota within individuals remains 
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relatively stable over time however, there is extensive variability between 
individuals(321, 322). 
The composition of the microbiota is unique to each individual and it has 
been demonstrated that the faecal microbiome of identical twins share less 
than 50% of species phylotypes(323). In the elderly population, there are 
age-related physiological changes in the gut microbiota, which may result in 
a microbial imbalance due to chronic low-grade inflammation(324, 325). 
High throughput sequencing analysis has demonstrated a differing 
composition of gut microbiota of older people (above 65 years) compared to 
younger people with a predominance of the phylum Bacteroidetes(326). 
Bacteroidetes have been identified primarily in residents in long-stay care 
environments and these individuals demonstrated considerably less diverse 
microbiota with loss of the community-associated flora, which was 
associated with frailty(327). 
Environmental changes may account for the differences in intestinal 
microbiota at the same anatomical site at various points in time(328). This 
includes dietary changes, use of antimicrobials, vaccination and sanitation. 
The strong impact of diet on the intestinal microbiota is already 
demonstrated before weaning in babies. The microbiota of breastfed babies 
is less diverse than formula-fed babies, with a predominance of 
Bifidobacterium spp(329, 330). This is assumed to be the effect of human 
milk oligosaccharides serving as metabolic substrates to only a limited 
number of bacteria(331). With the introduction of solid foods, a shift towards 
an adult-like microbiota is observed(332). Variations in geographical 
location impact on the composition of the intestinal microbiota. Non-Western 
populations, who consume a diet high in plant-rich carbohydrates, have 
been observed to have a more diverse microbiome enriched in Prevotella 
spp, at the expense of Bacteroides spp, compared to a Western diet high in 
animal protein, fat, sugar and starch(333). A diet high in resistant starch has 
demonstrated an increase in Eubacterium rectale and Ruminococcus bromii 
species, which are recognized for their saccharolytic properties(334). 
Increased protein and animal fat in the diet has been associated with the 
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Bacteroides enterotype whereas a diet enriched in carbohydrates is 
associated with the Prevotella enterotype. In addition, obese individuals 
demonstrate an increase in Firmicutes and a decrease in Bacteroidetes, 
which is likely secondary to differences in diet(335). Short-term 
modifications in diet appear to only have a modest change in the microbial 
composition(122, 336). 
Table 5 below demonstrates factors, which influence the intestinal 
microbiome at different life stages. 
Table 5: Life stages factors influencing the intestinal microbiome 
Life Stages Age Specific Factors Generic 
Factors 
 
Prenatal 
Overall health status (e.g. maternal stress, 
pregestational diabetes) 
 
 
Diet 
 
Antibiotics 
 
Genetics 
 
Geographical 
location 
 
Social 
context 
Prenatal probiotics supplementation, maternal 
diet  
Neonate Gestational age at delivery 
Mode of delivery (vaginal delivery vs C-
section) 
Infant Breast milk vs formula, antibiotic exposure 
Familial environment vs daycare, pets, 
siblings 
Toddler Familial environment/daycare, siblings 
Adolescent Hormone levels, ethnicity 
Life events (e.g. pregnancy) 
Adult Obesity, lifestyle (changes in diet) and overall 
health status (infection/antibiotic use) 
Urban vs rural environment 
Geriatric Nursing home vs community living 
Decline in health, impaired dentition, fraility 
(Adapted from Greenhalgh K et al. The human gut microbiome in health: establishment and 
resilience of microbiota over a lifetime. Environ Microbiol 2016(315)) 
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Alterations of the intestinal microbiome have been implicated in various 
gastrointestinal diseases including, IBS, Clostridium Difficile infection and 
IBD(306).  
 
1.4.2 Functional Aspects of the Gut Microbiome 
The gastrointestinal tract has a surface area of around 32 square metres 
and is the largest human interface with our environment(337). This complex 
interface forms the mucosal barrier and is composed of the microbial flora, 
soluble anti-microbial molecules, mucus, epithelial layer, the intestinal 
lamina propria containing connective tissue and immune cells, intraepithelial 
compartment and mucosa-associated lymphoid tissue. The mucosal barrier 
plays the vital role of protecting against environmental threats and 
promoting nutrient absorption(338). 
Physiological Functions 
The gut microbiota contains at least 100 times as many genes as the 
human genome, most of which confer physiological functions. These 
recognized roles include metabolic functions such as vitamin synthesis, 
regulating the uptake and deposition of dietary lipids, absorbing indigestible 
carbohydrates and modulating the intestinal epithelium’s absorptive capacity 
for optimum nutrient metabolism. Colonic bacteria, including Bacteroides, 
Roseburia, Bifidobacterium, Fecalibacterium, and Enterobacteria ferment 
carbohydrates and indigestible oligosaccharides to produce SCFAs. These 
are mainly composed of butyrate, propionate and acetate, which confer a 
rich energy source for the host(339, 340). Bacteroides are the main 
organisms responsible for the metabolism of carbohydrates and perform this 
by expressing enzymes such as glycoside hydrolases, glycosyl transferases 
and polysaccharide lyases(341). This is important as the production of 
butyrate prevents the accumulation of toxic metabolic by-products such as 
D-lactate(342). Metabolism of proteins is conducted via amino acid 
transporters located on the bacterial cell wall. This facilitates entry of amino 
acids from the intestinal lumen into the bacteria, where gene products 
convert them into antimicrobial peptides (AMPs - bacteriocins) and small 
signaling molecules(341). Suppression of the inhibition of lipoprotein lipase 
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(LPL) has been observed by the intestinal microbiota with increased LPL 
activity in adipose tissue encouraging fatty acid uptake into adipocytes(343). 
 
Protective functions 
Protective functions incorporate the maintenance of intestinal barrier 
integrity and barricading against invading pathogens by competitive 
exclusion through production of antimicrobial peptides, engagement of 
attachment sites and consumption of nutrient supplies(311). The presence 
of commensal bacteria and products of bacterial metabolism allows for 
induction of the expression of AMPs and their activation to protect against 
invading pathogens and prevent overgrowth of the indigenous bacteria 
themselves(311). Paneth cells, which are located at the base of small 
intestinal crypts, express a variety of AMPs, which is mediated by the 
presence of normal intestinal microbiota(344, 345). They also produce 
matrilysin, a matrix metalloproteinase that activates defensins (an AMP). 
Defensins are produced in their inactive form (prodefensins), which require 
proteolytic cleavage for activation. Colonisation of B. thetaiotaomicron in 
germ-free mice has been observed to induce matrilysin expression(346). 
SCFAs and lithocholic acid, which are bacterial metabolic products, induce 
the expression of cathelicidin (AMP) by mechanisms involving histone 
deacetylation and the mitogen activated protein kinase/extracellular signal 
regulated kinases pathway(347-349).  
Members of the genus, Lactobacillus, produce lactic acid, which not only 
provides an inhibitory environment for the growth of many bacteria, but also 
potentiates the antimicrobial effect of lysozyme in disrupting the bacterial 
cell wall membrane(350). This specific genus also generates antimicrobial 
substances that are active against a wide breadth of both gram negative 
and positive enteropathogenic bacteria(351). 
Various microbiota contribute to the maintenance of the intestinal epithelium 
barrier integrity, including B. thetaiotaomicron, which has demonstrated 
induction of the expression of small proline-rich protein 2a (sprr2a), a 
protein important in desmosome maintenance(352). Several probiotic 
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strains of Lactobacillus, have been observed in helping maintain tight 
junctions within the intestinal wall, protecting against intestinal injury or 
pathogen attack(353). In vivo, microbial cell wall peptidoglycan principally 
stimulates signaling via TLR2, which has been shown to maintain tight 
junctions and decrease apoptosis, thus contributing to the integrity of the 
intestinal epithelium(354). Microbial regulation of angiogenesis, which 
contributes to the structural development of the intestinal mucosa has been 
observed by indigenous bacteria inducing Transcription factor angiogenin-3, 
a protein implicated in the development of intestinal microvasculature(355). 
Immunomodulation Functions 
Immunomodulation functions include tolerance to dietary and microbial 
antigens. This is mediated by the induction of regulatory T cells as well as 
inhibiting overgrowth of the gut microbiota and translocation to systemic 
sites through activating intestinal dendritic cells (DCs), which selectively 
induces the production of IgA from plasma cells. Despite infiltration of the 
lamina propria with activated immune cells and only a single epithelial layer 
allowing for separation from the gut microbiota, healthy individuals do not 
demonstrate pathological features. Therefore, regulatory mechanisms exist 
to ensure intestinal immune homeostasis in a healthy gut but to also 
stimulate a protective immune response in the presence of pathogen 
invasion. Small numbers of live commensal organisms penetrate the 
Peyer’s patches and the bacterial antigens are taken up by the DCs 
resulting in mucosal immune responses and induction of IgA B cells. These 
B cells occupy the lamina propria by recirculating through the lymph and 
bloodstream to secrete protective IgA. This safeguards against mucosal 
penetration of bacteria as the DCs loaded with bacteria are confined to the 
mucosal immune compartment by the mesenteric lymph nodes, ensuring 
local induction of immune responses to the bacteria while the systemic 
immune system remains relatively ignorant of these organisms(356-359).  
 
 
1.4.3 The Gut Microbiome, Dysbiosis and Bile Acid Signalling 
Dysbiosis occurs when pathological imbalances in gut bacterial colonies 
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precipitate disease and has been linked to the dysmetabolism of BAs in the 
gut(360). Figure 2 below illustrates a proposed relationship between gut 
dysbiosis, modified BA pool and disease. 
Figure 2: Proposed schema of interplay between gut dysbiosis, 
modified BA pool and disease. 
 
In health, secondary BAs are modified by microbial BSH and HSDH enzymes through 
deconjugation, oxidation and epimerization as well as dehydroxylation via 7α-
dehydroxylation activity. The BA metabolites as a result of microbial transformations act as 
signaling molecules via the TGR5 and FXR receptors to regulate intestinal homeostasis. In 
disease, it is unclear how gut dybsiosis causes a modified BA pool, which then results in 
disease, which is possibly secondary to impaired BA signaling. (BSH – bile salt hydrolases; 
HSDH - hydroxysteroid dehydrogenases; TGR5 – G protein coupled BA receptor; FXR – 
farnesoid x receptor)(360)  
BA Signaling 
As a result of microbial transformations, BA metabolites act as signaling 
molecules and through activation of the BA activated receptors TGR5 and 
FXR, have demonstrated regulation of intestinal homeostasis by inhibiting 
inflammation, preventing pathogen invasion and maintaining cell integrity. In 
the intestine, TGR5 is expressed by enteric neurons and enterochromaffin 
cells and is principally activated by secondary BAs, including DCA and LCA 
to release glucagon-like peptide 1 and 5-hydroxytryptamine(361, 362). The 
receptor TGR5 has been shown to mediate the prokinetic effects of 
intestinal BAs with faster colonic transit and increased defecation frequency 
observed in TGR5-transgenic mice(363). In patients with IBS-D, TGR5 
single nuclear polymorphism has been associated with faster small bowel 
transit time(364). TGR5 has been found to regulate intestinal barrier 
integrity as TGR5 (-/-) mice have demonstrated a modified architecture of 
epithelial tight junctions with increased expression and abnormal subcellular 
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distribution of zonulin-1, a tight junction protein. This resulted in increased 
intestinal permeability and susceptibility in developing dextran sulphate 
sodium (DSS) induced colitis in rodent models(365). TGR5 also minimizes 
production of pro-inflammatory cytokines (IL-1α, IL-2β, IL-6 and TNFα) 
stimulated by lipopolysaccharides in macrophages and Kupffer cells through 
inhibition of NF-kB(366).  
 
Physiological Effects of BA Signalling 
The BA receptor FXR has been implicated in participating in barrier function 
and immune regulation of the intestine. In vivo and in vitro models have 
demonstrated an FXR agonist inhibiting an inflammatory cytokine (TNF-) 
secretion in different human immune cell populations and preventing 
chemically induced intestinal inflammation, with improvement of colitis 
symptoms, reduced goblet cell loss and inhibition of epithelial permeability 
in wild-type mice(367). Intestinal FXR has a key role in limiting bacterial 
overgrowth and translocation in the distal small intestine with resultant 
disruption to the gut epithelial barrier through the regulation of several 
genes, including Ang1, iNOS and IL18, which have recognized antimicrobial 
actions(368). The cytokine IL-18, which is induced by FXR activation, 
stimulates defense and resistance to a breadth of pathogens, including 
intra- and extracellular bacteria and mycobacteria(369). 
The Relationship between Dysbiosis and BAs 
The degree of activation of BA receptors is influenced primarily by the gut 
microbiota and therefore dysbiosis may result in abnormal BA modification 
resulting in the development of gastrointestinal disease. It is hypothesized 
that BA modification is shared by a variety of bacterial species/genus and 
that an increase in some species may be associated with the inhibition of 
other species involved in BA metabolism(370). Through expansion of 
regulatory T cells or downregulation of inflammatory cytokines, 
Faecalibacterium, Roseburia, Lactobacillus, particular Clostridial clusters 
and Bacteroides fragilis have been associated with reduced intestinal 
inflammation. These bacteria have a role in BA deconjugation and may be 
lost in IBD, especially Crohn’s disease(338, 371-373). Intestinal dysbiosis 
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has been associated with BA dysmetabolism in patients with IBD, indicated 
by the observation of a reduction in faecal secondary BA concentrations and 
an increase in sulphated forms. These forms were particularly increased in 
active IBD patients (assessed by disease activity indices). In vitro, 
secondary BAs exerted anti-inflammatory effects, whereas sulphation of the 
secondary BAs eliminated their anti-inflammatory properties, signifying that 
dysbiosis in IBD led to impaired microbiota enzymatic activity. This in turn 
modified the BA pool composition, resulting in disease(374).  
 
The inverse, where BAs may influence the composition of the intestinal 
microbiota may also be true. BAs have direct antimicrobial action on 
intestinal microbes, with DCA being more potent than CA, due to its 
hydrophobicity, which increases its affinity for the phospholipid bilayer of the 
bacterial cell membrane(375). They also have indirect effects via FXR-
induced AMPs(376). A rodent study demonstrated rats who were fed a diet 
of CA, had phylum-level modifications of their intestinal microbiome, with an 
expansion of Firmicutes at the expense of Bacteroidetes, with outgrowth of 
several bacteria in the classes Clostridia and Erysipelotrichi(377). 
Hydrolysis of conjugated BAs by BSHs yields free BAs, which become weak 
acids and in the neutral physiological pH range where most of the BAs are 
in a non-ionised form, provides them with strong bactericidal activity. The 
hydrophobicity of these molecules is further increased by the 7α-
dehydroxylation reactions by the intestinal microbiota in the large intestine, 
which eliminates the functional hydroxyl group at C-7386. The bactericidal 
activity of the BAs increases as the molecules are transported from the 
duodenum to the distal colon. Increased levels of BAs in the gut favour 
Gram-positive members of the Firmicutes, including 7α-dehydroxylating 
bacteria. Reduced levels of BAs appear to favour Gram-negative bacteria, 
some of which produce potent lipopolysaccharide (a component of the cell 
wall) and include potential pathogens(378). 
BA Modification and Disease 
In IBS-D patients, modifications in faecal BA composition have 
demonstrated a significant increase in primary BA and a parallel decrease in 
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secondary BA compared to healthy controls. In this study, this observation 
correlated with a higher stool frequency and reduced stool consistency. This 
may reflect the influence of dysbiosis found in this study with IBS-D patients 
demonstrating a reduction in bifidobacterium, an increase in E. coli and 
decreased counts of leptum. The leptum group encompasses many bacteria 
(in particular Ruminococcus and Clostridia) that are involved in BA 
transformation therefore reduced numbers of these bacteria may account 
for the decreased transformation activity of the microbiota, resulting in 
increased primary BAs and reduced secondary BAs(370, 371). This would 
suggest that the altered gut microbiome is the primary driver for BA 
dyregulation in IBS. Results from this study are supported by another 
randomized controlled study where CDCA, a primary BA, was given to 
healthy subjects and was found to significantly accelerate colonic transit, 
increase stool frequency and decrease stool consistency(72). A recent 
study supports this hypothesis with IBS-D patients being found to have 
increased faecal CDCA, compared to healthy controls and patients with 
IBS-C(370). At the intestinal mucosal level, CDCA inhibits water absorption, 
thereby inducing watery diarrhoea, as seen in patients with IBS-D(379-381). 
The study also reported increased faecal sulfated BAs in IBS-D patients, 
which was thought to arise from reduced sulfatase activity in the context of 
overall reduced BA biotransformation(370). These findings support the 
presence of dysbiosis and an altered BA pool in IBS-D patients. 
 
Uncontrolled levels of BAs may exert damaging health effects. Increased 
concentrations of hydrophobic secondary BAs are cytotoxic, resulting in 
DNA damage and cell death through the induction of oxidative stress and 
production of reactive oxygen species(382, 383). BAs are important 
regulators of intestinal homeostasis with antimicrobial and amphipathic 
properties. At a concentration of 0.5 mM, DCA can successfully prevent 
bacterial growth in cell culture demonstrating regulation of gut microbial 
composition through environmental stress(384). Micromolar concentrations 
of DCA and CDCA may increase intestinal paracellular permeability through 
phosphorylation of the epithelial growth factor receptor (EGFR), resulting in 
occludin dephosphorylation and cytoskeletal rearrangement at the tight 
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junction level(385). In rodent jejunum and ileum, taurocholate and 
glycocholate (BAs) have demonstrated an apoptotic effect through reduced 
production of ATP via uncoupling of oxidative phosphorylation and 
increasing the ATP-ase activity of mucosal homogenates(386).  
It is unclear whether gut dysbiosis results in modified BA metabolism or vice 
versa, although a bidirectional interaction is likely(338). 
1.4.4 Dysbiosis in IBS and BAD  
The pathophysiology of IBS remains incompletely understood but may 
involve an altered gut microbiome. The existence of abnormal colonic 
fermentation (increased hydrogen colonic gas production seen in IBS 
patients compared to controls), improvement with antibiotic therapy in 48% 
of patients with both small intestinal bacterial overgrowth and IBS and a 
high incidence of IBS after gastrointestinal infections implies a role for gut 
microbes in IBS as acute enteritis is associated with an increase in mucosal 
cytotoxic T lymphocytes and an increase in enteroendocrine hypersensitivity 
with these physiological effects impacting on the gut microbiota 
environment(129, 228, 387, 388). Increased levels of serum antibodies 
specific for bacterial flagellins have been observed in patients with post-
infectious IBS(389). This reflects the increased abundance of flagellin-
producing bacterial species, belonging to Clostridium cluster XIVa, which 
has been demonstrated in IBS(390). Further support of potential association 
of dysbiosis in IBS is suggested by treatment with probiotic therapy using 
Lactobacillus plantarum 299V, or the VSL3 capsule (mixture of lactobacilli 
and bifidobacteria)(225, 391, 392). These treatments have demonstrated an 
improvement in IBS symptoms (though not sustained), in particular 
abdominal pain and bloating which emphasizes the known ability of 
probiotics in balancing intestinal microbiota.  
Evidence of an immune engagement between the gut microbiota and host in 
IBS has been shown by the increased expression of Toll-like receptors 
(TLRs) 4 and 5, a family of pathogen-recognition receptors of the innate 
immune system, in IBS patients, generating a low-grade inflammatory 
response(393). Mucosa-associated bacteria interact with the intestinal 
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lumen via TLRs and NOD2 protein. TLRs are located on the processes of 
dendritic cells that pass through tight enterocyte junctions from the lamina 
propria into the lumen, as well as being expressed on the apical and 
basolateral membranes of enterocytes. The pathogenicity of the bacteria 
determines whether dendritic cells respond aggressively or tolerance is 
auto-induced through the secretion of anti-inflammatory cytokines, such as 
IL-10 and TGF-β(312). In addition, significantly elevated levels of human 
beta-defensin-2 (an antimicrobial protein whose expression is induced by 
pro-inflammatory cytokines and probiotic microorganisms) were 
characterized in patients with active IBS compared to healthy controls, 
signifying an activation of the mucosal innate defense system towards a 
pro-inflammatory response(394).  
Both an increase and decrease in the variation of the gut microbiota has 
been demonstrated in IBS, as well as the suggestion that the microbiota in 
these individuals is more heterogenous than that of healthy controls(395). 
The composition of the gut microbiota has been found to reflect symptom 
severity in IBS with the presence of the Ruminococcus torques phylotype 
being associated with an increase in severity of bowel symptoms. R torques 
is a recognized mucin degrader and produces pro-inflammatory flagellin 
proteins therefore this fact may contribute to an altered mucus barrier 
function(390, 396). An increased abundance of Cyanobacterium in IBS 
subjects has been associated with bloating, satiety and an increased total 
gastro-intestinal symptom rating scale-IBS score (GSCR-IBS). Abundance 
of Proteobacteria was associated with an increased pain threshold and an 
increased mental component (on completion of short form-36). The family 
Actinomycetacea has been inversely associated with clinically significant 
depression in IBS subjects(292). The Doreo spp bacteria are the main gas-
producing bacteria in the gastrointestinal tract and have been observed to 
be abundant in patients with IBS. The overproduction of gas is associated 
with IBS, which may account for the symptoms of abdominal pain and 
flatulence experienced by these patients(397, 398). Excessive production of 
gas may result in faster colonic transit time in patients with IBS-D, given that 
the colons in these patients are more sensitive to increased intestinal 
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volume than healthy controls(399). 
There appears to be a difference in the microbial composition within varying 
IBS subtypes. Lactobacillus and Collinsella have been found to distinguish 
healthy control samples from all IBS subtypes. Bacteroides and Allisonella 
characterized IBS-M in particular, IBS-C was composed mainly of 
Ruminococci, while IBS-D contained numerous Streptococcal sequences. 
Bifidobacterium clones were minimally present in IBS-D samples(400). 
Another study investigating the mucosa-associated microbiota in IBS 
observed a reduction in Bifidobacteria in IBS-D compared to patients with 
IBS-C and healthy controls. IBS-D patients also demonstrated an increase 
in Bacteroides and Clostridia(401). 
Published data on the microbial composition in IBS subjects are inconsistent 
and sometimes contradictory. This is likely secondary to high inter-subject 
variations (phenotypic heterogeneity), differences in molecular techniques 
employed, environmental factors (e.g. diet, medications) and time point of 
sampling during fluctuating symptoms (periods of remission, relapse and 
changes in bowel function) as studies suggest IBS gut microbiomes are less 
stable(402, 403). Generally, data has revealed an increase in the ratio of 
Firmicutes to Bacteroidetes in IBS subjects(292, 296, 395, 397, 400, 404). 
IBS-D patients have been observed to be adundant in streptococci and 
demonstrate a distinctive set of dominant Clostridia(395). 
Table 6 summarizes findings of studies of the intestinal microbiome in adult 
IBS-D patients. 
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Table 6: Intestinal microbial composition in IBS-D 
Study Sample Method Findings 
Krogius-Kurikka 
L et al, 
2009(404) 
Faecal GC-based 
profiling and 
fractioning, 16s 
rRNA sequencing 
↑Proteobacteria, Firmicutes with 
Lachnospiraceae 
↓Actinobacteria, Bacteroidetes 
Lyra R et al, 
2009(405) 
Faecal 16s rRNA 
sequencing 
94% similarity phylotype to 
Ruminococcus torques 
Carroll IM et al, 
2011(406) 
Faecal TRFP-
fingerprinting of 
16s rRNA - PCR 
↓Aerobes 
↑Lactobacillus 
Maukonen J et 
al, 2006(407) 
Faecal DGGE, TRAC 
(hybridization-
based technique) 
Clostridium coccoides-Eubacterium 
rectale: 50% of total bacteria 
Kerckhoffs AP et 
al, 2009(408) 
Mucosal FISH, PCR ↓Bifidobacteria 
Tana C et al, 
2010(296) 
Faecal PCR, culture ↑Veillonella, Lactobacillus 
Matto J et al, 
2005(409) 
Faecal PCR-DGGE, 
culture-based 
techniques 
↑Aerobe:anaerobe ratio 
↑coliforms 
Rajilić-Stojanović 
M et al, 
2011(397) 
Faecal Pylogenetic 
microarray, qRT-
PCR 
2-fold ↑Firmicutes:Bacteroidetes 
ratio 
↑Dorea, Ruminococcus, 
Clostridium 
↓Bifidobacterium, Faecalibacterium 
Dior M et al, 
2016(370) 
Faecal Real-time PCR ↑Escherichia coli  
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1.5 16s rRNA gene as a Marker for Profiling of Bacterial 
Community 
 
1.5.1 Ribosomes and the Bacterial 16s RNA Gene 
 
In living organisms, the genetic information is stored in the genomic 
sequences of their DNA (deoxyribonucleic acid). These sequences encode 
proteins, which are responsible for functioning tasks in living systems. DNA 
polymerase replicates the genome, to preserve the genetic information in 
DNA. Consequently, at every cell division, each daughter cell can receive 
one genome copy. RNA (ribonucleic acid) polymerase undertakes 
transcription of DNA into mRNA, and translation of mRNA is carried out by 
ribosomes. Each sequence of mRNA is composed of ribonucleotides, with 
one of four bases: A (adenine), C (cytosine), G (guanine) and U (uracil). 
One or several triplets of bases (codons) encode an amino acid. The mRNA 
sequence is decoded, starting with the AUG codon that is then succeeded 
by a sequence of codons to specify the order of insertion of amino acids in 
the emerging protein. This is then followed by a termination codon, 
indicating that the protein is ready to dissociate from the ribosome to fold 
into its functional state(410).  
 
Transfer RNA (tRNA) helps to decode the mRNA sequence into a protein 
and functions at specific sites in the ribosome during translation(410). The 
loop end of tRNA interacts with the complementary codon of the mRNA that 
carries the genetic information and is identified as the ‘anticodon loop’. The 
other, single-stranded end, terminates with the CCA nucleotides, and must 
be in as close proximity to the ribosome as possible, to allow transfer of the 
peptide bond, at a site known as the peptidyltransferase centre(411).  
 
An intricate mesh of 3 RNAs (23S and 5S for the large subunit; 16S for the 
small subunit), along with approximately 50 different proteins, forms the 
bacterial ribosome(411). The rRNA genes are transcribed from the 
ribosomal operon as 30S rRNA precursor molecules in bacteria and are 
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then cleaved by RNase III into 5S, 23S and 16S rRNA molecules(412). The 
helix of the 16S RNA runs vertically along the entire length of the small 
subunit body, on the interface side, and is referred to as helix 44. It is 
connected to the decoding center and connects with several bridges in 
contact with the large subunit, therefore it is thought that helix 44 may have 
a role in coordinating the actions of the 2 subunits and initiation of 
translation(411, 413).  
 
In the late 1970s, Carl Woese and George Fox started to analyse and 
sequence the 16S rRNA genes of various bacteria and discovered the third 
kingdom, the Archaea, based on phylogenetic taxonomy of 16S rRNA. They 
demonstrated that phylogenetic trees could be identified by comparing 
relatively stable parts of the genome (e.g. the 16S rRNA gene)(414). 16S 
rRNA, which has approximately 1500 base pairs, is the most conserved of 
the 3 rRNA genes and has been coined as an ‘evolutionary clock’, which 
has resulted in the reconstruction of the tree of life(412, 415). Consequently, 
classification of uncultivable bacteria has been achievable, several bacterial 
genera and species have been reclassified and the discovery and 
classification of novel bacterial species has been facilitated(416). Studies 
have reported 16S yielded genus identification rates of >90%, with species 
rates of 65-83% and 1-14% of isolates remaining unidentified after 
testing(417). 16S rRNA is present in all prokaryotic cells and is well adapted 
for the amplification and measurement of both close and distant 
phylogenetic relationships due to its conserved and variable sequence 
regions evolving at very different rates. This enables the use of the 16S 
rRNA in providing genus and species identification for isolates that do not fit 
any recognised biochemical profiles(418, 419). 
 
For a large number of bacterial strains, there are dedicated 16S databases, 
including BLAST (http://www.ncbi.nlm.nih.gov) and Seqmatch 
(http://rdp.cme.msu.edu), which include near full-length sequences, 
enabling sequences from unknown strains to be compared against these 
sequences(412, 415). In a variety of bacteria, broad-range PCR primers 
recognise conserved sequences, while amplifying highly variable regions 
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between the primer binding sites. These regions demonstrate sufficient 
interspecies variability. The amplified segment is sequenced and then 
compared with the dedicated databases to identify isolates(420). A new 
species is demonstrated when 16S rRNA gene sequence data on an 
individual strain exhibits a similarity score of <97% with a nearest neighbour. 
However, the definition of similarity scores >97% is not clear as this may 
represent a new species or signify clustering within a previously defined 
taxon. Difficulties observed in identifying bacteria include species sharing 
similar and/or identical 16S rRNA sequences or too few sequences 
deposited in nucleotide databases(417). Relying on non-full length 16S 
rRNA gene sequences limits the taxonomic resolution and taxonomic 
coverage is dictated by the specific hypervariable region(421, 422). 
 
1.5.2 Culture-Based and Culture-Independent Approaches to 
characterizing Bacterial Populations 
 
In 1881, Robert Koch invented plating techniques and culture-based 
techniques dominated microbiology for a century. Stains such as Gram, 
which utilized biochemical or physiological properties, identified microbial 
species. This method however, is biased and is limited the breadth of 
detectable bacteria to those that were favoured to proliferate in laboratory 
culture conditions, such as easily growing, aerobic bacteria like Escherichia 
Coli.  In the 1980s, the advent of DNA-based culture-independent 
techniques arose, changing the microbial landscape and allowing for the 
investigation of several aspects of microbial communities, including 
taxonomic composition and functional metagenomics(414). The earliest 
DNA-based techniques include amplifying specific genes by polymerase 
chain reaction (PCR), cloning in Escherichia Coli and then sequencing(423). 
Alternatively, fluorescent in situ hybridization (FISH) was utilized, where 
fluorescently labelled, specific oligonucleotide probes for marker genes 
were hybridized to the DNA. Since the mid-1970s, DNA sequencing 
techniques such as Sanger sequencing have been available but this method 
was observed to be too time consuming for extensive use and 
expensive(424). 
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For at least the last three decades, microbial profiling has been centered 
around the 16S rRNA gene. Environmental metagenomic research provided 
the basic resources and preceded application to the human body, when in 
1990, clone libraries of 16S rRNA genes from environmental bacteria 
(Sargasso Sea picoplankton) were amplified and sequenced using the 
Sanger technique(425, 426). In 2005, the revolutionary technology of high-
throughput (HTS) or next-generation sequencing (NGS) was announced, 
which was proven to advance the Sanger method by being more cost and 
time efficient, as bacterial genomes could be analysed in hours to days 
rather than months to years(427). Emanating from this was the introduction 
of two centrally controlled, large-dimensioned research programs – the 
Metagenomics of the Human Intestinal Tract (MetaHIT) project and the 
Human Microbiome Project (HMP). MetaHIT aimed to sequence the 
microbial genomes from faecal samples from both healthy and diseased 
individuals, while HMP characterized the diversity of the microbiota sampled 
at multiple body sites in healthy subjects(428, 429). 
 
Despite molecular approaches, including whole metagenome shotgun 
(WGS) sequencing and 16S rDNA amplicon sequencing, being able to 
provide in-depth insights into microbial composition, they appear to neglect 
the detection of low-abundant organisms. A study reported that compared to 
transmission electron microscopy and Gram stain, 16S rDNA sequencing 
underestimated counts of Gram-negative prokaryotes(414, 430). However, it 
is estimated that fewer than 20% of environmental bacteria from all 
branches of the phylogenetic tree have been discovered and are able to be 
grown in defined growth media(423). Reasons for this include bacteria 
failing to grow in conventional media due to inappropriate conditions 
including pH, temperature and acquisition of essential nutrients. In addition, 
high-abundant and fast-growing microorganisms may outcompete low-
abundant and slower growing ones(414).  
 
In recent times, NGS technologies have developed rapidly with historical 
methods, including terminal restriction fragment length polymorphism (T-
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RFLP), automated ribosomal internal transcribed spacer analysis (ARISA) 
and denaturing gradient gel electrophoresis (DGGE) being made redundant 
in favour of high-throughput NGS methods(414). These methods are 
performed on a single-molecule basis with no initial DNA amplification 
step(431). At the genomic level, there are two options for NGS-based 
sequencing of microorganisms. The first, is PCR amplification of the 16S 
rRNA or other phylogenetically conserved marker sequences with 
consequent NGS of the constructed amplicon library. Secondly, is whole 
metagenomic shotgun (WMS) sequencing of the whole genetic content. 
These techniques include extracting the genomic DNA, constructing 
appropriate sequencing libraries, NGS, bioinformatic analysis and 
comparison to dedicated reference databases(414). There are nine variable 
regions (V1-V9) in the 16S RNA gene, which are discriminating sites and 
these are essential for accurate richness assessments of microbial 
diversity(432). 
 
An attractive use of 16S rRNA gene NGS is the identification of rare 
bacteria or isolates with atypical phenotypic characteristics. The Microseq 
500 16S rRNA-based identification system was found to identify 89% 
unusual aerobic Gram-negative bacilli to the species level and 81% of 
bacteria with ambiguous biochemical profiles that are clinically 
significant(420, 433). In general, 16S rRNA sequencing identifies a higher 
percentage of species than conventional methods. Identification of slow-
growing bacteria is an additional advantage of 16S rRNA sequencing whilst 
reducing the time required to identify these bacteria, such as mycobacteria, 
which can otherwise take 6-8 weeks to grow in culture. A clinically important 
use of 16S rRNA sequencing is the identification of uncultivable bacteria, 
which is achieved through the universal presence and sequence 
conservation of the 16S rRNA gene, permitting the design of broad-range 
PCR primers(416). 
 
In order to detect subtle differences between samples or resolve rare 
species, the sequencing depth of the quantity of reads produced during 
sequencing is important. Each sequencing technology has a maximum 
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capacity of number of reads. The quantity of samples that can be analysed 
simultaneously, as well as the robustness of the data, is influenced by the 
number of sequence reads that can be undertaken. High depth of coverage 
permits the detection of more operational taxonomic units (OTUs) for 
amplicon sequencing-based techniques and for the detection of more genes 
for WMS analyses(431).  
 
There are several different NGS techniques available on the market with 
their own platform-specific error profiles. The accumulation of errors may 
produce false positive variants, overestimating species richness(414). Some 
have superior read length, accuracy or speed while other sequencing 
platforms may generate the largest total throughput per run(431). Table 7 
demonstrates a comparison of some of the NGS techniques. 
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Table 7: Comparison between NGS technologies 
Sequencing 
platform 
454 GS FLX + 
(Roche) 
MiSeq 
(Illumina) 
5500xl W 
SOLiD (Life 
Technologies) 
Ion PGM (Life 
Technologies) 
Sequencing 
methodology 
Pyrosequencing Reversible 
terminator 
Ligation Proton 
detection 
Read length 
(base pairs) 
700 2 x 250 1 x 75 Frag,  
2 x 50 MP 
100 or 200 
Run time 23 hours 27 hours 8 days 3 hours 
Reads per run ~1,000,000 
shotgun 
~700,000 
amplicon 
6.8 million 1.4 billion x 2 2-5.5 million 
Advantages Fast, read 
length 
High 
throughput 
Accuracy, low 
cost 
Fast 
Disadvantages High cost, low 
throughput, 
error rate with 
polybase more 
than 6 
Short read 
assembly, 
high cost 
Short read 
assembly, 
slower than 
other methods 
Polybase 
errors 
(Adapted from Di Bella and Liu(431, 434)). 
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1.6 Volatile Organic Compounds (VOCs) 
 
1.6.1 VOCs in Health and Disease 
VOCs are a diverse group of carbon-based chemicals, which are defined by 
their boiling point (ranging from 50°C to 260°C) and retention time(435). 
Humans emit a wide selection of VOCs from the body, which are both 
odorous and non-odorous(436). VOCs exist in the gaseous phase and may 
be retrieved from the headspace of cells in vitro, as well as being present in 
bodily fluids such as sweat, blood, urine and faeces and emitted from the 
body in exhaled breath(435, 437). It is thought that VOCs are shared by 
individuals in health with specific changes occurring in disease. As early as 
400 BC, Hippocrates identified the diagnostic value of body odours and 
reported on various disease-specific odours emanating from sputum or 
urine(436). Varying profiles of VOCs have been associated with differing 
diseases including diabetes mellitus, IBS, IBD, colorectal cancer, COPD 
and TB and therefore display a good relationship with the exposure or 
disease in question(435, 438). As a result, this and the fact VOCs can be 
sampled non-invasively and analysed by readily available and simple 
analytic techniques, renders them as attractive disease biomarkers. This is 
particularly true given that within a shorter timeframe, VOCs can accurately 
identify bacterial species compared to traditional culturing methods(439). In 
their role as biomarkers, VOCs have also been found to be highly sensitive 
and specific, fast and accurate, require simplistic interpretation and have 
been thoroughly validated(440). 
A compendium of all the VOCs emanating from the human body 
demonstrates the presence of 1840 VOCs: 381 were identified in the 
faeces, 279 in urine, 872 in breath, 532 in skin secretions, 256 in milk, 154 
in blood and 359 in saliva. Only 12 of these VOCs were found to be 
omnipresent in all bodily fluids and breath and these included acetaldehyde, 
2-propanone (acetone), benzaldehyde, 1-butanol, 2-butanone, hexanal, 
heptanal, octanal, pentanol, benzene, styrene and toluene(441). The latter 
three compounds are smoke-derived substances as well as being common 
environmental pollutants(442). Hydrocarbons represented the greatest 
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number of VOCs from bodily fluids, which is thought to result from ingestion 
of a large amount of unsaturated fatty acids in the diet that undergo 
peroxidation and chain cleavage, producing hydrocarbons such as heptane, 
pentane, octane and alkenes. The abundance of nitrogen containing 
compounds was found to be greatest in breath and least in blood. Most 
sulphur containing compounds were observed in urine, with the least in 
blood. Out of the VOCs, 225 volatile alcohols and 103 aldehydes were 
identified with the greatest abundance being present in skin secretions and 
the least in milk. In total, 102 volatile acids were identified. VOCs were 
present in certain bodily fluids and not others and this was thought to result 
from biotransformations by various organs. For example, VOCs present in 
faeces may not appear in breath due to conversion in the bloodstream by 
the liver, which may result in some compounds dropping in concentration 
below the detectable level. A compound detected in blood and not urine 
may have been transformed by the kidneys(441). 
VOCs in Gastrointestinal Disease 
The potential of VOCs playing a role in the early diagnosis of 
gastrointestinal disease is illustrated by data demonstrating faecal VOCs in 
neonates who developed necrotizing enterocolitis (NEC) having fewer 
esters compared to their healthy counterparts. These esters were then 
reported to have often ‘disappeared’ from faeces, after being present a few 
days earlier. This change arose prior to NEC being clinically recognised by 
physicians(443). Table 8 summarises some of the studies, which have 
identified key volatiles in gastrointestinal disease. 
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Table 8: VOCs in gastrointestinal disease 
Disease Study Sample 
source 
Volatile compound 
BAD Covington et al, 
Sensors, 
2013(54) 
Urine ↑ 2-propanol, acetamide 
IBD Rieder et al, Clin 
Transl 
Gastroenterol, 
2016(444) 
Ahmed I et al, 
Aliment 
Pharmacol Ther, 
2016(445) 
Hicks LC et al, J 
Crohns Colitis, 
2015(446) 
Breath 
 
 
Faecal 
 
Breath 
↑ 1-octene, 3-methylhexane, 1-decene 
↓ 1-nonene, 2-nonene, hydrogen sulfide 
 
 
 
↑ Heptanal, 1-octen-3-ol, 2-piperidinone, 6-methyl-
2-heptanone 
↓ methanethiol, 3-methyl-phenol 
 
 
↑ dimethyl sulphide, hydrogen sulphide, hydrogen 
cyanide, ammonia, butanal,  
nonanal 
IBS-D Ahmed I et al, 
PLoS One, 
2013(447) 
Faecal ↑ cyclohexanecarboxylic acid  
 
Coeliac disease Arasaradnam 
RP et al, PLoS 
One, 2014(448) 
Urine ↑ 1,3,5,7 cyclooctatetraene 
Hepatic 
encephalopathy 
Goldberg EM et 
al, J 
Chromatogr, 
1981(449) 
Blood ↑ 3-Methylbutanol  
 
Liver Cirrhosis 
 
Advanced fibrosis 
in chronic liver 
disease 
Fernández Del 
Río R et al, 
EBioMedicine, 
2015(450) 
Alkhouri N et al, 
Clin Transl 
Gastroenterol, 
2015(451) 
Breath 
 
 
Breath 
↑ Limonene, methanol, 2-pentanone 
 
 
↑ Isoprene 
Table summarizing key volatiles in gastrointestinal disease. 
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Fermentation of nonstarch polysaccharides by gut microbiota produces an 
odorous gas composed of various VOCs(238). This is illustrated by a study 
demonstrating the ability of dogs in correctly identifying the ‘smell’ of stool 
samples infected with Clostridium difficile(452). Analysis of faecal VOCs 
from neonates observed fewer VOCs being present in premature neonates 
compared to healthy adults, with a very low frequency of nitrogen 
compounds, and barely any sulphides detected at all in the neonatal 
faeces(453). This reveals the simplicity of neonatal gut microbiota compared 
to that found in adults as most VOCs are produced by fermentation of 
dietary substrates by the indigenous gut flora. Volatiles such as ammonia 
and methanethiol are presumed to derive from methionine by Clostridium 
sporogenes and methanethiol is known to be damaging to colonic 
epithelium(454, 455). 
Mechanisms of VOC Profiles in Disease 
The underlying mechanism of the VOC profiles observed in disease states 
remains unclear. Quorum sensing, where bacterial cells communicate with 
each other via diffusible molecules such as VOCs, is regarded as a possible 
mechanism in regulating bacterial balance(238, 456). It is hypothesized that 
VOCs reflect microbial metabolic activity and are a surrogate marker for 
intestinal dysbiosis in disease(360). The resultant VOC profile is evident in 
urine secondary to altered gut permeability observed in disease(438). As a 
consequence of disease, pathological processes may either produce new 
VOCs that are not produced under normal physiological circumstances or 
that there is an alteration in the concentration of the individual VOCs 
present(435). There is data that shows a reduced range of VOCs in 
disease, in particular patients with ulcerative colitis, Campylobacter jejuni 
and Clostridium difficile. This study hypothesized that this was secondary to 
a relatively lower abundance of other intestinal microbes given the 
abundance of Campylobacter jejuni and Clostridium difficile in the gut. This 
diminished biodiversity in bacteria was thought to account for the reduced 
number of secondary metabolites. It was also thought that the increased 
transit time observed in these patients with diarrhoeal conditions meant that 
fewer compounds would be synthesized(457). 
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In inflammatory processes, VOCs are often compounds manufactured 
during processes induced by excessive reactive oxygen species (ROS) 
production such as lipid peroxidation(440). Inflammation has been 
associated with nitric oxide, nitrate, nitrogen- and sulphur- containing 
VOCs(458). Volatiles generated during lipid peroxidation include pentane, 
ethane, hexanal, octanal, nonanal, propanol and butanol(459). Oxidative 
stress is associated with the pathophysiology of IBD and arises from either 
an overproduction of ROS or an impairment of the endogenous antioxidant 
defense system(281). VOCs found in infection are not only derived from the 
bacteria but are also often related to metabolic processes occurring in the 
infectious organism as all organisms produce VOCs in their role of 
metabolism(460). Certain infections bear a distinct smell in vivo and in 
vitro(440).  
 
1.6.2 Urinary VOCs 
From a chemical perspective, urine is a complex medium, owing to its high 
number of constituents(461). Its composition is significantly variable and 
depends on various factors including age, gender, hormonal status, physical 
activity, food habits and presence of specific pathologies(462-465). 
 
In our experience, urine is the most ‘user-friendly’ of biological samples for 
patients and clinicans alike in analysing VOCs, compared to faeces, breath 
and blood. Although breath analysis is another attractive non-invasive 
option, it is hindered by the difficulty in detecting and quantifying very small 
amounts of gases/VOCs in the presence of atmospheric gases, which 
frequently exist in larger molecular weights and quantities. In addition, 
inhaled particles in breath arise from varying sources and compete with 
metabolites from oral microbes. Inhaled VOCs may also be degraded 
endogenously, modifying the ratio between inhaled and exhaled gas 
concentrations(466).  
 
The compounds in urine are intermediate or end products of various 
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metabolic pathways, with some of the substances, including alcohol, ketone, 
pyrrole, furan and sulphide, producing characteristic urine odours(436). 
Urinary VOC profiles are not only affected by disease, but also by ingestion 
of foods, with asparagus giving rise to a sulphurous odour(467). 
 
Urinary volatiles encompass a range of molecular classes including 
alcohols, acids, ketones, aldehydes, amines, N-heterocycles, O-
heterocycles, sulphur compounds, hydrocarbons with an insignificant 
number of esters being described. A significant number of terpenes, which 
are derived from foods, have been reported(461). A review of urinary VOCs 
in elderly, generally well men demonstrated five compounds that were 
present, irrespective of the urine pH - acetone, methylene chloride, 4-
heptanone, 2-pentanone and 2-butanone(468). The large quantity of 
ketones seen in urine is likely to arise from decarboxylation from 
corresponding oxo-acids by intestinal bacteria(461). During periods of rapid 
fat oxidation, acetoacetate, hydroxybutyrate and propanone are 
manufactured in the liver, when the rate of fat breakdown surpasses the 
capacity of the Krebs cycle to process the ensuing acetylCoA(469).  
Despite being able to identify specific classes of urinary volatiles, there is a 
paucity of data quantifying their specific measurements in urine. Varying 
levels of significant ketone bodies, propanone (acetone) and acetoacetate, 
at 1.16–14 mmol L-1 and 1.3–15 mmol L-1 respectively, have been 
observed(470). Increasing protein intake has been observed to increase 
concentrations of p-cresol (typically 52 mg day-1 excreted in urine) and 
phenol (typically 10 mg day-1 excreted in urine). These compounds are 
thought to originate from intestinal microbial action on tyrosine with aerobic 
bacteria in the ileum/caecum producing p-cresol and in the left colon, 
anaerobic bacteria producing phenol. With the addition of a high fibre diet to 
ingestion of high protein, the resulting decreased transit time causes a 
smaller increase in these compounds(471).   
 
With regards to urinary volatile short chain fatty acids (and semi volatile 
acids), the greatest concentrations are as follows: hippuric > glycolic > 
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benzoic > ethanoic > 2-ketoglutaric > 2- hydroxyisovaleric > lactic, 2-
hydroxyisobutyric > oxaloacetic > pyruvic acids, with isobutyric, propionic, 
butyric and 2- methylbutyric acids in minor concentrations(472).   
Our research group have demonstrated that total gas/vapour emissions 
from urine samples reduced over time with loss of chemical signal, as the 
samples aged. In the initial nine months of storage, there was less variation 
with greater stability and uniformity of concentrations of VOCs together with 
tighter clustering of the quantity of chemicals released. As equilibrium is 
reached between the urine and airspace in the storage container, all 
vapours and gases will emanate from a sample over time. Potential reasons 
for loss of chemical signal as urine samples age include water in the urine 
evaporating over time with the consequent release of water-soluble 
volatiles, bacterial activity in very old samples causing a higher chemical 
output and the plastic from the standard specimen storage bottles absorbing 
volatiles over time. As a result, we proposed that nine months could be 
considered a general reference to the shelf-life of a urine sample(473). This 
is demonstrated in the two graphs (figure 3) below showing (a) a change in 
total number of urinary VOCs over time and (b) chemical diversity of urinary 
VOCs over time. 
 
Figure 3a: Change in total number of urinary VOCs over time (from 
December 2009 to May 2014)(473). 
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Figure 3b: Chemical diversity of urinary VOCs over time (from 
December 2009 to May 2014), with linear fit to emphasise output 
change(473). 
 
 
 
1.6.3 VOCs in IBS and BAD  
There is a significant lack of data, investigating the use of VOCs as 
biomarkers in IBS and BAD. To date, there are only three IBS studies and 
one BAD study, the latter being undertaken by our research group. The 
studies are outlined in table 9. 
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Table 9: VOC studies in IBS and BAD 
Study Diseas
e 
Sampl
e 
Analytical 
Method 
VOCs identified 
Ahmed I, et 
al. PLoS 
One, 
2013(447) 
IBS-D 
CD 
UC 
HC 
Faecal GC-MS IBS-D: esters of short 
chain fatty acids, 
cyclohexanecarboxyli
c acid and its ester 
derivatives . 
IBD: aldehydes 
Baranska A, 
et al. Aliment 
Pharmacol 
Ther, 
2016(474) 
IBS 
HC 
Breath Thermal 
desorption-gas 
chromatograph
y combined 
with time-of-
flight mass 
spectrometry  
 
IBS: n-Hexane; 1,4-
Cyclohexadiene, n-
Heptane, Aziridine 
(Ethylenimine) 
 
Arasaradna
m RP, et al. 
PLoS One, 
2014(448) 
IBS-D 
Coeliac 
disease 
Urine FAIMS and  
GC-MS 
Coeliac: 1,3,5,7 
Cyclooctatetraene 
(not found in IBS-D) 
 
Covington 
JA, et al. 
Sensors, 
2013(54) 
BAD 
UC 
HC 
Urine AlphaMOS Fox 
4000 electronic 
nose, FAIMS 
and GC-MS 
BAD: 2-propanol and 
acetamide (much 
reduced or not 
present in UC/HC 
groups) 
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1.6.4 Analytical Techniques used in the Study of VOCs 
Only recently, has there been an explosion in an interest in the analysis of 
VOCs for medical purposes. Analyses of VOCs have already been 
established and are routinely used in the assessment of forensic science, 
cosmetics, environmental contamination and the fragrance and flavor 
industries(475).  
 
A single analytical method may not be suitable for measuring VOCs from 
various bodily fluids and breath and it is usual practice for researchers to 
utilize equipment that is available to them. Not all reported VOCs may be 
endogenous in origin and some may arise from artifacts including oxidation 
or degradation and contamination, which may result during the collection, 
storage or measurement of samples(441).  
 
GCMS 
There are several analytic methods, which may be used to detect VOCs 
with gas chromatography mass spectrometry (GCMS) being the main 
technique employed. Compound identification of VOCs using GCMS may 
be inaccurate as spectral library matches on their own are often used to 
identify peaks, which may be misleading for isomers. The compound may 
not also be present in the MS libraries or there may be mass spectral 
similarities, predominantly with hydrocarbons and isomers, resulting in 
misidentification of the VOC(441). More recently, the addition of retention 
time matching to library matching has been applied and this ‘double check’ 
allows for increased accuracy in identifying VOCs(441). In direct mass 
spectrometric methodologies, the recorded spectrum reflects the 
composition of the total sample, as there is no separation of sample 
components prior to ionization. This may cause some ambiguity, as the 
fragmentation pattern of ions of particular mass-to-charge ratio needs to be 
considered when being assigned to certain substances(441).  
 
FAIMS 
Field asymmetric ion mobility spectroscopy (FAIMS) is an instrument, which 
separates ionised gas molecules at room temperature and atmospheric 
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pressure. Separation of gas/vapour molecules in the ionised samples 
produces an asymmetric waveform. This is achieved by the sample being 
inserted between two metal plates, where an asynchronous high-voltage 
waveform has been applied, causing some ions to remain between the 
plates and others to drift and hit the plates. A complex composition of gases 
can be separated by their differences in mobility in high electric fields by 
applying a range of dispersion and compensation voltages(456).  
 
Electronic Nose 
The electronic nose is a term used to identify a method rather than specific 
analytical technology. These instruments emulate the human olfactory 
system in identifying patterns in a collection of non-specific sensors, rather 
than detecting individual chemical components. An array of 8-32 differing 
chemical sensors form a conventional electronic nose, which broadly detect 
various chemical groups including ketones, alcohols and low pressure 
gases(466). An electronic nose generally consists of three different systems 
– sample delivery, detection and data computing(465). The ‘headspace’ (air 
above the biological sample) is injected into the electronic nose, resulting in 
a unique response from each sensor within the array(466). The profile of 
sensor responses is used to produce a ‘fingerprint’ of an aroma(456). The 
most commonly used sensors are polymeric, metal-oxide and quartz 
microbalance sensors(465). It is possible to teach the device to recognise a 
variety of different conditions by extracting a feature of the sensor response 
(e.g. the maximum change) and employing a pattern recognition engine. 
Therefore, when the device is delivered a sample from the same disease 
group, the sensors are able to repeat the response pattern, allowing for 
identification of the disease(465, 466). Multivariate statistical analysis is 
used to process the data, the most common being linear discriminant 
analysis (LDA) and principal component analysis (PCA). LDA aims to 
accomplish maximum separation of data groups and dimensional reduction 
before future classification by presenting an algorithm, which identifies a 
linear combination of features characterizing or separating two or more 
events or objects. PCA maintains the main information present in the 
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original data by aiming to visualize the data within a low dimensional 
space(465).  
 
Table 10 describes the advantages and disadvantages of some of the 
modalities used to analyse VOCs in clinical practice. 
 
Table 10: Analytical techniques in VOC studies 
Technique Electronic nose GCMS FAIMS 
Breadth of 
analysis 
Medium High High!
Sensitivity High Very high (pre-
concentration 
required) 
High!
Specificity Medium Very high High!
Accuracy High High High!
Speed Real-time Off-line Real-time 
User skill level Low High High 
Consumable 
cost per item 
Low Medium Low 
Maintenance Low High Medium 
Sample cost Low Medium Low 
Estimated cost 
(£) 
<40,000 >150,000 <50,000 
(Adapted from Arasaradnam RP et al, Review article: next generation diagnostic modalities 
in gastroenterology - gas phase volatile compound biomarker detection. Aliment Pharmacol 
Ther. 2014)(466) 
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2.1 Introduction and Aims 
 
2.1.1 Introduction 
 
The human intestinal microbiota is responsible in regulating gut 
homeostasis and has become the focus of extensive interest in recent years 
due to its implied role in precipitating host disease. The complexity of this 
massive and diverse community, harbouring approximately 1014 
microorganisms of 500 to 1000 bacterial species, remains poorly 
understood(18).  
The gut microbiota maintains intestinal homeostasis, both directly and 
indirectly via bile acid receptors and bile acid signalling. Primary bile acids 
(cholic acid – CA; chenodeoxycholic acid - CDCA) undergo 
biotransformation through a series of reactions by the gut microbiota to form 
secondary bile acids (deoxychenocholic acid – DCA, lithocholic acid - LCA). 
These reactions include deconjugation (removal of the amino acid side 
chain), epimerization (of 3-, 7-, and 12-hydroxy groups), oxidation (removal 
of H), dehydroxylation (replacement of a hydroxyl group with a hydrogen), 
and hydroxylation (replacement of a hydrogen with a hydroxyl group)(17). 
The resulting bile acid metabolites act as signaling molecules via the TGR5 
(G protein coupled bile acid receptor) and farnesoid X receptor (FXR) to 
inhibit inflammation, prevent pathogen invasion and maintain the integrity of 
the gut epithelial barrier(360).  
In bile acid diarrhoea, interruption of the normal enterohepatic recirculation 
of the recycling of bile acids ensues in an excess of bile acids entering the 
colon. This is significant as only certain microbial populations, which are 
able to tolerate normal physiological concentrations of bile acids in the 
intestine, are able to survive. The amphipathic nature of bile acids which 
allows them to act as detergents of dietary fats also enables them to interact 
with bacterial lipid membranes, conferring them with potent antimicrobial 
abilities in breaching the integrity of the cell membrane, resulting in leakage 
of cellular components and apoptosis(17, 377). The concept of dysbiosis of 
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pathological imbalances occurring in gut bacterial colonies has been used to 
explain the initiation and outcome of disease in the host. Modification of bile 
acid hormones is influenced primarily by the intestinal microbiota and may 
perturb regulatory FXR-mediated signalling, resulting in impaired intestinal 
homeostasis(476).  
Irritable bowel syndrome (IBS) is the most common functional 
gastrointestinal disorder with a prevalence of 10-25% in developed 
countries and despite its clinical significance, the underlying 
pathophysiology of this debilitating condition remains ambiguous(158). Bile 
acid diarrhoea (BAD) is commonly overlooked in the differential diagnosis of 
chronic diarrhoea and has been demonstrated in excess of a quarter of 
patients who were previously diagnosed with IBS-D(39).  
 
Although the aetiology of IBS is multifactorial, the impact of the gut 
microbiota has generated much attention. Changes observed in the faecal 
microbiota composition, the presence of abnormal colonic fermentation with 
increased hydrogen colonic gas production, improvement of symptoms with 
antibiotic therapy, and an increased incidence of IBS after gastrointestinal 
infections imply a role for gut microbiota in IBS as acute enteritis is 
associated with an increase in mucosal cytotoxic T lymphocytes and an 
increase in enteroendocrine hypersensitivity which will impact the gut 
microbiota environment(129, 387, 477). Production of the pro-inflammatory 
cytokines including TNF-alpha, IL- 1, and IL-6 causing an augmented 
cellular immune response as well as significantly elevated levels of human 
beta-defensin-2 (expression induced by pro-inflammatory cytokines and 
probiotic microorganisms) detected in patients with IBS further supports the 
pathological role of gut microbiota(394, 478). The hypothetical association 
of dysbiosis in IBS and balancing of the gut microbiota is suggested by the 
improvement in symptoms observed with probiotic therapy using 
Lactobacillus plantarum 299V, or the VSL3 capsule (mixture of lactobacilli 
and bifidobacteria)(225, 391, 392). Despite numerous studies profiling the 
gut microbiome in IBS, no research has been similarly undertaken in 
patients with BAD. 
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2.1.2 Aims 
This study is the first to investigate the faecal microbiome in patients with 
BAD. The aim of this study was to compare the faecal bacterial composition 
in patients with IBS and BAD using 16S rRNA gene sequencing. 
 
2.2 Materials and Methods 
 
2.2.1 Recruitment and Sample Collection 
 
Ethical Approval 
Patients were recruited as part of the FAMISHED (Food and Fermentation 
using Metagenomics in Health and Disease) study. Scientific and ethical 
approval was acquired from the local Research and Development Office as 
well as Warwickshire Ethical committee ref: 09/H1211/38. Written informed 
consent was obtained from all participants in the study.  
 
Study Participants 
Patients from the Nuclear Medicine department at University Hospitals 
Coventry and Warwickshire (UHCW NHS Trust) were recruited from April 
2012 to May 2015 after being referred for a SeHCAT scan via attending a 
gastroenterology clinic with chronic diarrhoea. 14 patients with Rome III 
criteria IBS-D and 20 patients with BAD in total participated in the study.  
Demographic and clinical data including age, gender, ethnicity, BMI, C-
reactive protein (CRP – marker of inflammation) and faecal calprotectin 
levels (a measurement of the protein calprotectin in the stool, which is 
elevated during intestinal inflammation therefore used to ensure patients 
with IBD are in remission) for patients with type 1 BAD and co-existing IBD, 
SeHCAT result, severity and type of BAD were collected. 
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Sample Collection 
Stool samples were collected in standard specimen collection bottles in the 
nuclear medicine department and stored at -80oC within two hours of 
collection. They were transferred to the University of Warwick on dry ice  (-
78oC) within a polybox and then stored at -80oC. The samples were then 
thawed on ice for 45 minutes prior to DNA extraction. 
 
Inclusion and Exclusion Criteria 
To be included in this cross-sectional study, both male and female 
participants were required to meet the following criteria: (1) have chronic 
diarrhoea, (2) diagnosis of BAD based on a SeHCAT retention value of 
≤15% (3) patients with IBD (inflammatory bowel disease) may only be 
included if type 1 BAD is present, (4) patients who have had a previous 
cholecystectomy may only be included if type 3 BAD is present. 
 
Participants were excluded from the study if they suffered from coeliac 
disease, IBD (if type 1 BAD is not present), active IBD (defined as FCP >50 
mg/kg stool or CRP >11 mg/L at the time of the SeHCAT scan), colorectal 
cancer or had been on antibiotics/probiotics in the last three months. 
 
2.2.2 DNA Extraction, Quantification, PCR and Purification 
 
(i) Isolation of DNA from stool samples using QIAamp Fast DNA Stool 
Extraction kit (Qiagen, UK) 
1 mm glass beads were inserted into the bottom of a 2 ml microcentrifuge 
tube and 200mg of stool was weighed out into the tube. To help the lysis of 
cells, 0.2g of 100-300 µM acid washed glass beads (Sigma-Aldrich, Poole, 
UK) were added followed by disruption with 2 x 30 sec pulses at 6.2 m/s in a 
FastPrep FP120 machine. 1 ml InhibitEX buffer was added to the stool 
sample and then vortexed for 1 minute until the stool sample was thoroughly 
homogenized. The purpose of the InhibitEX buffer is to bind potential PCR 
inhibitors in the sample.  
 
! 114!
The suspension was heated for 5 minutes at 70°C, vortexed for 15 seconds 
and then centrifuged for 1 minute at 13,000 rpm to pellet stool particles. 15 
µl of Proteinase K was pipetted into a new 1.5 ml microcentrifuge tube. 
200µl of the centrifuged sample was added to the tube containing 
Proteinase K. 200 µl of buffer AL was then added and the tube was 
vortexed for 15 seconds. Proteinase K degrades and digests proteins in the 
sample and buffer AL is a lysis buffer.  
 
The tube was incubated at 95°C for 10 minutes, 200 µl of 100% ethanol was 
added to the lysate and mixed by vortexing. 600 µl of lysate was applied to 
the QIAamp spin column and then centrifuged at 13,000 rpm for 1 minute. 
The QIAamp spin column was then placed in a new 2 ml collection tube and 
the collection tube containing the filtrate was discarded. 500 µl of buffer 
AW1 was added to the QIAamp spin column and then centrifuged at 13,000 
rpm for 1 minute. The QIAamp spin column was then placed in a new 2 ml 
collection tube and the collection tube containing the filtrate was discarded. 
500 µl of buffer AW2 was added to the QIAamp spin column and then 
centrifuged at 13,000 rpm for 3 minutes. The QIAamp spin column was then 
placed in a new 2 ml collection tube and the collection tube containing the 
filtrate was discarded. The QIAamp spin column was then centrifuged at 
13,000 rpm for another 3 minutes to remove any residual buffer. AW1 buffer 
contains an increased proportion of ethanol to improve the pH conditions 
and remove excess salt. AW2 is a lengthier spin to remove digested 
proteins or other impurities. The QIAamp spin column was transferred into a 
new 1.5 ml microcentrifuge tube. 200 µl of Buffer ATE was pipetted directly 
onto the QIAamp membrane. It was then incubated for 1 minute at room 
temperature and centrifuged at 13,000 rpm for 1 minute to elute DNA. 
Eluted DNA was stored at -20 oC until required.  
 
(ii) DNA Quantification 
The eluted DNA was quantified using the broad-range Qubit kit. A working 
solution was prepared by diluting Qubit dsDNA reagent (Life technologies, 
USA) 1:200 with dsDNA buffer. 190 µl of working solution for standards and 
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198 µl for samples were added to 0.5 ml tubes. 10 µl of Qubit standard was 
added to the standard tubes and 2 µl of sample was added to the sample 
tubes. The tubes were mixed by vortexing for three seconds and then 
incubated at room temperature in the dark for two minutes prior to 
quantification on the fluorometer and the concentrations recorded. 
(iii) Polymerase Chain Reaction (PCR) 
To amplify genes for coding and sequencing, PCR was used. All designed 
primer pairs were manufactured by Life Technologies and had similar 
melting temperatures (Tm). The primer sequences are outlined in table 11. 
V3-V4 primers and extensor ready mix (Thermo scientific) were used to 
amplify the 16s rRNA gene v3-v4 fragment from isolated metagenomic DNA 
using the following PCR thermal cycler program: 
• 95°C for 3 minutes 
• 25 cycles of: 
o 95°C for 30 seconds 
o 55°C for 30 seconds 
o 72°C for 30 seconds 
• 72°C for 5 minutes 
• Hold at 4°C 
 
Table 11: Primer sequences that were used in this study Region! Primer!Sequence!5’:3’!V3F! TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNG
GCWGCAG  V4R! GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVG
GGTATCTAATCC !
 
(iv) Analysis of DNA by Agarose Gel Electrophoresis 
After PCR, the DNA samples were analysed by electrophoresis on 1% 
agarose gels (figure 4). Agarose was dissolved in the working stock of TAE 
buffer and then melted in a microwave. 5 µl of SYBR safe (Life 
Technologies) was added to 50ml melted agarose once it had cooled 
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sufficiently. The agarose was then poured into a plastic cast and wells were 
created by inserting a plastic comb, which was removed once the agarose 
gel had set. The gel was then inserted into an electrophoresis tank with 
further TAE buffer added to ensure the level was high enough to cover the 
gel. Loading dye was added to each sample at a ratio of 5:1 and run at 100 
volts for 40 minutes. On all gels, Hyperladder 1 kb (Bioline, UK) was utilized 
as the DNA ladder. The gel was then transferred to a BioRad gel-doc 
system to visualize the DNA. 
Figure 4: Gel electrophoresis of the BAD samples - DNA bands 
separated on a gel with the length of the DNA fragments being compared to 
the DNA ladder (marker on far left – Hyperladder 1kb) containing fragments 
of known lengths. 
 
 
TAE Buffer 
This buffer was prepared as a 50 x stock solution and diluted to 1 x with 
distilled water for the working solution. The stock solution was made up of 
242 g Tris base, 57.1 ml glacial acetic acid and 100 ml 0.5 M EDTA (pH 8.0) 
for one litre. 
 
(v) Post-PCR DNA Purification 
After checking for DNA by gel electrophoresis, the samples were then 
purified. After PCR, 22.5 µl of dH2O was added to 22.5 µl of the post-PCR 
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product. 72 µl of AMPure beads were then added and mixed by pipetting up 
and down 10 times before incubating for 10 minutes at room temperature. A 
magnetic rack was used to pellet the beads against the side of the low-
binding microfuge tube and the supernatant was then removed. 200 µl of 
80% ethanol was then used to wash the beads twice and then the beads 
were air dried for 10 minutes at room temperature. The beads were 
resuspended in 20 µl of elution buffer and then placed on the magnetic rack 
to pellet the beads against the side of the low-binding microfuge tube with 
the supernatant being removed. Purified DNA was stored at -20oC until 
required. 
 
(vi) DNA Sequencing: Illumina 16S rRNA gene sequencing library 
preparation   
PCR products were diluted to 4nM and pooled in equimolar amounts. 
To denature the DNA, 5 µl of the library pool was added to 5 µl of 0.2 N 
NaOH, which was, then vortexed and centrifuged at 300 rpm for 1 minute. 
The denatured pool was then incubated for 5 minutes at room temperature 
before 990 µl of chilled HT1 buffer was added. This was then vortexed and 
centrifuged at 300 rpm for 30 seconds before 360 µl of the mixture was 
added to 240 µl of chilled HT1 buffer in a new tube to make up a 
concentration of 12pM. The denatured DNA pool was then sequenced on a 
MiSeq using the Illumina Miseq V2 2x300 bp paired end protocol. 
 
2.2.3 Statistical and Bioinformatic Analysis 
 
Demographic data are presented as means and standard deviations (SD). 
Default Illumina software trimmed sequences to remove adapter sequences, 
primers, barcodes and low-quality reads. Sequences with less than 1000 
reads were removed. Using a custom java program, formation of contigs 
was performed by joining together forward and reverse reads with a quality-
filtering step to remove contigs that had more than three mismatches. The 
contigs were de-replicated and then clustered at 97% identity to form OTUs 
using the UPARSE pipeline. Singleton contigs from the dataset were 
discarded and chimeras were removed. The UPARSE pipeline calculated 
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the abundance of each OTU by mapping the de-replicated contigs against 
the OTUs sequences. Taxonomy was assigned to 16s RNA gene OTU 
sequences using QIIME (Quantitative Insights into Microbial Ecology) and 
the RDP classifier. 
 
Using the QIIME pipeline, the level of alpha diversity in our samples was 
determined by generation of rarefied OTU tables, computing measures of 
alpha diversity for each rarefied OTU table, collating the rarified OTU tables 
and then generating rarefaction curves. The depth of rarefaction was 
defined by either the lowest number or median number of sequences 
assigned to a sample within a group that was analysed. The Shannon index 
was used to calculate alpha diversity indexes from rarefied samples. 
 
QIIME calculated beta diversity using weighted and unweighted UniFrac. 
Rarefaction was performed on OTU tables to remove sample heterogeneity. 
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2.3 Results 
 
Demographic Data 
 
Demographics of the 34 patients are seen in the Table 12.  
 
Table 12: Demographic data of the study participants 
 BAD (n=20) IBS (n=14) 
Age (years) 56.9 ± 12.4 45.3 ± 15.6 
Gender 12/20 (60%) F 
8/20 (40%) M 
8/14 (57.1%) F 
6/14 (42.9%) M 
Ethnicity 18/20 (90%) Caucasian 
 
2/20 (10%) Indian 
12/14 (85.7%) 
Caucasian 
2/14 (14.3%) Indian 
BMI  28.7 ± 6.5 27.8 ± 5.6 
SeHCAT value (%) 6.9 ± 0.04 33.6% ± 0.2 
Severity of BAD 3/20 (15%) Mild 
8/20 (40%) Moderate 
9/20 (45%) Severe 
N/A 
Type of BAD 3/20 (15%) Type 1 
14/20 (70%) Type 2 
3/20 (15%) Type 3 
N/A 
• 26 of the 34 patients (15 with BAD and 11 with IBS) had a body mass index (BMI) 
recorded.  
• Results expressed as mean ±SD. 
 
The BAD cohort of patients (12 female and 8 male) aged 28 to 79 years had 
a mean BMI of 28.7, defining them as being overweight. The mean SeHCAT 
value was 6.9%, which is consistent with moderate BAD. Of the 20 patients, 
3 (15%) had mild, 8 (40%) had moderate and 9 (45%) had severe severity 
of disease respectively. Most (14 – 70%) patients had type 2 BAD, 3 (15%) 
patients had type 1 and 3 (15%) had type 3 BAD. 
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The IBS cohort of patients (8 female and 6 male) aged 20 to 77 years had a 
mean BMI of 27.8, defining them as being overweight. The mean SeHCAT 
value was 33.6%, which excluded them from having BAD. 
 
OTUs 
 
Of the samples collected, 668 OTUs were identified. There was significant 
difference in the diversity of the OTU in BAD vs IBS patients (p = 0.007216). 
This is demonstrated in the rarefaction curve (Figure 5a) and Shannon’s 
diversity box plot (Figure 5b) seen below, where BAD patients are observed 
to have reduced diversity compared to IBS patients. The overall variation 
observed in the bacterial communities in BAD and IBS patients is 8%. The 
heatmap plot and dendogram linkages (Figure 6) seen below depicts the 
relative abundance of each bacterial family in the samples (variables 
clustering on the Y-axis) within each OTU (X-axis clustering). There were 
significant differences in the abundances of 10 OTUs, but this was not 
robust to adjusted p values. Of these 10 OTUs, 6 OTUs (OTUs 283, 17, 
268, 127, 319 and 553) were more abundant in patients with BAD vs IBS 
and 4 OTUs (OTUs 136, 519, 72 and 356) were more abundant in IBS vs 
BAD. These are outlined in Table 13 and plotted as box plots in Figure 7, 
which demonstrate the relative abundance of each OTU in patients with 
BAD vs IBS. 
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Figure 5: (a) Rarefaction curve (b) Shannon’s diversity box plot. 
(a) 
!!(b)!
     
Both demonstrate reduced bacterial diversity in patients with BAD vs IBS. 
(a) Rarefaction analysis is a calculation of species richness for the limited number of 
samples analysed. The growth of the curve is rapid at first as the most common species 
are identified but then plateaus once the rarest species remain to be found. 
(b) The box plot compares bacterial diversity at the rarefied level. 
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Figure 6: Heatmap plot 
 
Heatmap plot depicting bacterial diversity and relative abundance of OTUs in the samples 
collected by colour intensity with the legend indicated at the top left of the figure. For each 
sample, the plot describes the relative abundance of each taxonomic class and aids in 
determining which samples have similar phylogenetic profiles. 
 
Table 13: OTUs whose abundance is significantly higher in BAD (light 
grey) or IBS (white). 
OTU BAD_mean IBS_mean p pa Bacteria (family) 
136 1.978952 e-02 4.046352 e-03 0.001348043 0.1986392 Lachnospiracheae 
283 6.588814 e-04 4.547205 e-05 0.001348043 0.1986392 Bifidobacteriaceae 
17 7.387914 e-02 1.247412 e-05 0.002183045 0.1986392 Prevotellaceae 
268 2.048619 e-04 0.000000 e+00 0.002979467 0.1986392 Lachnospiracheae 
519 2.375111 e-04 5.384334 e-06 0.003470017 0.1986392 Ruminococcaceae 
72 1.504455 e-02 8.195882 e-04 0.004033018 0.1986392 Bacteroidaceae 
127 1.620633 e-02 0.000000 e+00 0.004677735 0.1986392 Prevotellaceae 
356 3.626509 e-04 5.384334 e-06 0.004677735 0.1986392 Ruminococcaceae 
319 1.859629 e-04 0.000000 e+00 0.007209571 0.1986392 Verrucomicrobiaceae 
553 7.954283 e-05 0.000000 e+00 0.008293898 0.1986392 Bacteroidaceae 
This table demonstrates the mean (BAD and IBS) log values of specific OTUs that were 
found to have significant differences in abundance in BAD and IBS. p values denote 
significance levels; pa values denote corrected significance levels. 
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Figure 7: Box plots demonstrating the relative abundance of each OTU 
in patients with BAD vs IBS-D. 
 
The box plots demonstrate the median values and interquartile ranges for 
each OTU. 
 
2.4 Discussion 
 
These results demonstrated that there were significant differences in the 
intestinal milieu of bacterial species in patients with IBS and BAD. Six OTUs 
were observed to be more abundant in patients with BAD compared to 
those with IBS. Bacterial diversity was significantly reduced in patients with 
BAD compared to those with IBS, despite the abundance of various 
anaerobic taxa, including Bifidobacteria, Prevotella, Lachnospiraceae, 
Verrucomicrobia and Bacteroides. The presences of Prevotella and 
Ruminococcus taxa have previously been shown to be indigenous members 
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of a healthy intestinal microbiome, whereas this data contradicts this finding 
as both taxa were observed in abundance in those with BAD and IBS, 
respectively(341). The occurrence of reduced bacterial diversity, parallels 
that of patients with inflammatory bowel disease  (IBD), where a loss of 
normal anaerobic bacteria such as Bacteroides, Lactobacillus and 
Eubacterium species has been observed(479). Using PCR and culture 
based techniques, the intestinal microbiome in IBS patients has also 
demonstrated an increased aerobe to anaerobe ratio with decreased 
numbers of Bifidobacteria and Lactobacilli(409, 480, 481). This study data 
resembles this observation with Bifidobacteria being found to be more 
prevalent in BAD, rather than in IBS.  
 
Ruminococcus lies within the Firmicutes phyla and the greater abundance 
of this genera demonstrated in patients with IBS rather than in BAD 
contradicts animal data, which demonstrated that rats who were fed a diet 
containing cholic acid, resulted in an increase in the Firmicutes proportion of 
the intestinal microbiota from 54% to 95% - specifically, an increase in 
Ruminococcus was noted(377). Ruminococcus is a 7a-dehydroxylating 
bacteria and is capable of converting CA to DCA, which has greater 
antimicrobial properties compared to CA(482). Consequently, we 
hypothesize that an increased proportion of primary bile acids (CA) in the 
bile acid pool will result in reduced bacterial diversity. Our findings may have 
occurred due to a shift in the bile acid pool from unexpected reduced 
amounts of Ruminococcus, resulting in a disproportionate increase in cholic 
acid, which is less bactericidal, allowing for the greater survival and 
outgrowth of other microbes, which all compete for nutritional resources. 
Therefore, there would not be a selective enrichment of the 
Ruminococcaceae bacteria in this environment. This hypothesis is 
supported by a study conducted in liver cirrhosis, which demonstrated a 
reduced bile acid pool with decreased conversion of primary to secondary 
bile acids being associated with decreased intestinal bacterial diversity. With 
increasing disease severity, a reduction in Ruminococcacaea was also 
observed with a positive correlation between this taxa and DCA/CA ratio 
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(r=0.82).  Dysbiosis was evident with an expansion in pathogenic, pro-
inflammatory taxa(483).  
 
The dysbiosis observed in this study may have resulted in disease through 
modified bile acid metabolism - a theory reinforced in IBD patients where 
intestinal dysbiosis was associated with bile acid dysmetabolism. In this 
study, a decrease in secondary bile acids and an increase in the sulphated 
form, which in vivo, had the potential to induce the production of pro-
inflammatory cytokines by colonic epithelia was demonstrated. Interestingly, 
despite the reduction in secondary BA concentrations, the overall BA pool 
size was maintained with normal overall total BA levels. This decrease was 
thought to arise from impaired intestinal metabolism of BAs by the gut 
microbiota. This hypothesis was strengthened by the observation of germ-
free mice exhibiting undetectable levels of secondary BAs and a higher 
proportion of conjugated and sulphated BAs, compared to conventional 
mice, illustrating the role of microbiota enzymatic activity(374). Gut bacteria, 
including Bacteroides (which were found to be abundant in our BAD 
patients) and Clostridium, are known to support sulphatase activity(484, 
485), which may have further contributed to the dysbiosis observed in our 
study. Consequently, colonic epithelial inflammation is enhanced, thereby 
creating a hostile environment for other groups of bacteria to flourish. This in 
turn, may result in limiting the presence of bacteria bearing bile salt 
hydrolase activity (important in the biotransformation of primary to 
secondary BAs).    
 
As well as 7α-dehydroxylation reactions increasing the hydrophobicity of 
bile acid molecules, other reactions by bacterial enzymes contribute to their 
antimicrobial effects, which may result in the reduction and expansion of 
certain bacterial communities. Hydrolysis of conjugated BAs by bile salt 
hydrolases (BSHs) yields free bile acids. Conjugation of BAs demonstrates 
strong bactericidal activity and bacterial BSH production appears to aid 
detoxification of bacterial microenvironments(486). BAs have demonstrated 
various activities on bacterial cells including interrupting macromolecule 
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stability, inducing DNA damage and activating enzymes involved in DNA 
repair(487). These BSHs are evident in Bifidobacterium and Bacteroides, 
both of which were detected in greater abundance in patients with BAD(18). 
Through dysbiosis, the greater BSH activity and reduced dehydroxylation 
effects (as increased Ruminococcus was observed in our IBS cohort) that 
may occur in our BAD patients, may represent limiting steps in the bile acid 
biotransformation pathway for an effective bile acid pool as further bacterial 
enzymatic reactions including dehydroxylation and dehydrogenation can 
only occur after deconjugation(486). This may potentially trigger disease as 
modification of bile acid composition influences host health and 
metabolism(486).  
 
Intestinal bacterial hydroxysteroid dehydrogenases (HSDHs) enzymes 
catalyse the stereospecific oxidation of bile acid hydroxyl to oxo groups. 
Epimerisation of hydroxyl groups requires both α– and β–HSDHs and 
occurs  via sterospecific oxidation followed by stereospecific reduction of the 
ensuing oxo group(18). These metabolic reactions by HSDHs may 
neutralize the activity of antimicrobial BAs and provide an energy source for 
the indigenous microbiota(486). HSDH enzymes are evident in several 
intestinal bacteria, including species of the genera Ruminococcus and 
Bacteroides, both of which were found to have a higher abundance in our 
IBS cohort, with the latter being abundant in both IBS and BAD cohorts(18). 
Therefore, given this overlap of microbial communities, it is difficult to 
ascertain their role in the dysbiosis observed within each disease.   
 
Gram-negative bacteria are believed to inherently be more resistant to bile 
than Gram-positive bacteria, which our data partially suggests by the 
increased abundance of Prevotella, Verrucomicrobia and Bacteroides 
seen(17). However, based on studies of the effect of bile salts on a 
collection of 38 strains of Lactobacillus, where varying degrees of bile 
tolerability were found, it has also been suggested that bile tolerance is 
strain-specific and variability may occur in microbial members of the same 
species or genus(17). This would therefore explain why an abundance of 
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the gram-positive taxa, Bifidobacteria and Lachnospiraceae, was also 
detected. The biological significance of the complex interaction between the 
gut commensals, host and bile acid metabolism is presently speculative. As 
well as benefits to the host through direct ‘detoxification’ and facilitation of 
bile acid absorption, it is hypothesised that the gut microbiota also gain from 
this interaction through the harvesting of energy and nutrients, which confer 
a survival benefit over other microbes(338).  
 
2.5 Conclusions 
 
An important limitation of this study is the significant heterogeneity within the 
patient cohorts, which is likely to account for the inconsistencies in the 
reported data and ours. This is secondary to high inter-subject variations 
(phenotypic heterogeneity), differences in molecular techniques employed in 
analysing the intestinal microbiota, potential confounding environmental 
factors (e.g. diet, medications) and time point of sampling during fluctuating 
symptoms (periods of remission, relapse and changes in bowel function) as 
studies suggest IBS gut microbiomes are less stable(292, 402, 403). 
Although the adult intestinal microbiome is considered to be stable, 
environmental factors including antibiotics, diet, alcohol and smoking status, 
may all contribute to modified bile acid metabolism(378). Nevertheless, this 
is the first study to report observations of the microbiome milieu in those 
with BAD compared with those with IBS in whom BAD has been excluded. 
 
There is clearly paucity in knowledge, especially of the role of indigenous 
microbiome in both BAD and IBS. Further large-scale, prospective studies 
with matching analytic approaches and patient cohorts are required to 
determine if the global composition of the intestinal microbiome, rather than 
the presence of single microbes, are relevant in the pathogenesis of both 
conditions. The current diagnostic tool of choice for BAD, the tauroselcholic 
[75 selenium] acid (SeHCAT) scan, is limited by its cost and availability, as 
is the management of this disease with empirical use of bile acid 
sequestrants, which often results in low compliance due to unpalatability. 
! 128!
Therefore, there is significant clinical need to ascertain the role of the gut 
microbiome as a potential non-invasive diagnostic biomarker in BAD, which 
may open up new avenues in creating management strategies through 
manipulation of the gut flora.  
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Chapter 3: 
Measurement of 
SCFAs in BAD 
and IBS-D 
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3.1 Introduction and Aims 
 
3.1.1 Introduction 
 
Short chain fatty acids (SCFAs) are produced by anaerobic bacterial 
fermentation of non-digestible carbohydrates and certain amino acids and 
are the end products of metabolism. The three primary SCFAs produced are 
acetate, propionate and butyrate (usually in a 3:1:1 ratio) with a total 
concentration of 50-150 mM in the colon(488). The com(241)position of the 
microbiome and environmental conditions, including hydrogen partial 
pressure, available substrates and pH all influence the synthesis of the 
different fermentation products(488). Modifications in intestinal fermentation 
can result in physiological abnormalities such as altered motility and 
excessive intraluminal gas production in IBS(489). The role of SCFAs in 
other gastrointestinal conditions, including ulcerative colitis and diversion 
colitis, has already been implicated.  
 
SCFAs are integral to host health and provide 5-10% of human basal 
energy requirements. They have many important functions and are essential 
to intestinal homeostasis through a range of mechanisms including exerting 
regulatory pro-absorptive/anti-secretory effects on colonic transepithelial ion 
transport, mediation of colonic tropism through stimulating cell proliferation 
in the crypts, increasing visceral blood flow to improve tissue oxygenation, 
bearing anti-carcinogenic properties such as inducing apoptosis, improving 
nutrient digestion in slowing the passage of food in the upper 
gastrointestinal tract and maintaining the intestinal wall defense 
barrier(241). The concentration of butyrate in the systemic circulation is low 
as it is preferentially used as an energy source by intestinal epithelial 
cells(490). Propionate is largely metabolised in the liver and only acetate 
attains relatively high serum concentrations (0.10-0.15 mM)(488).  
 
There is evidence to support the aetiological role of the intestinal microbiota 
in IBS. In addition, it is vital that the function of the microbiota is also 
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considered, as this may be as important as the phylotype in the initiation of 
disease. Microbial metabolites, in the form of SCFAs may be used as broad 
markers of microbial functionality, mostly associated with diet originating 
metabolites. Given the limited use of the SeHCAT scan in clinical practice, 
there is a significant, unmet requirement for the development of a novel 
biomarker test to diagnose BAD with this void being potentially fulfilled by 
utilising SCFAs.  
 
To date, there is minimal data with none at all that examines the metabolic 
activity in terms of SCFA production in IBS-D and BAD, respectively. It is 
conceivable that the synthesis of SCFAs may be different in these two 
conditions given that we would expect differences in the various aspects 
that are known to determine SCFA concentration in the lumen, including 
gastrointestinal transit time, motility and physiology, gut microbiota 
composition and the amount and type of fermentable substrate ingested (if 
patients have already modified their diet to help with symptoms). To our 
knowledge, this is the first study of its kind to examine the concentrations of 
SCFAs in BAD and compares them to patients with IBS-D. 
 
3.1.2 Aims 
 
Expanding on our previous study of delineating the intestinal microbial 
composition in IBS-D and BAD patients, the primary aim of this study was to 
understand the functional role of the microbiota in the aetiology of IBS and 
BAD. This was undertaken by measuring major bacterial metabolites in the 
faecal samples of both cohorts of patients.  
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3.2 Materials and Methods 
 
3.2.1 Recruitment and Sample Collection 
 
Ethical Approval 
Patients were recruited as part of the FAMISHED (Food and Fermentation 
using Metagenomics in Health and Disease) study. Scientific and ethical 
approval was acquired from the local Research and Development Office as 
well as Warwickshire Ethical committee ref: 09/H1211/38. Written informed 
consent was obtained from all participants in the study.  
 
Study Participants 
Patients from the Nuclear Medicine department at University Hospitals 
Coventry and Warwickshire (UHCW NHS Trust) were recruited from 
December 2010 to July 2016 after being referred for a SeHCAT scan via 
attending a gastroenterology clinic with chronic diarrhoea. 20 patients with 
Rome III criteria IBS-D and 20 patients with BAD participated in the study.  
 
Demographic and clinical data including age, gender, ethnicity, BMI, C-
reactive protein (CRP – marker of inflammation) and faecal calprotectin 
levels (FCP - a measurement of the protein calprotectin in the stool, which is 
elevated during intestinal inflammation therefore used to ensure patients 
with IBD are in remission) for patients with type 1 BAD and co-existing IBD, 
SeHCAT result, severity and type of BAD were collected. 
 
Sample Collection 
Stool samples were collected in standard specimen collection bottles in the 
nuclear medicine department and stored at -80oC within two hours of 
collection. They were transferred to the University of Glasgow in dry ice  (-
78oC) within a polybox and then stored at -70oC.  
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Inclusion and Exclusion Criteria 
To be included in this cross-sectional study, both male and female 
participants were required to meet the following criteria: (1) have chronic 
diarrhoea, (2) diagnosis of BAD based on a SeHCAT retention value of 
≤15%, (3) patients with IBD (inflammatory bowel disease) may only be 
included if type 1 BAD is present, (4) patients who have had a previous 
cholecystectomy may only be included if type 3 BAD is present. 
 
Participants were excluded from the study if they suffered from coeliac 
disease, IBD (if type 1 BAD is not present), active IBD (defined as FCP >50 
mg/kg stool or CRP >11 mg/L at the time of the SeHCAT scan), colorectal 
cancer or had been on antibiotics/probiotics in the last three months. 
 
3.2.2 Power Calculation 
 
This was an exploratory pilot study to investigate SCFA concentrations in 
BAD and IBS-D. Assuming the standardized difference is 0.5, which 
corresponds to a moderate difference, a power of 31% (based on sample 
size) for a 2-sided test at 20% significance was deemed reasonable.  
 
3.2.3 Molecular Data Collection 
 
Analysis was undertaken at the University of Glasgow, School of Medicine, 
by Dr Konstantinos Gerasimidis, Margarita Kokkorou and Vaios Svolos. This 
required special expertise available in very few centres, hence why this 
work was unable to be conducted locally. Short chain fatty acids (C2-C8) 
and branched chain fatty acids (isobutyrate, isocaproic and isovaleric) were 
measured utilising a method outlined by Laurentin and Edwards (2004) as 
well as the use of gas chromatography in ether extracts. 
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3.2.4 Preparation of Faecal Samples Prior to SCFA Analysis 
 
0.8 – 1.5g of faecal specimens were placed into a 7ml bijoux tube with an 
equal volume of 1M NaOH. SCFAs are susceptible to oxidation therefore 
conversion to their salt form by substitution of their free carboxylic hydroxyl 
group by divalent bonds is required to stabilize the samples. This is 
conducted in strong alkaline solution to reduce their volatility, preserve from 
oxidation and prevent continuing bacterial metabolic activity.  
 
Pre-weighed small beads or magnetic stirrer were used in specimens of 
firmer consistency to optimize homogenization. Each tube was mixed by 
vortexing for one minute. This procedure was repeated a further two times 
and the samples were then stored at -20°C until required. 
 
Moisture content was measured the day prior to SCFA analysis with the 
samples being freeze dried for 24 hours using Edwards apparatus (Freezer 
Dryer Micro Modulyo). The sample dry weight was calculated and the 
moisture content was expressed as a percentage of water per mass of stool 
specimen.  
3.2.5 Identification of SCFAs by Gas Chromatography 
 
An Agilent 7890 gas chromatograph (ThermoQuest Ltd, Manchester, UK), 
which included a flame ionization detector (250°C) and a Zebron ZB-Wax 
capillary column (15m x 0.53mm x 1 µm film thickness) made of 
polyethylene glycol (catalogue No. 7EK-G007, Phenomenex, Cheshire, UK) 
was used to calculate the SCFAs present in the specimens. Nitrogen 
(30ml/min) was used as the carrier gas. 
100µl of concentrated orthophosphoric acid and 100µl of internal standard 
solution (86.1 mmol/l 2-Ethylbutyric acid) were added to 300µl of distilled 
water, which contained 50µg freeze dried faeces. The mixture was vortexed 
for 15 seconds and 1.5ml diethyl ether was then added to each tube. The 
sample was vortexed for 1 minute with the ether phase supernatant being 
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recovered and pooled into a clean tube. This process was repeated a 
further two times. The pooled extract (1ul) was injected (injector temp 
230°C, splitless) onto the column. The temperature of the column was 
initiated at 80°C for 1 minute, increasing by 15°C per minute to a final 
temperature of 210°C.  
For calibration, an external standard (pH 8) consisting of 166.5 µmol/l 
acetic, 135 µmol/l propionic, 113.5 µmol/l isobutyric, 113 µmol/l butyric, 97.9 
µmol/l isovaleric, 97.9 µmol/l valeric, 86.1 µmol/l hexanoic, 76.8 µmol/l 
heptanoic and 69.3 µmol/l octanoic was used. The external standard was 
run once more and after every 12 samples, the coefficient of covariance 
was calculated. The reagents used were Analytical Reagent Grade and 
were supplied by Sigma-Aldrich Company Ltd (Dorset, UK), except for 
acetic acid (glacial), which was supplied by Fisher Scientific (Loughborough, 
UK). All reagents were stored in universal tubes wrapped in aluminium foil 
or in dark bottles and left in room temperature before use. 
To minimize inter-assay error, all serial samples from each patient were 
analysed in the same run. Due to evaporation of the very volatile SCFAs, 
time effect was accounted for by extracting and analysing each sample in 
duplicate (two different extractions) and in reverse order, to improve 
accuracy of results. Unless there was a widened variance, the results from 
the two extracts were averaged. To ensure repeatability of the assay and 
intra-assay comparison of the results between different runs, a quality 
control sample of thoroughly homogenized freeze-dried stock faecal 
material was included at the initiation and termination of each run.  
In collaboration with Dr Konstantinos Gerasimidis’s research group at the 
School of Medicine, University of Glasgow, healthy controls (HCs) were also 
recruited for this study. In total, 26 patients participated and none of them 
had any evidence of chronic disease, were on regular medications 
(including probiotics and prebiotics), pregnant or taken antibiotics in at least 
3 months. Their stool samples were analysed within 2 days of the samples 
from the patients with BAD and IBS-D. 
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3.2.6 Statistical Analysis 
 
Statistical analyses were performed using SPSS Statistics version 24. 
Normality of the distribution of the data was assessed by using the Shapiro-
Wilk test. For normally distributed data, comparisons of the means were 
assessed using the Student’s t test. The Mann-Whitney U test was used for  
data, which was not normally distributed. Given this is a pilot study, p values 
of less than or equal to 20% were considered as statistically significant (p ≤ 
0.20). Reported p values and 95% CI are based on two-sided tests. 
 
When data was normally distributed in all 3 patient cohorts, comparison of 
means was undertaken by analysis of variance (ANOVA). Kruskal-Wallis 
analysis was used to determine comparison of the means in the 3 groups 
where data was not normally distributed. 
 
The data are presented with means, standard deviations (SD), mean 
differences, 95% confidence intervals (CI) and p-values.  
 
3.3 Results 
 
Demographic Data 
 
Demographics of the 66 participants (20 BAD: 20 IBS-D: 26 HCs) are seen 
in the table 14. The 40 IBS-D and BAD patients were matched for age (up to 
5 years) and sex. 
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Table 14: Demographic data of the study participants 
 BAD (n=20) IBS-D (n=20) HCs (n=26) 
Age (years)  54.4 ± 12.3 55.4 ± 13.1 24.3 ± 3.0 
Gender 17/20 (85%) F 
3/20 (15%) M 
17/20 (85%) F 
3/20 (15%) M 
15/26 (57.7%) F 
11/26 (42.3%) 
M 
Ethnicity 18/20 (90%) 
Caucasian 
2/20 (10%) Indian 
19/20 (95%) 
Caucasian 
1/20 (5%) Indian 
25/26 (96.2%) 
Caucasian 
1/26 (3.8%) 
African 
BMI 28.5 ± 8.1 27.3 ± 5.1 22.4 ± 2.6 
SeHCAT value 
(%) 
7 ± 4 39 ± 0.1 N/A 
Severity of 
BAD 
4/20 (20%) Mild 
6/20 (30%) 
Moderate 
10/20 (50%) 
Severe 
N/A N/A 
Type of BAD 2/20 (10%) Type 1 
14/20 (70%) Type 2 
4/20 (20%) Type 3 
N/A N/A 
• 35 of the 40 patients (17 with BAD and 18 with IBS-D) had a body mass index 
(BMI) recorded. 
• Results expressed as means ± SD. 
 
 
The BAD cohort of patients (17 female and 3 male) aged 35 to 79 years had 
a mean BMI of 28.5, defining them as being overweight. The mean SeHCAT 
value was 7%, which is consistent with moderate BAD. Of the 20 patients, 4 
(20%) had mild, 6 (30%) had moderate and 10 (50%) had severe severity of 
disease respectively. Most (14 – 70%) patients had type 2 BAD, 2 (10%) 
patients had type 1 and 4 (20%) had type 3 BAD. 
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The IBS-D cohort of patients (17 female and 3 male) aged 32 to 77 years 
had a mean BMI of 27.3, defining them as being overweight. The mean 
SeHCAT value was 39%, which excluded them from having BAD. 
 
The HCs (15 female and 11 male) aged 21 to 35 years had a mean BMI of 
22.4, defining their weight as normal. 
 
SCFAs in each group 
 
Below are three pie charts demonstrating the SCFA profile (the three main 
SCFAs of acetate, propionate and butyrate with the remaining SCFAs 
classified as ‘others’) of the HCs (figure 8) and each disease group (Figures 
9 and 10 – BAD and IBS-D, respectively).  
 
As expected with each group, acetate is responsible for the majority of 
SCFAs, however the ratio of acetate to propionate and butyrate is 4:1:1, a 
slight increase from the ratio quoted in the literature, as discussed earlier 
(22-29). The proportion of propionate (19%) in BAD exceeds that of the 
proportions found in HCs (15%) and IBS-D (14%). 
 
 
Figure 8: Faecal SCFA profile in HCs 
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Figure 9: Faecal SCFA profile in BAD 
 
 
 
Figure 10: Faecal SCFA profile in IBS-D 
 
 
 
Comparisons of SCFAs between the 3 groups 
 
Below are three tables demonstrating the water content and proportional 
ratios (%) and concentrations of the major bacterial metabolites in the faecal 
samples of patients with BAD/IBS-D and HCs (Table 15), BAD and IBS-D 
(Table 16), BAD and HCs (Table 17) and IBS-D and HCs (Table 17).  
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Table 15: Comparison of the mean concentrations and proportional 
ratios (%) of the major bacterial metabolites in the faecal samples of all 
3 cohorts of patients: BAD, IBS-D and HCs. 
 
SCFA Mean 
(BAD) 
Mean 
(IBS-D) 
Mean  
(HC) 
p-value 
Faecal water content 
(%) 
75.4% 74.1% 68.1% 0.05 
Acetic acid (C2), µmol/g  464.2  
 
381.9  
 
343.8 0.29 
 
% Acetic acid (C2) 63.1% 64.4% 64.7% 0.87 
Propionic acid (C3), 
µmol/g  
 
156.6  
 
95.8  
 
81.6 0.11 
 
% Propionic acid (C3) 19.0% 14.4% 15.0
% 
0.20 
Butyric acid (C4), 
µmol/g 
116.9  
 
87.5  
 
75.0 
 
0.98 
 
% Butyric acid (C4) 12.9% 13.0% 13.5
% 
0.48 
Valeric acid (C5), 
µmol/g  
10.9  
 
11.6  
 
12.9 0.44 
 
% Valeric acid (C5) 1.5% 2.3% 2.3% 0.04 
Caproic acid (C6), 
µmol/g  
1.7  
 
5.5  
 
 5.4 
 
0.14 
% Caproic acid (C6) 0.1% 1.1% 0.94
% 
0.01 
Heptanoic acid (C7), 
µmol/g  
0.2  
 
0.7  
 
0.73 0.17 
 
% Heptanoic acid (C7) 0.03% 0.3% 0.13
% 
0.11 
Octanoic acid (C8), 
µmol/g  
 
0.5  
 
0.4  
 
0.32 
 
0.91 
 
% Octanoic acid (C8) 0.2% 0.1% 0.06
% 
0.85 
Iso-butyric acid (iC4), 
µmol/g  
7.9  
 
9.3  
 
8.3 0.57 
% Iso-butyric acid 
(iC4) 
1.2% 2.2% 1.7% 0.07 
Iso-valeric acid (iC5), 
µmol/g 
10.0  
 
9.1  
 
8.25 
 
0.68 
% Iso-valeric acid 
(iC5) 
1.6% 2.3% 1.7% 0.70 
Iso-caproic acid (iC6), 
µmol/g  
0.7  
 
0.3  
 
0.4 
 
0.01 
 
% Iso-caproic acid 
(iC6) 
0.1% 0.1% 0.07
% 
0.11 
Total SCFA, µmol/g  769.6 602.2 536.6 0.30 
Values highlighted in bold signify statistically significant results (p ≤ 0.20). 
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Table 16: Comparison of the mean concentrations and proportional 
ratios (%) of the major bacterial metabolites in the faecal samples of 
patients with BAD and IBS-D  
SCFA Mean 
(BAD) 
Mean 
(IBS-D) 
Mean 
difference 
(95% CI) 
p-value 
Faecal water content 
(%) 
75.4% 74.1% 1.3 
(-4.8 to 7.4) 
0.67 
Acetic acid (C2), 
µmol/g  
464.2  
 
381.9  
 
82.3 
* 
0.14 
 
 
% Acetic acid (C2) 63.1% 64.4% 1.3 
(-8.9 to 6.4) 
0.75 
Propionic acid (C3), 
µmol/g  
 
156.6  
 
95.8  
 
60.8 
* 
0.11 
 
 
% Propionic acid (C3) 19.0% 14.4% 4.6 
(-0.6 to 9.8) 
 
0.08 
Butyric acid (C4), 
µmol/g  
 
116.9  
 
87.5  
 
29.4 
* 
0.39 
 
 
% Butyric acid (C4) 12.9% 13.0% 0.1 
* 
0.31 
Valeric acid (C5), 
µmol/g  
10.9  
 
11.6  
 
0.5 
* 
0.80 
 
 
% Valeric acid (C5) 1.5% 2.3% 0.8 
* 
0.04 
Caproic acid (C6), 
µmol/g  
 
1.7  
 
5.5  
 
3.8 
* 
0.14 
 
 
% Caproic acid (C6) 0.1% 1.1% 1.0 
* 
0.00 
Heptanoic acid (C7), 
µmol/g  
0.2  
 
0.7  
 
0.5 
* 
0.16 
 
 
% Heptanoic acid (C7) 0.03% 0.3% 0.27 
* 
0.10 
Octanoic acid (C8), 
µmol/g  
 
0.5  
 
0.4  
 
0.1 
* 
0.66 
 
 
% Octanoic acid (C8) 0.2% 0.1% 0.1 
* 
0.57 
Iso-butyric acid (iC4), 
µmol/g  
7.9  
 
9.3  
 
1.4 
(-4.6 to 1.8) 
0.38  
 
 
% Iso-butyric acid (iC4) 1.2% 2.2% 1.0 
* 
0.06 
Iso-valeric acid (iC5), 
µmol/g 
10.0  
 
9.1  
 
0.9 
* 
0.99 
 
 
% Iso-valeric acid (iC5) 1.6% 2.3% 0.7 
* 
0.43 
Iso-caproic acid (iC6), 
µmol/g  
0.7  
 
0.3  
 
0.4 
* 
0.10 
 
 
% Iso-caproic acid 
(iC6) 
0.1% 0.1% 0 
* 
0.58 
Total SCFA, µmol/g  769.6 602.2 167.4 
* 
0.17 
(*Mann-Whitney U test used and hence no CI) 
Values highlighted in bold signify statistically significant results (p ≤ 0.20). 
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Table 17: Comparison of the mean concentrations and proportional 
ratios (%) of the major bacterial metabolites in the faecal samples of 
patients with BAD and HCs as well as in patients with IBS-D and HCs. 
SCFA Mean 
(SD) 
BAD 
Mean 
(SD) 
HC 
Mean 
difference 
(95% CI) 
p-
value 
 Mean 
(SD)  
IBS-D 
Mean 
(SD) 
HC 
Mean 
difference  
(95% CI) 
p-
value 
Faecal 
water 
content 
(%) 
75.4% 
(10.1) 
68.1% 
(8.9) 
7.3 
(2.7 to 11.9) 
0.00 74.1% 
(5.0) 
68.1% 6.0 
(1.8 to 10.2) 
0.00 
Acetic 
acid (C2), 
µmol/g  
464.2 
(250.8)  
 
343.8 
(109.8) 
120.4 
* 
0.24 
 
381.9  
(255.1) 
343.8 38.1 
* 
0.81 
 
% Acetic 
acid (C2) 
63.1% 
(13.1) 
64.7% 
(4.8) 
-1.5 
(-7.1 to 4.1) 
0.59 64.4% 
(10.7) 
64.7% -0.3 
(-5.0 to 4.5) 
0.91 
Propionic 
acid (C3), 
µmol/g  
 
156.6  
(135.9) 
 
81.6 
(37.8) 
75.0 
* 
0.04  
 
 
95.8  
(76.2) 
81.6 14.2 
* 
0.88 
 
% 
Propionic 
acid (C3) 
19.0% 
(9.5) 
15.0% 
(3.4) 
4.0 
* 
 
0.12 14.4% 
(6.4) 
15.0% 0.6 
* 
0.52 
Butyric 
acid (C4), 
µmol/g  
 
116.9  
(135.5) 
 
75.0 
(35.5) 
41.9 
* 
0.98 
 
 
87.5  
(66.0) 
75.0 
 
12.5 
(-17.9 to 43.0) 
0.41 
 
% Butyric 
acid (C4) 
12.9% 
(8.1) 
13.5% 
(3.8) 
-0.57 
(-4.2 to 3.0) 
0.75 13.0% 
(4.6) 
13.5% 0.5 
* 
0.91 
Valeric 
acid (C5), 
µmol/g  
10.9  
(11.2) 
12.9 
(9.0) 
2.0 
* 
0.24 
 
11.6  
(6.0) 
12.9 1.3 
* 
0.84 
 
% Valeric 
acid (C5) 
1.5% 
(1.3) 
2.3% 
(1.1) 
0.8 
* 
0.02 2.3% 
(1.4) 
2.3% 0 
* 
0.91 
Caproic 
acid (C6), 
µmol/g  
 
1.7  
(0.9) 
 5.4 
(5.3) 
3.7 
* 
0.04 
 
5.5  
(5.4) 
 5.4 
 
0.1 
* 
1.0 
 
 
% Caproic 
acid (C6) 
0.1% 
(0.3) 
0.94% 
(0.8) 
0.84 
* 
0.0 1.1% 
(1.3) 
0.94% 0.16 
* 
0.88 
Heptanoic 
acid (C7), 
µmol/g  
0.2  
(0.2) 
0.73 
(1.0) 
0.53 
* 
0.05 
 
 
0.7  
(1.3) 
0.73 0.03 
* 
0.69 
 
 
% 
Heptanoic 
acid (C7) 
0.03% 
(0.05) 
0.13% 
(0.15) 
0.1 
* 
0.03 0.3% 
(0.4) 
0.13% 0.17 
* 
0.81 
Octanoic 
acid (C8), 
µmol/g  
 
0.5  
(1.7) 
 
0.32 
(0.72) 
0.18 
* 
0.78 
 
0.4  
(0.9) 
0.32 
 
0.08 
* 
0.91 
 
 
% 
Octanoic 
acid (C8) 
0.2% 
(0.58) 
0.06% 
(0.11) 
0.14 
* 
0.69 0.1% 
(0.25) 
0.06% 0.94 
* 
0.93 
Iso-butyric 
acid (iC4), 
µmol/g  
7.9  
(5.4) 
8.3 
(3.1) 
-0.36 
(-2.9 to 2.2) 
0.78 
 
9.3  
(4.5) 
8.3 1.0 
(-1.2 to 3.3) 
0.35 
 
% Iso-
butyric 
acid (iC4) 
1.2% 
(0.9) 
1.7% 
(0.7) 
-0.43 
(-0.9 to 0.05) 
0.08 2.2% 
(1.7) 
1.7% 0.5 
* 
0.49 
Iso-valeric 
acid (iC5), 
µmol/g 
10.0  
(5.9) 
8.25 
(3.7) 
1.75 
* 
0.43 
 
9.1  
(4.9) 
8.25 
 
0.9 
(-1.7 to 3.4) 
0.48 
 
 
% Iso-
valeric 
acid (iC5) 
1.6% 
(0.9) 
1.7% 
(0.9) 
0.1 
* 
0.79 2.3% 
(1.9) 
1.7% 0.6 
* 
0.55 
Iso-
caproic 
acid (iC6), 
µmol/g  
0.7  
(1.1) 
0.4 
(0.6) 
0.3 
* 
 
0.00 
0.3  
(0.2) 
0.4 
 
0.1 
* 
0.32 
 
 
% Iso- 0.1% 0.07% 0.03 0.05 0.1% 0.07% 0.03 0.13 
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caproic 
acid (iC6) 
(0.3) (0.1) * (0.05) * 
Total 
SCFA, 
µmol/g  
769.6 
(457.5) 
536.6 
(179.1) 
232.9 
(35.4 to 
430.4) 
0.02 602.2 
(387.3) 
536.6 
(179.1) 
65.6 
(-107.0 to 
238.2) 
0.45 
(*Mann-Whitney U test used and hence no CI) 
Values highlighted in bold signify statistically significant results (p ≤ 0.20).  
Results stated as means and (SD). 
 
BAD versus IBS-D versus HCs 
 
Between these three groups, there were statistical significant differences 
observed for the faecal water content (figure 11), concentrations of 
propionic, caproic, heptanoic and iso-caproic acids, as well as for the 
proportions of propionic, valeric, caproic, heptanoic, iso-butyric and iso-
caproic acids. 
 
BAD versus IBS-D 
 
A greater concentration of total SCFAs was observed in BAD compared with 
IBS-D (769.6µmol/g in BAD versus 602.2µmol/g in IBS, p = 0.17), which 
reached statistical significance (figure 12). Of the SCFAs, acetic acid was 
the metabolite with the greatest concentration observed in both BAD and 
IBS-D (464.2 µmol/g in BAD versus 381.9 µmol/g in IBS-D), which 
accounted for 63-64% of the total composition of SCFAs (figure 13). In both 
BAD and IBS-D, propionic acid and butyric acid represented the second and 
third greatest proportion of SCFAs respectively, with propionic acid 
accounting for 14-19% and butyric acid for 13% of the total composition of 
SCFAs. Statistical significance was achieved for greater concentrations of 
acetic acid (p = 0.14), concentrations (p = 0.11) and proportions (p = 0.08) 
of propionic acid in BAD patients compared to those in IBS-D.   
 
Statistical significance for the difference in concentrations and proportions of 
SCFAs demonstrated in BAD and IBS-D was attained for % valeric acid, 
caproic acid, % caproic acid, heptanoic acid, % heptanoic acid, %isobutyric 
acid and iso-caproic acid. With the exception of the concentration of iso-
caproic acid, these metabolites were observed to be present in greater 
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quantities/proportions in IBS-D patients compared to those with BAD. These 
metabolites represented minimal quantities (0.03 to 2.3%) of the total 
composition of SCFAs. Please see table 3 for full details. 
 
BAD versus HCs 
 
A greater concentration of total SCFAs was observed in BAD compared with 
HCs (769.6µmol/g in BAD versus 536.6µmol/g in HCs), which reached 
statistical significance (p = 0.02). The proportion of water in the faecal 
samples of those with BAD (75.4%) was statistically higher (p = 0.00) 
compared to the faecal water proportion in patients with HCs (68.1%). Of 
the SCFAs, acetic acid was the metabolite with the greatest concentration 
observed in both BAD and HCs (464.2 µmol/g in BAD versus 343.8 µmol/g 
in HCs), which accounted for 63-65% of the total composition of SCFAs. In 
both BAD and HCs, propionic acid and butyric acid represented the second 
and third greatest proportion of SCFAs respectively, with propionic acid 
accounting for 15-19% and butyric acid for 13-14% of the total composition 
of SCFAs. Statistical significance was achieved for a greater concentration 
of propionic acid (p = 0.04) in BAD (156.6µmol/g) compared to patients with 
HCs (81.6µmol/g) (figure 14).  
 
Statistical significance for the difference in concentrations and proportions of 
SCFAs demonstrated in BAD and HCs was attained for % valeric acid (p = 
0.02), caproic acid (p = 0.04), % caproic acid (p = 0.00), heptanoic acid (p = 
0.05), % heptanoic acid (p = 0.03), iso-caproic acid (p = 0.00) and %iso-
caproic acid (p = 0.05). With the exception of the concentration and 
proportion of iso-caproic acid, these metabolites were observed to be 
present in greater quantities/proportions in HCs patients compared to those 
with BAD. These metabolites represented minimal quantities (0.07 to 2.3%) 
of the total composition of SCFAs. Please see table 4 for full details. 
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IBS-D versus HCs 
 
The proportion of water in the faecal samples of those with IBS-D (74.1%) 
was statistically higher compared to the faecal water proportion in patients 
with HCs (68.1%). Of the SCFAs, acetic acid was the metabolite with the 
greatest concentration observed in both IBS-D and HCs (381.9 µmol/g in 
IBS-D versus 343.8 µmol/g in HCs), which accounted for 64-65% of the total 
composition of SCFAs. In both IBS-D and HCs, propionic acid and butyric 
acid represented the second and third greatest proportion of SCFAs 
respectively, with propionic acid accounting for 14-15% and butyric acid for 
13-14% of the total composition of SCFAs. With the exception of the 
concentrations of propionic acid in patients with IBS-D and HCs, these three 
main metabolites were present in similar concentrations and proportions in 
both cohorts and did not reach statistical significance. 
 
There was a greater concentration of total SCFAs in patients with IBS-D 
(602.2µmol/g) compared to HCs (536.6µmol/g) but this did not reach 
statistical significance (p = 0.45).  
 
Figures 11-14: Percentage of faecal water (11), concentration of total 
SCFAs (12), concentration of acetic acid (13) and concentration of propionic 
acid (14) in BAD, IBS-D and HCs. Error bars indicate SDs. Brackets denote 
statistically significant results with p values. 
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Figure 11: Percentage of faecal water                              
                P=0.05 
!Figure 11 represents a statistical significance in the percentage of faecal water between 
the 3 groups.  !!!!
Figure 12: Concentration of total SCFAs                                       !
           P=0.02                               P=0.17!
 
Figure 12 represents a statistical significance in the concentration of total SCFAs between 
the BAD and HCs groups as well as the BAD and IBS-D cohorts. 
 
 
 
 
P!!
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Figure 13: Concentration of acetic acid 
                                                         P=0.14 
!!
Figure 13 represents a statistical significance in the concentration of acetic acid between 
the BAD and IBS-D groups. 
 
 
 
 
Figure 14: Concentration of propionic acid                   !
                                                             P=0.04          P=0.11 
 
Figure 13 represents a statistical significance in the concentration of propionic acid 
between the BAD and HCs groups as well as between all 3 groups. 
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3.4 Discussion 
 
Patients with IBS exhibit evidence of the condition being inflammatory in 
nature by demonstrating an imbalance of pro-inflammatory (TNF-α) and 
anti-inflammatory (IL-10) cytokines and activation of the immune 
system(305, 491). SCFAs are recognised to possess anti-inflammatory 
effects as potential mediators involved in the effects of the intestinal 
microbiota on the intestinal immune function by acting on leucocytes and 
endothelial cells through two main mechanisms. These involve inhibition of 
histone deactylase (HDAC) and activation of G-coupled protein receptors - 
GPCRs (GPR41 and GPR43). Murine studies have implicated GPR41 and 
GPR43 in chronic inflammatory disorders such as colitis, obesity, asthma 
and arthritis although studies remain contradictory(492). These receptors 
are located at multiple sites, including gut endocrine cells, adipose tissue, 
immune cells and pancreatic islets(242). In vitro, activation of these 
receptors by SCFAs induces neutrophil chemotaxis (SCFA-16). The affinity 
of SCFAs for these receptors differs in that GPR43 preferentially binds 
propionate and acetate, whereas GPR41 favorably binds propionate and 
butyrate with acetate being significantly less potent(239). Inhibition of HDAC 
activity allows for SCFAs to increase the acetylation of histone and non-
histone proteins, which modulates gene expression to suppress the 
production of pro-inflammatory cytokines, including nitric oxide (NO), tumour 
necrosis factor (TNF-α) and interleukin-6 (IL-6). Butyrate is the most potent 
inhibitor of HDAC activity with acetate being the least potent(239). In 
addition to this, propionate and butyrate induce the differentiation of 
regulatory T cells, which express FOXP3, a transcription factor and this 
plays a vital role in controlling intestinal inflammation(488). All these 
signaling pathways mediated by SCFAs contribute to control of active 
inflammation.  
 
Given the anti-inflammatory role of SCFAs, as well as its production in 
concomitantly decreasing colonic pH, inhibiting pathogenic microorganisms 
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and increasing the absorption of nutrients, one would expect a more 
‘healthy’ intestine with greater concentrations of SCFAs present(493). This 
was not demonstrated in our study and a statistically significant difference in 
the total number of SCFAs was observed with BAD patients having a 
greater concentration of SCFAs than patients with IBS-D and HCs. Patients 
with IBS-D were also observed to have a greater concentration of SCFAs 
than that in HCs. This may represent an upregulatory response of SCFAs to 
an inflammatory insult to the colon in disease. Another possibility is that the 
relative amount of individual SCFAs may be more important in the 
pathophysiology of BAD and IBS-D than the total amount of SCFAs. Studies 
in this area have generated conflicting results. For example, higher levels of 
acetic and propionic acid have been observed in IBS patients compared to 
HCs with raised levels correlating with significantly worse gastrointestinal 
symptoms, negative emotions and quality of life(296). Another study in 
patients with IBS-D observed decreased faecal SCFAs compared with 
HCs(489).  
 
Interestingly, patients with constipation-predominant IBS (IBS-C) have been 
found to have significantly lower faecal SCFA levels compared to those with 
IBS-D, which suggests the possibility of an association between levels of 
SCFAs and colonic motility(489). The bowel transit rate may be a 
determinant of faecal SCFA concentration with one study demonstrating 
accelerated transit with the aid of senna resulting in an increase in SCFA 
concentrations whilst loperamide (slowing bowel transit) caused the inverse 
effect(494). This may help to explain the raised levels of SCFAs seen in 
both our disease cohorts (compared to HCs), both conditions resulting in 
increased bowel transit. 
 
It is assumed that the overall rate of fermentation and therefore production 
of SCFAs is influenced by changes in diet with resistant starches being 
substrates for the intestinal microbiota and contribute the most to the 
production of SCFAs(240). However, it has been demonstrated that a diet 
increased in residual starch intake results in greater fermentation with 
increased breath H2 production but surprisingly, the faecal concentration of 
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SCFAs remains unchanged, suggesting that any change is localized within 
the intestine and this may be secondary to changes in the composition of 
the gut microbiota(240). A high abundance of butyrate-producing Clostridial 
cluster IV bacteria is associated with diets enriched in resistant starches and 
is thought to contribute to increased SCFA production(495). Another 
important point to consider when measuring the production of SCFAs is the 
fact their concentrations are expressed per gram of the faecal sample with 
the total volume (mass) of faeces varying between and within the same 
participants. 
 
The statistically significant increase in total SCFA, acetic acid and propionic 
acid concentrations observed in patients with BAD compared to those with 
IBS-D and HCs may also reflect altered colonic fermentation by the 
intestinal microbiota. IBS patients have demonstrated significantly higher 
counts of Veillonella and Lactobacillus with expression of significantly higher 
levels of SCFAs, acetic and propionic acid. Interestingly, high acetic acid 
levels were associated with increased scores of abdominal pain and 
bloating, with these symptoms being common in both BAD and IBS-D. 
These patients were diagnosed with IBS based on Rome criteria 
alone(296). BAD presents similarly to IBS-D, with 28% of patients 
misdiagnosed with IBS-D for BAD therefore it is conceivable that a 
significant proportion of these patients may have had their diagnosis revised 
after a SeHCAT scan(39). Further evidence of dysbiosis associated with 
altered SCFA levels has been observed in patients with small bowel 
bacterial overgrowth and colon-like microbiota having total SCFA 
concentrations that were four times greater than in healthy subjects(300). It 
is assumed therefore, that varying concentrations of individual SCFAs rather 
than an overall concentration of total SCFAs contributes to the genesis of 
disease. 
 
Butyrate in particular, plays an important role in maintaining the colonic 
epithelium and is the preferred fuel used by colonocytes(496). Therefore, 
there should be an expected reduction in the level of butyrate in our disease 
cohorts compared to HCs but surprisingly, similar proportions were found 
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between the three patient groups. A possible explanation for this is the small 
sample size as butyrate-producing micro-organisms such as 
Ruminococcaceae, Clostridiales and Erysipelotrichaceae, have been found 
to be less abundant in patients with IBS-D(497). Butyrate appears to exert 
potent anti-inflammatory effects both in vivo and in vitro and blocks the 
development of DSS-induced experimental colitis via reducing 
concentrations of pro-inflammatory cytokines, including IL-6 and TNF-
α(498). Therefore, lower levels of butyrate would help account for the 
possibly inflammatory component (which has been suggested in the 
literature) of IBS-D. 
An ‘intolerance’ to complex carbohydrates in the diet may also account for 
the statistically significant greater faecal water content being observed in 
patients with both BAD and IBS-D compared to HCs. Osmotically active 
FODMAPs are poorly absorbed by the small bowel and result in net 
secretion of fluid with increased water delivery to the colon(220). Specifically 
in the IBS-D cohort, gluten has demonstrated increased small bowel 
permeability, which may result in increased fluid flux towards the 
lumen(153). This is further supported by evidence of an impaired epithelial 
barrier with disruption of the apical junctional complex integrity in the jejunal 
mucosa of patients with IBS-D(146). Therefore this suggests that this cohort 
of patients may be more vulnerable to the effects of carbohydrates in the 
diet although the underlying causative mechanisms have not been fully 
elucidated. The increased faecal water content in our disease cohorts is 
also a reflection of the reduced reabsorption of water in the colon secondary 
to increased transit time(252).  
 
The literature states that proportions of SCFA in the lumen are 
approximately 60% acetate, 25% propionate and 10% butyrate and this ratio 
is mostly reflected in our data for both IBS and BAD patients(499). The 
proportion of propionic acid (14.4%) observed in the IBS-D cohort was 
almost half of the expected value seen in the HCs and significantly reduced 
compared to the proportion observed in patients with BAD. Interestingly, 
animal data has exhibited varying effects of differing SCFAs on colonic 
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motility. Butyrate demonstrated an increase in colonic propagation; 
propionate and to a lesser degree, acetate caused a decrease in 
propagation(500). Therefore, it can be extrapolated from this data that the 
role of propionate may be to reduce movement of bowel contents. This 
would fit with our data, where a reduction in levels of propionate observed 
could imply a tendency to the enhancement of propagation of colonic 
contents. This would clinically manifest as increased bowel frequency, a 
symptom hallmarking both IBS-D and BAD. 
 
The difference between subjects with and without IBS has been observed to 
be highly statistically significant for the propionic acid/butyric acid ratio as 
well as subtracting the concentration of butyric acid from propionic acid 
(Prop-But). A value greater than 0.015 mmol/l was deemed as a suitable 
cut-off for a positive test for IBS, with a value less than -0.13 mmol/l 
excluding the diagnosis and reaching a sensitivity of 100%(305). This is not 
verified by our data as with the significantly reduced concentration of 
propionate observed in our IBS-D cohort compared to patients with BAD, 
the Prop-But value would be lower in our IBS-D patients thereby dismissing 
this as a potential diagnostic property of SCFAs in IBS-D. 
 
The anti-inflammatory effects of specific SCFAs include acetate, propionate 
and butyrate decreasing the production of TNF-α by LPS-stimulated human 
neutrophils, as well as propionate and butyrate inhibiting the expression of 
pro-inflammatory mediators through diminution of NF-κB in rat 
neutrophils(239). Therefore, a reduction in the expected proportion of 
propionate observed in our IBS-D cohort compared to the general 
population as well as being statistically significantly lower than in patients 
with BAD may further implicate an inflammatory aetiological factor in this 
disease. 
 
Significantly reduced concentrations and proportions of the minor and 
branched SCFAs (valeric acid, caproic acid, heptanoic acid and iso-butyric 
acid) in patients with BAD compared to those with IBS-D and HCs. These 
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acids are found in the faeces in small amounts, which our data reflects and 
likely arise from bacterial degradation of proteins to amino acids. Branched 
SCFAs are recognised in modulating glucose and lipid metabolism in 
primary adipocytes but their clinical significance, particularly in relation to 
colonic disease, remains unknown(501). As well as these amino acids 
serving as precursors for the synthesis of SCFAs, they have been found to 
contribute to metabolic disease, such as insulin resistance and obesity(502). 
The FXR has a recognised role in triglyceride metabolism through 
modulating free fatty acids oxidation and triglyceride clearance as well as 
hepatic de novo lipogenesis(503). A study has demonstrated a third of 
patients with primary BAD having hypertriglyceridaemia (this was also 
associated with increasing BMI) with hypertriglyceridaemia being linked to 
increased BA synthesis and production. These patients were also observed 
to have high FGF19 concentrations(504). Therefore, reduced 
concentrations of branched SCFAs in patients with BAD may be a reflection 
this disease being metabolic in aetiology with disturbed amino acid 
homeostasis accounting for the metabolic effects of FXR-induced 
triglyceride dysmetabolism as well as impaired FXR-mediated BA signalling. 
 
In the general population, metagenomic analysis has demonstrated a 
bimodal distribution in the diversity of faecal microbiota with individuals 
either having a low gene count (LGC) or high gene count (HGC) as 
indicators of bacterial richness. The Bacteroides species dominate the LGC 
community and there is a reduction in the butyrate-producing 
Firmicutes(488). Therefore, the limitation of this study is that the underlying 
genetic make-up for the diversity in intestinal bacteria in our patient cohorts 
is unknown, which could be a contributory factor towards the SCFA profiles 
identified.  
 
Increasing evidence, including our own, supports an association between 
diet, the microbiota and SCFA production with the presence of dysbiosis in 
these patients (this is further discussed in chapter 6). With this is mind, 
therapeutic modification of the intestinal microbiome in IBS via probiotics, 
non-absorbable antibiotics (Rifaximin) and faecal microbiota transplant is 
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gaining rapid interest. Current management strategies in BAD are 
unsatisfactory with 40-70% of bile acid sequestrant treatment being 
discontinued mainly due to poor palatability. Therefore, refining our 
understanding of the microbiota and its functionality in these conditions is 
vital in facilitating mechanistic insight into the composition of the microbiome 
as well as developing targeted, effective and individualized treatment for 
these patients. Patients with IBS-D are often managed with a low 
FODMAPs diet to reduce gastrointestinal symptoms such as pain, bloating 
and diarrhoea. FODMAPs are poorly absorbed carbohydrates, which are 
rapidly fermented by the gut microbiota therefore reduced concentrations of 
SCFAs would be expected from this diet(220).  
 
Given that we assume the altered proportions of differing SCFAs in IBS-D 
and BAD compared to HCs is more likely to influence the development of 
disease rather than changes in the overall concentration of SCFAs, it is 
feasible that dietary interventions which increase/reduce particular SCFAs 
may be of benefit to these patients. 
 
3.5 Conclusions 
 
In conclusion, we have demonstrated a difference in the total and relative 
amounts of SCFAs in IBS-D and BAD. To our knowledge, there has been 
no previous study to evaluate bacterial fermentation in BAD, as well as its 
comparison to IBS-D and HCs. The exact underlying aetiology in IBS-D and 
BAD remains unclear but it is plausible that SCFAs help shape the immune 
system and impact on intestinal homeostasis via inflammatory pathways, as 
well as affecting bowel transit and intestinal epithelial permeability. Greater 
research that focuses on the role of branched chain SCFAs is vital given the 
significant difference in their concentrations in the two disease cohorts. 
Further prospective studies are required to validate the use of SCFAs as a 
potential biomarker candidate and to further improve knowledge of their 
metabolic function in the pathophysiology of BAD.  
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4.1 Introduction and Aims 
 
4.1.1 Introduction 
 
The enterohepatic cycle determines the composition of the bile acid (BA) 
pool with the BA pool size being defined as the total amount of BAs 
circulating in this cycle. The total BA pool of primary and secondary BAs is 2 
to 5 grams and circuits the enterohepatic circulation 6 to 10 times daily, or 2 
to 3 times per meal(505). The BA pool comprises of cholic acid (CA), 
chenodeoxycholic acid (CDCA) and deoxycholic acid (DCA) in an 
approximately 40:40:20 ratio(506). Within hepatocytes, the production of 
equal quantities of primary BAs, cholic acid (CA) and chenodeoxycholic acid 
(CDCA), are derived mainly through the classical pathway from cholesterol 
and conjugated with glycine or taurine before being secreted into the bile 
and small intestine(506, 507). The cholesterol 7α-hydroxylase (CYP7A1) 
enzyme catalyses the first and rate-limiting step in this pathway and 
therefore influences the overall rate of BA production. The microsomal sterol 
12α-hydroxylase (CYP8B1) enzyme is responsible for 12α-hydroxylation of 
the intermediate product of the CYP7A1 reaction, therefore this enzyme 
controls the CA:CDCA ratio in the BA pool (see figure 15)(506).  
 
Figure 15: Production of CA and CDCA through the classic and 
alternative pathways. 
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These primary BAs undergo gut microbial modification through various 
enzymatic reactions: deconjugation, dehydrogenation, dehydroxylation and 
sulfation(506, 507). Once deconjugated, this results in the transformation of 
primary to secondary BAs: CA into DCA and CDCA into lithocholic acid 
(LCA)(370). Consequently, the proportions of the differing components in 
the BA pool vary in bile, serum and faeces with minor and larger quantities 
of primary and secondary BAs, respectively, evident in faeces(371). Serum 
levels of BAs reflect their uptake by the portal vein and reconjugation during 
transit across the hepatocytes towards the bile(374). The specific 
transporter for the BAs, the apical sodium dependent bile acid transporter 
(ASBT), actively reabsorb conjugated BAs in the terminal ileum, while the 
secondary, unconjugated BAs are passively reabsorbed resulting in 5% of 
BAs being excreted in faeces(370). BAs leave the enterocyte via the 
OSTa/b transporter and sensing of the enterocyte BA pool by the farnesoid 
X receptor (FXR) is integral to BA homeostasis(19).  
As a result of passive absorption through the colon as well as the 
incapability of the liver to 7α-hydroxylate DCA and LCA back to their 
respective primary BAs, there is an accumulation of DCA (and LCA to a 
lesser extent) in the BA pool. Colonic transit time and pH also influence the 
quantity of DCA in the BA pool(371). At the 3-hydroxy position, LCA is 
sulfated and conjugated at C-24 by the liver before being excreted back into 
the bile. This resultant sulfated LCA is poorly reabsorbed from the intestine 
and does not accumulate in the enterohepatic circulation as it is lost in the 
faeces despite being deconjugated and desulfated to some extent by the 
intestinal microbiota(371).  
In the colon, the secondary BAs, LCA and DCA, preferentially stimulate the 
G protein-coupled BA receptor (GPBAR1 or TGR5). Activation of TGR5 in 
the small intestine by DCA in mice inhibits gastric emptying and transit in 
both the small bowel and proximal colon, thereby promoting absorption of 
nutrients by acting as an ‘ileal brake’(508). In a cohort of IBS-D patients, a 
TGR5 SNP demonstrated faster small bowel transit(364).  
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The control of BA synthesis and consequent motility effects of BAs in the 
colon is principally governed by the FXR, whose expression is highest in the 
liver and intestine (ileal enterocytes). FXR binds BAs and bears the 
strongest affinity for CDCA, with lower quantities of BAs such as LCA, 
displaying weaker affinity as FXR agonists. Activation of hepatic FXR results 
in expression of genes involved in BA metabolism, such as short 
heterodimer partner (SHP) transcription, which inhibits CYP7A1 and liver 
receptor homolog to inhibit BA synthesis. A second pathway, where ileal 
FXR activation causes upregulation of fibroblast growth factor 15 (FGF15) - 
the murine orthologue of human FGF19, and consequently fibroblast growth 
factor receptor 4 (FGFR4) in the hepatocyte also results in the inhibition of 
CYP7A1 and thus BA synthesis(509).  
 
The relationship between bile acids and functional gastrointestinal diseases, 
such as IBS, has become more apparent in recent times(509). Given that 
the clinical phenotype of patients with bile acid diarrhoea (BAD) presenting 
with chronic diarrhoea is similar to those with IBS-D, it is not surprising that 
BAD is frequently misdiagnosed for IBS-D. An excess of 28% of patients 
meeting the Rome criteria for IBS-D actually demonstrate SeHCAT 
evidence of BAD(39). Interestingly, despite patients with primary BAD 
bearing an absence of intestinal disease, they demonstrate a similar 
increase in faecal BA loss as those with secondary, ileal BAD(59). 
  
4.1.2 Aims 
  
The aim of this study was to establish the composition of the BA pool in both 
BAD and IBS-D patient cohorts to determine if there are any differences in 
the serum and faecal bile acid profiles in both diseases.  
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4.2 Materials and Methods 
 
4.2.1 Recruitment and Sample Collection 
 
Ethical Approval 
Patients were recruited as part of the FAMISHED (Food and Fermentation 
using Metagenomics in Health and Disease) study. Scientific and ethical 
approval was acquired from the local Research and Development Office as 
well as Warwickshire Ethical committee ref: 09/H1211/38. Written informed 
consent was obtained from all participants in the study.  
 
Study Participants 
Patients from the Nuclear Medicine department at University Hospitals 
Coventry and Warwickshire (UHCW NHS Trust) were recruited from 
January 2012 to August 2016 after being referred for a SeHCAT scan via 
attending a gastroenterology clinic with chronic diarrhoea. Serum and stool 
samples were retrieved from 15 patients with Rome III criteria IBS-D and 15 
with BAD. Patients with IBS-D and BAD were sex and age-matched (up to 
10 years). We endeavoured to yield both stool and serum samples from 
each patient but given that patients were matched for age and sex, this was 
only achievable in 5 patients with IBS-D and 5 with BAD.  
 
Demographic and clinical data including age, gender, ethnicity, BMI, C-
reactive protein (CRP – marker of inflammation) and faecal calprotectin 
levels (a measurement of the protein calprotectin in the stool, which is 
elevated during intestinal inflammation therefore used to ensure patients 
with IBD are in remission) for patients with type 1 BAD and co-existing IBD, 
SeHCAT result, severity and type of BAD were collected. 
 
Sample Collection 
Stool and serum samples were all collected in the morning at 9am in 
standard specimen collection bottles in the nuclear medicine department 
and stored at -80oC within two hours of collection, after the serum was 
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homogenised. They were transferred to Paris, France on dry ice (-78oC) 
within a polybox and then stored at -80oC.  
 
Inclusion and Exclusion Criteria 
To be included in this cross-sectional study, both male and female 
participants were required to meet the following criteria: (1) have chronic 
diarrhoea, (2) diagnosis of BAD based on a SeHCAT retention value of 
≤15% (3) patients with IBD (inflammatory bowel disease) may only be 
included if type 1 BAD is present, (4) patients who have had a previous 
cholecystectomy may only be included if type 3 BAD is present. 
 
Participants were excluded from the study if they suffered from coeliac 
disease, IBD (if type 1 BAD is not present), active IBD (defined as FCP >50 
mg/kg stool or CRP >11 mg/L at the time of the SeHCAT scan), colorectal 
cancer or had been on antibiotics/probiotics in the last three months.  
 
4.2.2 Measurement of Faecal and Serum Bile Acids 
 
Chemicals and Reagents 
Bile acid standards, CA, DCA, CDCA, LCA, ursodeoxycholic acid (UDCA), 
hyocholic acid (HCA), hyodeoxycholic acid (HDCA) as well as the 
corresponding glycine and taurine derivatives were acquired from Sigma-
Aldrich (Saint-Quentin-Fallavier, France). Acetic acid, ammonium carbonate 
and ammonium acetate were also obtained from Sigma-Aldrich. The 3-
sulphate derivatives were kindly donated by Dr J. Goto (Niigita University of 
Pharmacy and Applied Life Sciences, Niigata, Japan). The internal standard 
solution (23-nor-5a-cholanoic acid-3a,12b-diol) was purchased from 
Steraloids Inc., (Newport, RI, USA).  
Standard Solutions 
Standard stock solutions of the BAs were prepared in methanol (1mg/ml) 
and stored at -20°C in a sealed container. The stock solutions were then 
pooled together and further diluted in methanol to attain mixed calibration 
BA solutions with concentrations from 31.3 µg mL
-1 to 31.3 ng mL-1.  
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Sample Preparation 
Using a Thermo Savant Speedvac (Thermo Fisher Scientific, Saint Herblain, 
France) (SPD 111V) coupled to a cooled vapour trap (RTV400; Thermo 
Fisher Scientific), 2 µl of the internal standard solution was added to 0.1g of 
lyophilized faecal samples. At a ratio of 4ml/1ml of sample, 0.4 mol L-1 
ammonium carbonate was added to release the BA from the binding 
protein. The samples were then incubated at 60°C for 30 minutes. 4mls of 
water was added to the faecal samples and then homogenized in an Ultra-
Turrax dis- perser (IMLAB, Lille, France) on two 30-second runs. 
Centrifugation (at 20,000 g for 20 minutes) followed by solid-phase 
extraction using reversed-phase silica Chromabond C18 cartridges (100 
mg; Macherey-Nagel, Duren, Germany) ensured pre-analysis clean up. 
Samples were then loaded on to the cartridge and a vacuum manifold was 
used to undertake subsequent elution steps. The cartridge was rinsed with 
20mls of water to discard salts and hydrophilic metabolites, followed by 
10ml hexane to discard neutral lipids and then 20ml of water again. The 
BAs were eluted with 5ml of methanol. The methanol was then evaporated 
off under a nitrogen stream at 50°C. The residue was dissolved in 150 µl 
methanol, of which 5 µl was injected into the high-performance liquid 
chromatography– tandem mass spectrometry (HPLC–MS/MS) system.  
HPLC–MS/MS Analysis 
An analytical column (Pinnacle II C18, Restek, Lisses, France; 250 x 3.2 
mm) with a 5 µm silica particle (Restek) fitted on an HPLC binary pump 
(Agilent 1100; Agilent Technologies, Massy, France) was used for the 
chromatographic separation of BAs. The column was thermostated at 35°C. 
The mobile phases consisted of buffer (A) (ammonium acetate 15mmol/L, 
pH 5.3) and solvent (B) (methanol) at 63:35 (v/v). By increasing B in A from 
65 to 95 (v/v) for 30 minutes, the BAs were eluted. To achieve separation, a 
flow rate between 0.3 and 0.5ml/minute for 30 minutes was set. Mass 
spectra were obtained using an API® 2000 Q-Trap (AB-Sciex, Concord, 
Ontario, Canada) equipped with a turbo ion-spray (ESI) source. 
Electrospray ionization was executed in negative mode with nitrogen as the 
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nebulizer gas. The temperature of the evaporation gas was fixed at 400°C. 
The ion-spray, declustering and entrance potentials were set at -4500, -60 
and -10 V, respectively. The MS/MS detection was operated with unit/unit 
resolution in the multiple reaction monitoring (MRM) modes. For each 
transition, the dwell time of the ion trap was set at 70 ms. Analyst® software 
(version 1.4.2, AB-Sciex) was used to acquire the data. 
4.2.3 Statistical Analysis 
 
Statistical analyses were performed using JMP statistical software version 
6.0, SPSS version 14.0 and XLSTAT 2012 (Addinsoft®, New York city, 
USA). For normally distributed data, comparisons of the means were 
assessed using the Student’s t test. The Mann-Whitney U test was used for 
data, which was not normally distributed. The total primary BAs is the sum 
of CA and CDCA and their respective glycol-, tauro- and sulpho-derivatives. 
The total secondary BAs is the sum of LCA and DCA and their respective 
glycol-, tauro- and sulpho-derivatives, as well as hyodeoxycholic acid 
(HDCA, which differs from DCA in that the 6α-hydroxyl group is the 12 
position) and its tauro-derivate. Results are presented as means ± standard 
deviations. p values of <0.05 were considered as statistically significant. 
4.3 Results 
Demographic Data 
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Demographics of the 30 patients (15 BAD: 15 IBS-D) are seen in table 18.  
Table 18: Demographic data of the study participants 
 BAD (n=15) IBS-D (n=15) 
Age (years)  53.1 ± 16.3 42.5 ± 17.4 
Gender 11/15 (73.3%) F 
4/15 (26.7%) M 
11/15 (73.3%) F 
4/15 (26.7%) M 
Ethnicity 15/15 (100%) 
Caucasian 
 
14/15 (93.3%) 
Caucasian 
1/15 (6.7%) Indian 
BMI 28.3 ± 4.6 30.2 ± 8.7 
SeHCAT value (%) 6 ± 3.0 33 ± 18.6 
Severity of BAD 1/15 (6.6%) Mild 
 7/15 (46.7%) Moderate 
7/15 (46.7%) Severe 
N/A 
Type of BAD 2/15 (13.4%) Type 1 
11/15 (73.3%) Type 2 
2/15 (13.4%) Type 3 
N/A 
• 24 of the 30 patients (12 with BAD and 12 with IBS-D) had a body mass index 
(BMI) recorded. 
• 2/15 IBS-D patients were diagnosed purely using the Rome III criteria (Rome IV 
was unavailable at the start of this study) and were not investigated with a SeHCAT 
study. 
• Results expressed as means ± SD. 
 
Bile Acid Composition in Serum 
All results are expressed as means ± the standard error of measurement. 
 
There was a trend towards an increased concentration of total serum BAs in 
patients with BAD compared to those with IBS-D, with a mean concentration 
of 2.90 ± 2.07 µmol L-1 g-1 and 2.28 ± 1.21 µmol L-1 g-1, respectively, but this 
did not reach statistical significance (p = 0.73) (figure 16).  
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Figure 16: Total serum BA concentrations                        
                    
Unit: µM 
 
The concentration of free (unconjugated) CDCA (against total concentration 
of serum BAs) was statistically higher in patients with BAD compared to 
those with IBS-D, with a mean concentration of 0.61 ± 0.84 µmol L-1 g-1 and 
0.08 ± 0.13 µmol L-1 g-1 (p = 0.05), respectively (figure 17). The percentage 
of free CDCA was also statistically higher in patients with BAD compared to 
those with IBS-D, with a mean percentage of 18.6 ± 20.5% and 2.76 ± 4.1% 
(p = 0.02), respectively (figure 18).  
 
Figure 17: Concentrations of serum CDCA      Figure 18: Proportions of serum  CDCA 
               
Y axis - Unit: µM                    Y axis -  Unit: % 
 
Concentrations of total sulphated BAs in the serum were similar for both 
patients with BAD and IBS-D, with mean concentrations of 0.15 ± 0.13 µmol 
! 165!
L-1 g-1 and 0.24 ± 0.15 µmol L-1 g-1 (p = 0.20), respectively (figure 19). There 
was a marked increase in the percentage of conjugated BAs in patients with 
IBS-D (mean percentage of 72.2 ± 23.1%) compared to those with BAD 
(mean percentage of 51.9 ± 24.4%) but this did not reach statistical 
significance (p = 0.09) (figure 20).  
 
                        Figure 19: Concentrations of total serum sulphated BAs 
 
      
Y axis - Unit: µM 
 
                     Figure 20: Proportions of serum conjugated BAs 
                                   
Y axis - Unit: % 
Bile Acid Composition in Faeces 
All results are expressed as means ± the standard error of measurement. 
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There was a statistically higher concentration of total faecal BAs in patients 
with BAD compared to those with IBS-D, with a mean concentration of 
10640 ± 5723 µmol L-1 g-1 and 5791 ± 5714 µmol L-1 g-1 (p = 0.02), 
respectively (figure 21).  
 
Figure 21: Total faecal BA concentrations 
                                 
Y axis - Unit: µM 
 
The concentration of primary BAs was statistically higher in patients with 
BAD compared to those with IBS-D, with a mean concentration of 3212 ± 
4537 µmol L-1 g-1 and 1472 ± 3669 µmol L-1 g-1 (p = 0.05), respectively 
(figure 22). There was a trend towards an increased concentration of 
secondary BAs in patients with BAD compared to those with IBS-D, with a 
mean concentration of 7139 ± 4801 µmol L-1 g-1 and 4184 ± 2202 µmol L-1 
g-1(p = 0.11), respectively, but this did not reach statistical significance 
(figure 23). However, the ratio of percentage faecal primary:secondary BAs 
was markedly increased in patients with BAD (mean percentage of 17.5 ± 
46.3%) compared to those with IBS-D (mean percentage of 0.5 ± 0.9%) but 
this did not reach statistical significance (p = 0.30). 
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Figure 22: Concentrations of faecal primary BAs       
 
   Y axis  - Unit: µM 
 
 
Figure 23: Concentrations of faecal secondary BAs 
                                         
    Y axis  - Unit: µM 
 
There was a notable trend towards an increased concentration of free 
(unconjugated) CDCA (similar to serum) in patients with BAD compared to 
those with IBS-D, with a mean concentration of 709.7 ± 1194 µmol L-1 g-1 
and 415.4 ± 997.7 µmol L-1 g-1(p = 0.19), respectively, but this did not reach 
statistical significance (figure 24). There was also a marked trend towards 
an increased concentration of total DCA in patients with BAD compared to 
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those with IBS-D, with a mean concentration of 5569 ± 3848 µmol L-1 g-1 
and 3264 ± 1905 µmol L-1 g-1(p = 0.11), respectively, but this did not reach 
statistical significance (figure 25). 
 
Figure 24: Concentrations of faecal CDCA 
                                   
        Y axis - Unit: µM 
 
Figure 25: Concentrations of faecal DCA 
                                  
           Y axis - Unit: µM 
A statistically greater concentration of total sulphated BAs was seen in 
patients with BAD compared to those with IBS-D, with a mean concentration 
of 499 ± 901.5 µmol L-1 g-1 and 190.6 ± 462.8 µmol L-1 g-1 (p = 0.04), 
respectively (figure 26). There was a marked increase in the percentage of 
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conjugated BAs (similar to serum) in patients with IBS-D (mean percentage 
of 3.1 ± 2.3%) compared to those with BAD (mean percentage of 1.7 ± 
1.4%) but this did not reach statistical significance (p = 0.20) (figure 27).  
 
Figure 26: Concentrations of total faecal sulphated BAs 
                              
       Y axis - Unit: µM 
 
Figure 27: Proportions of faecal conjugated BAs 
 
             Y axis - Unit: % 
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4.4 Discussion 
 
The efficiency of the liver in clearing BAs from the portal circulation, through 
the presence of the Na+-taurocholate co-transporting polypeptide (NTCP) on 
the basolateral membranes of hepatocytes, maintains low levels of serum 
concentrations of BAs with new BA synthesis only contributing to a small 
proportion of the BA pool size(510). The estimated hepatic fractional uptake 
of CA is 90% and 70-80% for CDCA and DCA(511). The efficiency of ileal 
resorption of BAs also allows for only small quantities of peripheral BAs with 
serum BAs increasing if there is reduced hepatic clearance or presence of 
portosystemic shunting but not by intestinal malabsorption. In patients with 
primary BAD, who have no intestinal disease, low plasma levels of FGF19 
have been observed, resulting in defective negative homeostatic feedback 
with increased BA synthesis and consequently, the BA pool is 
enlarged(512).  
 
This is the first study of its kind, which investigates the faecal and serum BA 
composition in patients with BAD and compares it to that in patients with 
IBS-D. The composition of the BA pool in both IBS-D and BAD to date has 
been poorly studied. There is minimal data on the measurement of BAs in 
IBS-D and none at all in patients with BAD. Duboc’s study has observed the 
total faecal BAs in IBS-D to be similar to those in healthy controls (HCs). In 
this study, a significant increase in the levels of primary faecal BAs in IBS-D 
was observed compared to HCs with a corresponding significant decrease 
in secondary BAs. A reduction in DCA but not LCA was demonstrated. The 
proportion of faecal primary BAs positively correlated with higher stool 
frequency and Bristol stool score (lower stool consistency)(157). In a more 
recent study, the same research group observed increased serum primary 
BAs in IBS-D and constipation-predominant IBS (IBS-C) patients compared 
to HCs. However, although reduced levels of serum secondary BAs in IBS-
D patients were observed compared to HCs, this was not replicated in IBS-
C patients. Faecal BA analysis in IBS-D and IBS-C patients revealed both 
an increase and parallel decrease in primary and secondary BAs, 
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respectively, compared to HCs. In patients with IBS-C, this difference with 
HCs did not reach statistical significance. An increase in faecal sulphated 
BAs was observed in patients with IBS-D compared to those with IBS-C and 
HCs(370).  
 
The overall increase in total serum and faecal BAs observed in patients with 
BAD compared to those with IBS-D is expected as they have an enlarged 
bile acid pool(513). Serum BA profiles have been found to reflect faecal BA 
profiles(374). The significant increase in total faecal BAs in the BAD cohort 
is likely secondary to a combination of reduced ileal absorption in those with 
ileal disease as well as increased BA delivery to the colon through an 
overall increased BA pool and impaired negative feedback through reduced 
FGF19 levels in patients with primary BAD. 
 
The observation of a statistically greater concentration of total faecal 
sulphated BAs in patients with BAD, with similar serum concentrations in 
both disease cohorts, is expected given that sulphated BAs are excreted in 
the faeces and not reabsorbed in the ileum(370). The intestinally expressed 
enzyme, sulfotransferase-2A1, catalyses the production of sulphated BA 
analogues, which aids in their detoxification, increases their solubility and 
excretion in urine and faeces(514). Certainly, it is assumed that increased 
concentrations of detoxified, sulphated BAs would help to maintain intestinal 
homeostasis but this effect may be reversed by dysbiosis occurring through 
BA dysmetabolism in BAD.  
 
A statistically higher concentration of faecal primary BAs and the markedly 
increased ratio of percentage faecal primary:secondary BAs was observed 
in patients with BAD. DCA accounts for more than half of the total faecal 
BAs therefore a relatively reduced proportion of secondary BAs may 
indicate overall reduced BA transformation activity by the gut microbiota 
given that secondary BAs are produced exclusively through bacterial 
enzymatic reactions(59, 371). Compared to conventional mice, germ-free 
mice demonstrate a discernible increase in primary BAs(374). Secondary 
BAs in particular, display anti-inflammatory properties through the 
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mechanism of preferentially activating TGR5, a G-protein-coupled receptor, 
which reduces the production of pro-inflammatory cytokines (IL-1α, IL-1β, 
IL-6 and TNF- α)(374). Therefore, a less than expected proportion of 
secondary BAs compared to the percentage of primary BAs observed in 
BAD will result in perturbed intestinal homeostasis. 
 
The reduced serum and faecal percentage of conjugated BAs observed in 
patients with BAD compared to those with IBS-D contradicts the assumed 
reduced intestinal microbial activity seen otherwise. Dysbiosis with 
increased numbers of non-deconjugating bacteria may prevail in this cohort, 
although this remains unknown. Given the laxative properties of BAs, it is 
plausible that the increased BA pool in patients with BAD may contribute to 
increased intestinal transit, with consequent reduced time for microbial 
deconjugation to occur. Most conjugated primary BAs are absorbed in the 
ileum therefore in patients with BAD who have ileal disease, a reduced 
serum percentage of conjugated BAs is expected(59). 
 
The concentration and percentage of free (unconjugated) serum CDCA was 
statistically higher in patients with BAD compared to those with IBS-D. 
Intestinal bacteria determine the proportion of unconjugated BAs, which are 
absorbed into the portal venous blood(515). Serum CDCA should therefore 
reflect the quantity of conjugated and unconjugated CDCA absorbed from 
the ileum and colon, with the colon being the primary source of 
unconjugated CDCA. 
CDCA is the most potent inducer of FGF19, through FXR agonism(76). 
Patients with primary BAD have demonstrated low levels of FGF19 and this 
inversely correlated with BA synthesis as measured by increased serum C4 
(7α-hydroxy-4-cholesten-3-one: a BA precursor and intermediary of BA 
synthesis) levels(11). With increased BA synthesis, there is associated 
increased C4 plasma levels as C4 spills over from the hepatocyte into the 
plasma in direct proportion to the rate of BA synthesis(513). As a result of 
impaired homeostatic feedback by FGF19, there is a net increase in BA 
production, evidenced by the raised proportion of serum CDCA, which may 
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also overspill from the portal into the peripheral circulation. Reduced FXR 
activation by CDCA as well as its reduced ileal absorption in patients with 
secondary BAD may result in increased colonic delivery and increased 
faecal concentration of free (unconjugated) CDCA observed in patients with 
BAD. This positive association between the raised serum and faecal 
unconjugated CDCA concentrations results from the CDCA fraction that is 
absorbed from the colon, which suggests a pathogenic role of CDCA in 
BAD. 
CDCA has been suggested as the cause of diarrhoea in patients with BAD, 
therefore the increased faecal and serum CDCA observed in this patient 
group is to be expected(59). Bile acids are known endogenous laxatives 
and when they exceed concentrations of 3 mmol/L in the colon, 
physiological changes occur(509). It is assumed that BAs cause secretion 
by accelerating colonic transit, an assumption supported by the observation 
of post-cholecystectomy diarrhoea resulting from presumed BA loss(72). 
DCA has demonstrated consistent secretion at 3mM and CDCA at 5mM 
concentrations, respectively(516). In human ileal and colonic tissue, CDCA 
and DCA have exhibited reduced net Na+ absorption and increased Cl- 
secretion, an effect not observed with CA(35, 37, 517). Rectal CDCA 
administration can induce colonic propagation waves with oral 
administration of the same BA, in a dose-dependent manner, accelerating 
colonic transit and increasing defecation frequency(72, 362). Previously, 
CDCA was given as treatment for gallstone dissolution but its frequent side 
effect of diarrhoea made way for UDCA to be utilized instead, given the fact 
it bears no motility or secretory role in the colon(518). 
 
The role of BAs in promoting fluid and electrolyte secretion through a range 
of effects in the colon is well documented in animals and cultured epithelia 
models(518). Mechanisms of action include high concentrations of BAs 
(≥1mM) increasing tight junction permeability, allowing for penetration of the 
epithelial cells basolateral membrane and increasing free cytosolic Ca2+, 
which is involved in transcellular Cl- secretion(519). The role of the intestinal 
microbiota in modifying BA structure has demonstrated structural specificity 
! 174!
of BA-induced Cl- secretion, with CDCA and DCA stimulating secretion. LCA 
and various epimers of DCA and CDCA were either inactive or less 
effective(520). CDCA, but not UDCA, induces dose-dependent Cl- secretion, 
which is thought to arise from mast cell and histamine-mediated processes 
and therefore, this is the likely mechanism of increased bowel transit seen in 
the BAD cohort of patients(521). DCA has exhibited actions on more than 
one target in the colon to induce secretion: luminal K+ channels with an 
increased cAMP production and Cl- secretion in mucosa and activation of 
Ca2+-regulated indirect Cl- secretion in the crypts(522). Promotion of 
secretion via varying concentrations of BAs differs significantly between 
species as well as between BA forms(35, 516).  
 
Opposing actions of BAs at high and low concentrations have been 
observed. In contrast to the pro-secretory and cytotoxic (decreased 
transepithelial resistance-TER) effects of BAs at pathophysiological levels, 
lower physiological levels have demonstrated chronic down-regulation of 
colonic epithelial secretory function. Anti-secretory effects of chronic (24 
hours) exposure to reduced DCA concentrations (10-200µM) were observed 
with inhibited responses to Ca2+ and cAMP-dependent secretagogues. 
Other BAs, including CA, CDCA and taurodeoxycholic acid revealed the 
same effects(516). It has therefore been proposed that the increased Cl- 
and fluid secretion response to increased BA concentrations, bears a 
protective function in diluting the luminal contents to avoid epithelial damage 
as it has been demonstrated that upon removal of DCA, the TER (a 
measure of epithelial barrier function) was restored(516). Therefore, despite 
the presence of an enlarged BA pool in BAD, there has been no data to 
suggest any colonic histological changes in this disease. 
 
Bile acids have been suggested to act as ‘osmosignals’ in controlling the 
fluidity of colonic contents. Normally, low colonic DCA concentrations are 
anti-secretory to aid promotion of colonic absorption. In vivo, BA 
concentrations increase as absorption progresses and luminal contents 
become dehydrated and when a threshold is breached, DCA performs a 
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pro-secretory role in rehydrating the luminal contents, therefore preventing 
the cytotoxic actions exerted by BAs(516). The raised faecal concentration 
of DCA observed in the BAD cohort may therefore demonstrate a 
pathophysiological role in this disease.  
 
Due to an improving knowledge of the regulatory role of BAs in intestinal 
fluid and electrolyte transport, the potential for targeting the FXR in treating 
diarrhoeal disease has been investigated. In vivo mouse models have 
demonstrated the anti-secretory effects of the FXR agonists, GW4064 and 
obeticholic acid (OCA), in the colon. The underlying mechanism resulted 
from direct inhibition of various components of the epithelial Cl- secretory 
pathway including diminution of both basolateral Na+/K+ ATPase activity and 
apical cystic fibrosis transmembrane conductance regulator (CFTR) Cl- 
channel currents. This in turn, inhibits fluid secretion by preventing Cl- 
uptake across the basolateral membrane and its exit across the apical 
membrane via CFTR(523). 
 
4.5 Conclusions 
 
It is likely that dysbiosis accounts for the raised faecal primary, sulphated 
BAs (with loss of this protective mechanism) observed in patients with BAD 
compared to those with IBS-D (this is further discussed in chapter 6). In 
addition, the raised concentrations of serum free  (unconjugated) CDCA and 
faecal DCA observed in the BAD cohort may indicate the underlying 
secretory mechanisms of increased intestinal transit. Serum free 
(unconjugated) CDCA may play a putative role as a surrogate biological 
marker of BAD, rather than subjecting patients to investigation with a 
SeHCAT scan. This would be a simpler test (only a single blood sample 
required), which would be more widely available, less expensive and time 
consuming as well as negating the need for repeated hospital visits. 
 
In order to pursue further diagnostic and therapeutic avenues, additional 
work with a larger population of patients is required to validate this study’s 
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findings and strengthen the relationship observed between bile acids, the 
intestinal microbiota and the diarrhoeal pathophysiology. Specifically, more 
detailed molecular studies of microbial enzymatic reactions and consequent 
BA modification are fundamental to the understanding of the true diversity of 
bile acid-modifying bacteria and their aetiological role in chronic 
gastrointestinal diseases. This may also enable establishment of a 
relationship between numbers and functionality of these bacteria and the 
risk of development of disease. 
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Chapter 5: 
Measurement of 
VOCs in BAD and 
IBS-D 
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5.1 Introduction and Aims 
 
5.1.1 Introduction 
 
Both BAD and IBS-D present with chronic diarrhoea and it is challenging to 
differentiate between the two on clinical grounds alone. The SeHCAT 
(75selenium homotaurocholic acid) scan is the gold standard diagnostic 
modality of choice in confirming a diagnosis of BAD however it is 
underutilized due to its prohibitive cost (approximately £210 per patient)(54). 
Thus, there is an unmet clinical requirement for a more widely accessible 
diagnostic test. 
Often, patients with gastrointestinal conditions report an abnormal and 
unfavourable faecal odour and therefore the ‘scent’ or composition of faecal 
gases (volatile organic compounds – VOCs) may be considered as a 
diagnostic biomarker(475). VOCs are carbon-based chemicals and are 
classified by their boiling point (ranging from 50 to 260°C) and retention 
time(435). They are the resultant gas by-products of colonic fermentation by 
indigenous gut bacteria deriving energy through oxidation of organic 
compounds (non starch polysaccharides), thereby reflecting bacterial 
metabolic activity and composition(238). It is assumed that the production of 
these gaseous products contributes to intestinal homeostasis, through 
regulating intestinal microbial balance via quorum sensing(238). VOCs are 
present in exhaled breath and all biological fluids including faeces, urine, 
blood and sweat(435).  
Given that intestinal bacteria are shared by most adults and remains 
relatively stable, it is presumed that the composition of VOCs is also shared 
in health with changes occurring in disease. Certainly in acute 
gastroenteritis, the microbial signature is altered by the pathogen often 
eclipsing the normal microbiota(457). Rapid intestinal transit has also 
demonstrated a disturbance in the natural habitat of anaerobes, creating an 
unfavourable environment for their growth(524). A reduction in the total 
number of faecal VOCs in diarrhoeal conditions (including ulcerative colitis 
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and infectious diarrhoea) has been observed compared to healthy donors, 
suggesting reduced overall biodiversity of the gut flora and decreased 
synthesis of compounds due to increased intestinal transit time(457).  
The measurement of VOCs in urine is possible because of disrupted 
intestinal permeability(438). Patients with IBS-D have demonstrated 
increased small bowel and colonic mucosal permeability with reduced gene 
and protein expression of tight junction (TJ) components of jejunal 
mucosa(144, 153). Bile acids themselves are considered to disrupt mucosal 
barrier function through various mechanisms. These include direct epithelial 
toxicity through their ‘detergent’ effect on the phospholipid bilayer of the cell 
membrane, apoptotic effects in reducing ATP production through uncoupling 
of oxidative phosphorylation and increasing ATP-ase activity as well as by 
increased bile acid hydrophobicity, concentration-dependent disruption of 
the intestinal membrane with increasing permeability and changes in TJ 
proteins mediated by epithelial growth-factor receptor(338).  
5.1.2 Aims 
In the quest to locate a simple, rapid and reliable biomarker which may be 
more broadly utilized, we proposed the use of real-time instruments to 
detect VOCs emanating from biological material to differentiate between 
IBS-D, BAD and healthy controls (HCs).  
 
5.2 Materials and Methods 
5.2.1 Recruitment and Sample Collection 
 
Ethical Approval 
Patients were recruited as part of the FAMISHED (Food and Fermentation 
using Metagenomics in Health and Disease) study. Scientific and ethical 
approval was acquired from the local Research and Development Office as 
well as Warwickshire Ethical committee ref: 09/H1211/38. Written informed 
consent was obtained from all participants in the study.  
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Study Participants 
Patients from the Nuclear Medicine department at University Hospitals 
Coventry and Warwickshire (UHCW NHS Trust) were recruited from May 
2016 to May 2017 after being referred for a SeHCAT scan via attending a 
gastroenterology clinic with chronic diarrhoea. 26 patients with Rome III 
criteria IBS-D, 13 patients with BAD and 13 healthy controls (HCs) 
participated in the study.  
 
Demographic and clinical data including age, gender, ethnicity, BMI, C-
reactive protein (CRP – marker of inflammation) and faecal calprotectin 
levels (a measurement of the protein calprotectin in the stool, which is 
elevated during intestinal inflammation therefore used to ensure patients 
with IBD are in remission) for patients with type 1 BAD and co-existing IBD, 
SeHCAT result, severity and type of BAD were collected. 
 
Sample Collection 
Urine samples were collected in standard specimen collection bottles in the 
nuclear medicine department and stored at -80oC within two hours of 
collection. They were transferred to the University of Warwick in dry ice  (-
78oC) within a polybox and then stored at -80oC.  
 
Inclusion and Exclusion Criteria 
To be included in this cross-sectional study, both male and female 
participants were required to meet the following criteria: (1) have chronic 
diarrhoea, (2) diagnosis of BAD based on a SeHCAT retention value of 
≤15%, (3) patients with IBD (inflammatory bowel disease) may only be 
included if type 1 BAD is present, (4) patients who have had a previous 
cholecystectomy may only be included if type 3 BAD is present. 
 
Participants were excluded from the study if they suffered from coeliac 
disease, IBD (if type 1 BAD is not present), active IBD (defined as FCP >50 
mg/kg stool or CRP >11 mg/L at the time of the SeHCAT scan), colorectal 
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cancer or had been on antibiotics/probiotics in the last three months. 
5.2.2 Urine Samples 
 
Urine samples with a shelf life of 12 months or less were only used as our 
previous work has demonstrated that the concentration and stability of 
urinary VOCs decreases over time, with optimal storage time being defined 
as no longer than 12 months. We observed less variation with greater 
uniformity and tighter clustering of the total number of urinary VOCs 
released in samples that were stored within 9 months(473).  
 
For this study, urine was the biological sample of choice given our 
experience of it being the most ‘patient and clinician user friendly’, when 
compared with breath, blood and faeces. This is likely due to its non-
invasive nature and allowance for being more easily attainable in a clinical 
setting as well as its availability in large volumes.  
 
5.2.3 FAIMS (Field Asymmetric Ion Mobility Spectrometry) 
 
All urine samples were analysed using a commercial Owlstone Lonestar 
FAIMS instrument (Cambridge, UK). FAIMS (ion-mobility spectrometry – 
IMS)  allows for gas molecules to be separated and analysed at room 
temperature and atmospheric pressure(54). It separates complex mixtures 
by measuring the mobility of ionised molecules in high electric fields. In our 
case, the vapour (or headspace) from a sample is first ionised with a 
radiation source (Ni-63 in our case) and passed between two parallel 
conductive plates. On these plates is applied an alternating electric field, 
which is created by applying a voltage across the plates(525). This field 
either attracts or repels and does not affect the ions as they pass between 
the plates. Any ions that touch the plates lose their charge and exit without 
being detected. To remove this movement, a fixed compensation voltage is 
added to the existing electric field. By scanning through a range of electric 
field strengths and compensation voltages, the instrument is able to produce 
a mobility map on a sample. To identify underlying trends within the ion 
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mobility data, pattern recognition techniques are employed and this can be 
correlated to the presence or absence of a disease process(526).  
 
Prior to testing, the samples were put in the fridge at 4°C to thaw overnight. 
Just before testing, 5mls of the sample was aliquoted into standard 10ml 
glass vials (Thames Restek, UK). The glass vial was then placed inside an 
ATLAS sampling system (Owlstone, UK) and heated to 40°C for 10 minutes. 
This enables production of a reasonable headspace of volatiles. Then, a 
flow of dry, clean air was passed over the sample at a rate of 500 ml/minute. 
An additional 1500 ml/minute was added to this sample air to make a total 
flow rate of 2 L/minute. The Lonestar unit is set up to cycle through a 
dispersion field of 0 to 100% in 51 steps (dispersion field is a measure of the 
electric field strength) and a compensation voltage from +6V and -6V in 512 
steps. To ensure the baseline response was returned, blanks of clean, dry 
air were run before and after each urine sample. 
5.2.4 Statistical Analysis 
 
The data was analysed using a previously developed processing pipeline. 
Each sample run generates 52,224 data points in a 2D matrix of 
compensation voltages and dispersion fields. The data was first 
decomposed using 2D discrete wavelet transform to extract subtle chemical 
signal (a wavelet is a form of data compression used for audio and visual 
applications). This also allows for the diffuse ‘peaks’ observed in the data to 
be preferentially extracted and correspond to different sets of chemical 
species. The signal is therefore concentrated in a relatively small number of 
wavelet coefficients to simplify and improve subsequent analysis steps. 
 
To identify features with discriminatory power, a 10-fold cross-validation was 
applied, using 90% of the data as a training set and 10% as a test set. 
Within each fold, a feature selection step was conducted to identify which 
features in the training set were best to predict disease. Feature selection 
was performed using the Wilcoxon rank sum test or Kruskal-Wallis test by 
calculating p-values between features and using only the features with the 
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lowest p-values (15 features).  These data were then used as an input for 
the PCA (principal component analysis). 
 
Five different classifies were used for prediction: Sparse Logistic 
Regression, Gaussian Process Classifier, Neural Network, Random Forest 
and Support Vector Machine. Of these, the Gaussian Process Classifier and 
Support Vector Machine produced the best classification results and 
predicted probability of a sample being either from a HC or a patient with 
IBS-D or BAD. From these analyses, receiver operator curves (ROC), area 
under curve (AUC), sensitivity, specificity, negative predictive value (NPV) 
and positive predictive value (PPV) were calculated. 
 
5.3 Results 
Demographic Data 
 
Demographics of the 52 patients (13 BAD: 26 IBS-D: 13 HCs) are seen in 
table 19.  
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Table 19: Demographic data of the study participants 
 BAD (n=13) IBS-D (n=26) HCs (n=13) 
Age (years)  47.8 ± 14.6 43.0 ± 13.6 34.5 ± 9.3 
Gender 6/13 (46.2%) F 
7/13 (53.8%) M 
21/26 (80.8%) F 
5/26 (19.2%) M 
8/13 (61.5%) F 
5/13 (38.5%) M 
Ethnicity 12/13 (92.3%) 
Caucasian 
1/13 (7.7%) South 
Asian 
23/26 (88.5%) 
Caucasian 
2/26 (7.7%) 
South Asian 
1/26 (3.8%) Afro-
Carribean 
8/13 (61.5%) 
Caucasian 
3/13 (23.1%) 
Indian 
2/13 (15.4%) 
Afro-Carribean  
BMI 30.0 ± 7.2 28.5 ± 7.0 N/A 
SeHCAT value 
(%) 
5 ± 0.0 36 ± 0.1 N/A 
Severity of 
BAD 
1/13 (6.7%) Mild 
4/13 (30.8%) 
Moderate 
8/13 (61.5%) 
Severe 
N/A N/A 
Type of BAD 1/13 (7.7%) Type 1 
9/13 (69.2%) Type 
2 
3/13 (23.1%) Type 
3 
N/A N/A 
• 35 of the 52 patients (12 with BAD, 23 with IBS-D, 0 HCs) had a body mass index 
(BMI) recorded. 
• Results expressed as means ± SD. 
 
 
The BAD cohort of patients (6 female and 7 male) aged 26 to 69 years had 
a mean BMI of 30.0, defining them as being overweight. The mean SeHCAT 
value was 5%, which is consistent with severe BAD. Of the 13 patients, 1 
(6.7%) had mild, 4 (30.8%) had moderate and 8 (61.5%) had severe 
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severity of disease respectively. Most (9 – 69.2%) patients had type 2 BAD, 
1 (7.7%) patients had type 1 and 3 (23.1%) had type 3 BAD. 
 
The IBS-D cohort of patients (21 female and 5 male) aged 20 to 66 years 
had a mean BMI of 28.5, defining them as being overweight. The mean 
SeHCAT value was 36%, which excluded them from having BAD. 
 
The HCs (8 female and 5 male) were aged 24 to 54 years. 
 
FAIMS Data 
 
Figure 28 demonstrates a typical FAIMS ‘plume’ output ion scan, where the 
change in total ion current was used as a feature for data processing.  
 
Figure 28: Raw data from the FAIMS instrument to an IBS patient urine 
sample 
 
Log of raw data from the FAIMS instrument where intensity is in arbitrary units of ion count. 
 
Figure 29a shows the PCA (non-classified technique) with no observable 
differences between the 3 groups. However, there is separation evident 
(sensitivity 81%, specificity 100%) between the IBS-D and HC groups 
(figure 29b) and between the BAD and HC groups (sensitivity 100%, 
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specificity 38%)  (figures 29c and 30). The separation between the IBS-D 
and HC groups is more distinct compared to the other groups (table 20, 
figure 31). Less clear separation is observed between the BAD and IBS-D 
groups (sensitivity 50%, specificity 92%)  (figure 29d, figure 32). Therefore 
for the IBS vs HC data (figure 29b), PCA analysis has most successfully 
demonstrated linear combinations of the different VOCs that separate out 
the different clusters (patient cohorts). PCA analysis aims to reduce high 
dimensional data to demonstrate similarities and differences between the 
data more clearly. The PC1 axis spans the most variation in the data with 
the PC2 axis spanning the second most variation in the data. 
  
Figure 29a: PCA plot of the three groups: BAD, IBS and HC 
 
 
Figure 29b: PCA plot of IBS and HC       
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Figure 29c: PCA plot of BAD and HC 
 
 
 
Figure 29d: PCA plot of BAD and IBS 
 
 
Table 20: Comparison of FAIMS diagnostic accuracy in differentiating 
between the different patient groups. 
 IBS vs BAD IBS vs HC BAD vs HC 
AUC 0.6 (0.42 – 0.78) 0.92 (0.84 – 1) 0.62 (0.38 – 
0.85) 
Sensitivity 0.5 (0.3 – 0.7) 0.81 (0.61 – 
0.93) 
1 (0.75 – 1) 
Specificity 0.92 (0.64 - 1) 1 (0.75 – 1) 0.38 (0.14 – 
0.68) 
PPV 0.93 1 0.62 
NPV 0.48 0.72 1 
• AUC: area under the curve; PPV: positive predictive value; NPV: negative 
predictive value; (95% confidence interval) 
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The ROC (receiver operating characteristic) curves below demonstrate 
relative trade-offs between true positive and false positive results with the 
best possible prediction method depicting a point in the upper left corner of 
the ROC space. 
 
Figure 30: ROC curve – BAD vs HC 
 
 
Figure 31: ROC curve – IBS vs HC 
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Figure 32: ROC curve – IBS vs BAD 
 
 
 
5.4 Discussion 
 
This study demonstrates the utility of a non-invasive IMS technology in 
differentiating between the main potential causes of chronic diarrhoea and 
its ability in separating these conditions from healthy controls. This is 
reflected by the unique VOC profiles of each of these groups. The sensitivity 
of the FAIMS instrument was greatest in differentiating IBS from HCs and 
BAD from HCs. The altered gas profile observed in patients with IBS and 
BAD highlights the important concept of intestinal dysbiosis, where 
pathological imbalances in the gut microbiota precipitates disease. 
Therefore, the presence of the VOC chemical footprints observed are the 
resultant effects of modified intestinal microbiota fermentation. 
 
The IMS technology demonstrated much greater sensitivity in differentiating 
BAD (100%) and IBS-D (81%) from HCs than between the two disease 
groups (50%). This suggests that the technology is more precise in 
recognising abnormal biological and metabolic processes occurring in 
disease, that differ to those in healthy subjects and therefore distinction 
between health and disease is clearer than between two disease states. 
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Certainly VOCs, which vary between patient groups, are thought to be 
reflective of cellular metabolism either leading to or being indicative of a 
diseased state(527). Low-grade intestinal inflammation is thought to play an 
aetiological role in IBS with significant increases in lamina propria immune 
cells being demonstrated in the colonic mucosa of these patients compared 
to healthy subjects. More specifically, immune activation, with increased 
density of T lymphocytes in the mucosa of IBS patients has been 
observed(528). There is no data to suggest inflammation plays a role in 
BAD and so it appears that activation of the immune system is the signal 
picked up the FAIMS instrument. On the contrary, BAs have consistently 
demonstrated anti-inflammatory properties through NF-κB inhibition and 
thus decreasing the synthesis of pro-inflammatory cytokines, such as TNF-α 
in monocytes and macrophages(374). The changes in the VOC profiles 
observed (greater separation of the IBS-D and HC groups compared to BAD 
and IBS-D as well as BAD and HCs) may represent this inflammatory 
pathogenic component to disease. This is further supported by previous 
work conducted by our research team where FAIMS was able to distinguish 
between active disease and remission in patients with inflammatory bowel 
disease(438).  
 
Faecal VOC analysis has reported distinct VOC patterns, which were able 
to distinguish between patients with IBS-D, active inflammatory bowel 
disease and HCs. In IBS-D, the volatile cyclohexanecarboxylic acid and its 
ester derivatives, as well as short chain fatty acids were found to be more 
abundant compared to the other groups(447). Breath analysis identified a 
combination of 16 VOCs in discriminating patients with IBS from HCs, which 
correlated with IBS symptoms(474). The use of FAIMS in patients with IBS-
D and coeliac disease has been observed to differentiate between the two 
disease entities based on their urinary VOC profiles(448). The only study to 
date in patients with BAD identified clear separation of this cohort based on 
their urinary VOC profile to HCs and patients with ulcerative colitis. In 
addition, two chemical peaks, corresponding to acetamide and 2-propanol, 
were observed in patients with BAD and were either absent or present in 
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significantly reduced quantities in the HCs and UC cohorts(54). Current 
research into the VOC profiles in patients with IBS-D and BAD is 
significantly limited with discordance in the methodologies employed due to 
heterogeneity in the type of biological sample collected and analytic 
technique used as well as small sample sizes, therefore clinically relevant 
inferences from the available data cannot be made. 
 
A particular strength of our study is the achievement of optimal stability of 
the urine samples. The stability of VOCs is crucial in medical diagnostics in 
ensuring detection of all available chemical compounds. Coupled with this is 
the requirement of optimal storage conditions however there is a lack of a 
standardized protocol for urine sample collection, storage and analysis 
which requires further work before clinical implementation. 
 
Limitations to the use of urinary VOCs as biomarkers of disease include the 
influence of multifactorial, uncontrolled variables such as sex, age, ethnicity, 
diurnal and daily variation, dietary and fluid intake. VOCs are derived from 
both endogenous and exogenous sources, including flavouring agents, 
foods and personal care products therefore a degree of inter-individual 
variation is expected(529). The impact of the intestinal microbiota on the 
‘fermentome’ (a term used to describe the complex relationship between 
diet, the gut microbiota and VOCs) also remains unknown(238).   
It is unclear whether the differing expressions of disease-associated VOCs 
are a direct consequence or a secondary effect of disease therefore before 
these can be used as potential biomarkers, the underlying biochemical 
pathways and mechanisms of origin must be elucidated. VOCs may be 
produced locally at the site of primary disease through the effects of 
inflammation, disturbed cell metabolism and cell death. They may also 
originate more systemically by downstream processes of disease including 
increased catabolism, immune activation and oxidative stress(525). In 
disease, new VOCs may be generated, which the body does not normally 
produce during normal physiological circumstances and/or there is a change 
in the concentrations of VOCs already present. 
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In this study, we used sensor technology linked with pattern recognition 
methods to identify the VOC profile signature in the different disease 
groups. Unfortunately, this does not allow for the identification of particular 
chemical compounds, which gas chromatography-mass spectrometry (GC-
MS) equipment is equipped to do so but this benefit is outweighed by its 
high cost. However, identifying an overall pattern of VOCs as a rapid 
diagnostic tool is likely to be more clinically useful in a busy outpatients 
clinic and is also transferrable to the primary care setting.  
The challenge of FAIMS to accurately and reproducibly detect biomarkers of 
disease occurring at low concentrations in a complex background of ‘noise’ 
continues with method development paralleling the rapid rate of clinical 
requirement for this technology. This technology lends itself to be 
programmed fairly easily through the sensor selectively focusing on 
disease-associated compounds after the initial biomarker validation 
steps(525). Advantages to employing FAIMS include its portability to clinical 
settings, cost-effectiveness compared to more expensive endoscopic 
procedures/radiological tests in the investigation of patients presenting with 
chronic diarrhoea, attainment of rapid results with real-time and point-of-
care diagnosis and its reliability given its high sensitivity and reproducible 
detector(525). 
 
5.5 Conclusions  
In conclusion, there are discernible differences in the VOC signatures of the 
three patient groups. Our study is limited by the small sample size and we 
would expect the trends observed from our data to be magnified with 
increasing study power. Nevertheless, we have been able to demonstrate 
the utility of the FAIMS in characterizing disease-specific VOC profiles 
through associated biological effects reflective of underlying gut bacterial 
fermentable activity for both BAD and IBS-D. It is plausible that 
inflammatory processes may either trigger or be a result of changes in the 
gut microbiota, which is demonstrated in the VOC profiles observed. In 
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place of the SeHCAT scan, VOCs may be used to confirm a diagnosis of 
IBS-D and exclude BAD given its stronger ability in differentiating patients 
with IBS-D from HCs rather than those with BAD from HCs. These 
preliminary findings may help to develop a point of care diagnosis based on 
FAIMS technology, which would certainly be more favourable to the patient, 
inexpensive and less time-consuming as well as being more practical and 
clinically applicable compared to bacterial culturing and metagenomic 
techniques.  
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6.0 Discussion 
 
6.1 Introduction and Rationale for Study 
 
During recent years, increasing evidence has supported human health 
being greatly influenced by the gut microbiota and for this reason, the 
intestinal microbiome is often symbolized as the ‘forgotten organ’ due to its 
extensive metabolic activity and abundance of genes impacting host 
metabolic pathways(530, 531). The recognised synthetic (e.g. production of 
vitamins B and K), metabolic (e.g. fermentation and absorption of 
indigestible carbohydrates) and immune (e.g. maintenance of intestinal 
barrier function, maturation and development of cell-mediated and innate 
immunity) functions of the gut microbiome maintain intestinal homeostasis 
and health(530).  
 
Historically, individual microbes have been related to pathogenic infection 
and a specific disease state however more recently, the concept of 
dysbiosis with a pathological imbalance in a microbial community has been 
recognised to explain complex phenotypes of disease, including IBD and 
IBS(157, 374, 532). In relation to this, dysmetabolism of BAs has been 
intricately linked to intestinal dysbiosis. Evidence suggests this is secondary 
to a reduction in bacteria bearing BSH activity, which is central to BA 
deconjugation and maintenance of normal BA metabolites and BA receptor 
signaling required to regulate intestinal homeostasis via the TGR5 and FXR 
receptors(530). Therefore, it is imperative that the composition and 
metabolic functionality of the intestinal microbiota and its relationship with 
BA metabolism must be closely examined to appreciate its implications in 
health and disease.  
 
rRNA gene amplicon sequencing allows us to profile the gut microbiota with 
the 16s rRNA gene representing the target of choice for bacterial ecological 
studies and taxon identification(533). However, this technique is restricted in 
providing information of how the microbiome dynamically interacts with the 
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host to influence health. Therefore beyond metagenomics, the use of 
metabolomics is vital in measuring bacterial metabolites and providing an 
insight into metabolic and biochemical pathways as a means of assessing 
bacterial function. Bacterial metabolites, including BAs, SCFAs and VOCs 
are influenced by dietary substrates, which in turn may alter the 
metabolomic profile, yielding variable effects on the host. The new, modified 
host physiology and phenotype can consequently have a feedback effect on 
the indigenous gut microbiota(531).  
 
The chronic diarrhoeal gastrointestinal diseases, BAD and IBS-D, share 
similar clinical presentations with most clinicians repeatedly missing the 
opportunity to diagnose BAD. This is further compounded by the fact that 
the gold standard diagnostic test (SeHCAT scan) for BAD is limited in its 
availability. Despite the fact that neither of these conditions predispose 
patients to severe illness, targeting treatment to the correct diagnosis is 
essential in improving quality of life as well as reducing significant economic 
costs through work absenteeism and patients frequently attending hospital 
for diagnostic tests and medical consultations.  
 
The aim of this thesis was to investigate the differences in intestinal 
microbial communities between the BAD and IBS-D patient groups and 
through study of the microbial metabolites produced, interrogate the 
underlying cellular mechanisms by which the microbes and metabolites may 
contribute towards the aetiology of these conditions. Given that the 
metabolome is influenced by the gut microbiome (as well as environmental 
and genetic factors), the microbial metabolites produced by the microbiome 
may perform as potential biomarkers of the underlying microbial 
composition and disease state. 
 
6.2 Summary and Implication of Results 
 
a) Link between Intestinal Microbiome and SCFAs 
A significant difference in bacterial diversity was observed between the BAD 
and IBS-D patient cohorts. Reduced diversity and an abundance of 
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anaerobic taxa, including including Bifidobacteria, Prevotella, 
Lachnospiraceae, Verrucomicrobia and Bacteroides were observed in the 
BAD group compared to patients with IBS-D. SCFAs are end products of 
anaerobic microbial metabolism and therefore this may account for the 
significant increase in the total concentration of SCFAs demonstrated in the 
BAD cohort compared to those with IBS-D(252). A bidirectional relationship 
where SCFAs shape the composition of the microbiota may also be true as 
a significant inverse relationship between total SCFA concentrations and 
faecal pH value has been observed with a reduction in pH enhancing 
populations of butyrate-producing bacteria and curtailing the growth of 
Bacteroides(240, 534). Therefore, the increased SCFA concentration in the 
BAD cohort may have caused the intestinal dysbiosis observed in this group 
or vice-versa.  
 
The concept of cross-feeding, where one gut commensal utilizes the end 
products of metabolism or the energy rich complex carbohydrate breakdown 
products from another commensal, has a significant impact on the overall 
production of SCFAs(493). This may explain the dysbiosis observed and 
proliferation of certain groups of bacteria in the disease cohorts. Some 
Bifidobacterium species are unable to use inulin-type fructans but can grow 
in the presence of inulin degraders by using the mono- and 
oligosaccharides released by these bacteria(535). Therefore outgrowths of 
taxa such as this, as was the case in the BAD cohort, may be explained by 
symbiotic relationships existing between groups of bacteria. 
 
The above mutualistic relationship existing between bacteria may also 
account for the significant increase in the concentrations of acetate and 
propionate demonstrated in the BAD cohort compared to those with IBS-D. 
There was also a significant increase in the concentration of propionate in 
BAD compared to HCs. It is recognised that bacterial cross-feeding mainly 
occurs from acetate to butyrate and to a lesser extent between butyrate and 
propionate but almost negligibly between propionate and acetate(493). An 
animal study demonstrated utilization of acetate produced by a species of 
Bacteroides (this genus was abundant in both BAD and IBS-D) by 
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Faecalibacterium prausnitzii(536). Therefore, intestinal dysbiosis with 
specific Bacteroides species may alter metabolic fluxes between 
commensals, preventing normal symbiotic relationships from occurring, 
which may result in unexpected proportions of individual SCFAs.  
Figure 33 depicts the metabolic pathways responsible for the biosynthesis 
of the three major SCFAs. Acetate production via the microbiota arises from 
two main metabolic routes. The majority arises from microbial fermentation 
of carbohydrates. A third arises from acetogenic bacteria, which through the 
Wood-Ljungdahl pathway, synthesise acetate from hydrogen and carbon 
dioxide or formic acid(493). Acetogenic bacteria belong to a large, diverse 
group of facultative (organisms able to survive in both aerobic and 
anaerobic habitats) and obligate (species for which oxygen is toxic) 
anaerobes. These include Bifidobacterium, Clostridium, Lactobacillus, 
Staphylococcus, Escherichia coli, Pseudomonas and Streptococcus(537). 
The BAD cohort demonstrated an abundance of Bifidobacterium compared 
to the IBS-D group, which may have contributed to the increased 
concentration of acetate observed.  
Three pathways contribute to the formation of propionate with the majority 
being mostly formed via the succinate pathway by Bacteroidetes (abundant 
in both the BAD and IBS-D cohorts) and some Firmicutes belonging to the 
Negativicutes class(488). The proportion of propionate present against the 
total faecal SCFA correlates with the relative abundance of 
Bacteroidetes(538). Despite the abundance of the Bacteroides genus of 
bacteria seen in both BAD and IBS-D, it may be hypothesised that particular 
propionate-producing species within the Bacteroides taxa are more 
abundant in the BAD cohort. It is recognised that an increased input of BAs 
results in a significant inhibition of the Bacteroidetes(377). Therefore, it is 
plausible that through excess BAs seen in BAD, certain species of the 
Bacteroides taxa are selectively knocked out, leaving behind ones that are 
capable of specifically producing propionate, which may be a protective 
mechanism towards their survival in an otherwise ‘toxic’ environment as 
BAs display antimicrobial properties in high concentrations(378).  
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The acrylate pathway, using lactate as a substrate in its conversion to 
propionate, is limited to a few members of the Lachnospiraceae and 
Veillonellaceae families. The third route of propionate production, the 
propanediol pathway, is characterized by conversion of deoxy-sugars to 
propionate and involves Proteobacteria and members of the 
Lachnospiraceae family(493). Surprisingly, an abundance of the 
Lachnospiraceae genus group of bacteria was observed in the IBS-D cohort 
compared to the BAD group, which suggests that the succinate pathway 
may be the main route for propionate production in BAD, given the 
significantly increased concentration of propionate in these patients 
compared to those with IBS-D. Also, through competition for nutritional 
resources, an abundance of certain bacterial species that are not involved in 
propionate production may be associated with inhibition of other species 
that are required for propionate production. It is therefore likely that through 
dysbiosis, the differences in microbial composition are accompanied by 
alterations in microbial metabolites that define these bacteria. 
 
Figure 33: The metabolic pathways responsible for the biosynthesis of 
the three major SCFAs: acetate, butyrate and propionate. 
 
The shaded geometric shapes represent the cross-feeding mechanisms for the production 
of the three main SCFAs: acetate, butyrate and propionate 
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b) Link between Intestinal Microbiota and Bile Acids 
The difference in the BA profiles between the BAD and IBS-D cohorts is 
expected given that a difference in bacterial diversity between the two 
groups has been demonstrated. The statistically significant increased 
concentration of primary BAs observed in BAD compared to those with IBS-
D is likely due to the reduced bacterial diversity seen in BAD with 
consequent reduced bacterial biotransformation activity in the conversion of 
primary to secondary BAs. In parallel to this, dysbiosis was detected in the 
faeces of BAD patients. The taxonomic group of Ruminococcus bacteria, 
which was found to be more abundant in IBS-D, contains many species with 
7α-dehydroxylating activity, crucial to the formation of secondary BAs(378). 
Therefore, a reduced quantity of these bacteria in BAD compared to those 
with IBS-D would lead to the increase in faecal primary BAs and primary to 
secondary BA ratio observed.  
 
As a result of dysbiosis, with reduced bacterial diversity and reduced 
biotransformation activity demonstrated in BAD, an increase in primary BAs 
such as CDCA is expected. The increase in free (unconjugated) serum and 
faecal CDCA in BAD is an interesting finding as it suggests that despite the 
dysbiosis observed in these patients, deconjugating activity via BSH-
producing bacteria is unaffected. However, the widespread distribution of 
BSHs across Gram-positive and negative intestinal bacteria with multiple 
isoforms of the enzyme existing in certain strains, does not permit an 
understanding of the mechanisms by which BSHs enable bacteria to 
colonise the colon(371). BA modification is therefore a widespread property 
of the intestinal microbiota however the data suggests that in BAD, 
dysbiosis is likely to affect the final stage in the pathway of BA modification. 
Despite functioning BSH-deconjugating activity, it is the final step of BA 7α-
dehydroxylation reactions, which is impaired and results in the retention of 
the primary BA, CDCA in the enterohepatic circulation, over spilling into the 
systemic circulation. This is likely to be a crucial factor in the mechanism of 
developing BAD.  
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An increase in faecal sulphated BAs in BAD was observed. The liver is the 
predominant site of BA sulphation and this process is considered to 
decrease BA toxicity and enhance BA elimination therefore, this finding may 
be an adaptive change to alleviate BA accumulation in BAD and a protective 
mechanism in the setting of intestinal dysbiosis(514).  
 
Altogether, these results suggest that BAD patients exhibit defective BA 
metabolism through intestinal dysbiosis. 
 
c) Link between Intestinal Microbiota, VOCs and SCFAs. 
The greatest separation of VOC profiles exist between the IBS-D and HC 
cohorts, followed by less clear separation between the BAD and HC groups 
with further minimal separation between the BAD and IBS-D groups. This 
supports the notion of VOCs reflecting the fermentation processes of 
underlying intestinal microbiota with evidence of dysbiosis in both disease 
cohorts (although this is greatest in BAD with overall reduced bacterial 
diversity) therefore, it is difficult to separate out these two group, which are 
both alike with respect to altered fermentation profiles. The separation of 
groups is therefore more apparent when comparing a diseased or abnormal 
(BAD or IBS-D) fermentation profile to a healthy one (HCs). 
 
On the other hand, the greatest differences in SCFA production were found 
between the BAD and HC cohort, rather than the IBS-D and HC groups, 
therefore it is assumed that fermentation is more altered in the former 
comparison of groups, which would suggest greater separation in their 
respective VOC profiles although this was not found to be the case. 
Therefore, it would appear that production of these metabolic by-products 
did not mirror altered fermentation. A possible explanation for this is that 
there were no observable differences in the branched SCFA levels between 
the IBS-D and HC groups however levels of these were mostly significantly 
lower in the BAD group compared to HCs. Little is known about microbial-
derived branched SCFAs, where protein fermentation occurs. The amino 
acid substrates may be utilized by the colonic bacteria to produce SCFAs, 
ammonia and other BCFAs(502). Therefore, with reduced 
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substrates/precursors being supplied to the intestinal microbiota, there may 
be an overall reduced production of metabolic end-products, resulting in a 
reduced VOC ‘signal’. 
 
  
6.3 Concluding Remarks and Future Directions 
 
The findings of these experiments collectively contribute to the existing body 
of scientific literature in IBS-D, where dysbiosis has been demonstrated in 
the presence of BA dysmetabolism and altered levels of SCFAs have been 
observed. It also parallels other VOC studies, which have discriminated IBS 
VOC profiles from other disease groups and HCs. However, the 
experiments within this thesis are the first in bringing new findings in 16s 
rRNA gene amplicon sequencing and metabolomics in BAD, which have not 
been previously studied and suggests alternative mechanisms to the 
aetiology of this disease. Moreover, this thesis measures and evaluates in 
turn, the role of the gut microbiome, SCFA and BA production to elucidate 
their intricate relationship in the pathophysiology of IBS-D and BAD, which 
no previous study has collectively achieved. Through these thesis’s studies, 
it is proposed that functional output of the microbiota, rather than 
abundance of specific genera, is the main modulator of disease.   
 
The main limitation of these experiments is cohort sample size, which 
impacted on the power of the studies. Further study with a larger cohort of 
samples is required to investigate if the trends observed in these studies 
can be replicated and reach statistical significance. Although there was 
some overlap in the patients used for each study within this thesis, utilising 
the same patient cohort consistently would confirm the relationship between 
the gut microbiome, SCFA and BA production and the resultant translation 
to differing VOC profiles.  
 
The 16S rRNA sequencing technique employed, analysed bacteria at the 
genus taxonomic level, which meant that some genera were found to be 
abundant in both disease cohorts as information on individual species was 
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unavailable. Although species identification may have improved 
characterization of the microbiome in the disease cohorts, BA metabolism 
and production of SCFAs occur via overlapping groups of bacteria, therefore 
assessment of specific bacterial species may not have provided further 
answers with regards to overall bacterial functionality and genesis of 
pathology. In addition to this, the reliability of species definition being based 
on 16S rRNA sequence similarity clustering, as well as the resolution of the 
16S rRNA gene being too low at times to allow the differentiation of closely 
related species, is a limiting factor(533). Developments in bacterial 
genomics and species interaction will enhance knowledge of bacterial 
community ecology and delineate the microbiome in further detail, 
facilitating understanding of new aetiological mechanisms underlying BAD 
such as specifically identifying bacteria involved in the proteolysis 
degradation of branched SCFAs. This may merit further study to assess 
whether the resultant impaired amino acid metabolism from dysbiosis 
affects FXR-mediated BA signalling causing dyslipidaemia and BAD. Our 
studies were not designed to answer these questions but further insights 
into the pathological role of the gut microbiota and the functioning role of its 
resultant metabolites would not only provide a platform to search for non-
invasive diagnostic biomarkers but also lead to the development of novel 
therapeutic targets. 
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FaMIsHED Study 
A study to look at how bowel fermentation and diet affect other diseases 
 
PATIENT INFORMATION SHEET (PIS) – for Gastroenterology patients 
 
1. Invitation  
 
You are being invited to take part in a research study.  Before you decide if you want to take part, you may 
wish to consider two things: firstly, why the research is being done and secondly what you would have to 
do. Please take time to read the information below and talk it over with someone else if you want to. If 
anything is not clear or you would like to know more, please ask.  
 
2. What is the reason for the study? 
 
Bowel problems are common and diet is known to be important in certain diseases of the large bowel 
(colon). Within the bowel there are large numbers of bacteria which help in the process of fermentation. 
Changes in diet may result in changes in the bacteria or fermentation which is thought to be contributory 
not only to certain bowel diseases but other metabolic diseases such as diabetes and obesity and even 
kidney, bladder, joint and heart disease. We hope that this study will give us a better understanding of the 
relationship between diet and bowel fermentation and its effects on other diseases.  
 
3. Why have I been chosen? 
 
Your consultant has invited you to participate in this research because you are having tests for, or have 
been diagnosed with a condition which is the subject of this research study. You may also have been asked 
to take part if you do not have a specific illness to act as a comparison with other people with different 
conditions or diseases.  
 
4. Do I have to take part? 
 
It is for you to decide whether you wish to take part.  If you do decide to take part you will be given this 
information sheet to keep. You will be asked to sign a consent form. Even if you decide to take part, you 
can withdraw at any time. If you decide to withdraw, you do not need to tell us why and it will not change 
your treatment in any way. 
 
5. What will happen to me if I take part? 
 
If you agree to take part, we will invite you to sign a consent form to participate. You may be eligible to 
donate some of the following samples- urine, stool, blood, breath, sputum, rectal mucosal swab or tissue 
biopsy. We will also ask your permission to look at your medical records, including your medical history and 
medication.  
 
Depending on the medical condition you are having tests for (or) if you are a healthy volunteer, we will 
collect certain samples e.g. urine, blood, and breath or bowel tissue. However, not all may be relevant to 
you. A member of the research team will explain in detail which samples we would like to collect from you. 
Most samples will be collected at your hospital appointment, but you may be asked to collect urine & stool 
samples at home and either post it or bring it with you to the hospital at your next appointment or drop off at 
GP. The research team will tell you if you need to do this and give you the necessary forms and specimen 
pots. 
 
For those attending Endoscopy 
If you are due to have an endoscopic procedure (including OGD, sigmoidoscopy or colonoscopy) as part of 
your medical care, we will ask your permission to take a tissue biopsy from you during the procedure). The 
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doctor doing the test will take pieces of tissue for examination under a microscope (this is known as taking 
a biopsy). An extra, 2 to 4 small pieces of tissue will be taken (each being the size of a grain of rice) for this 
study. Taking these extra biopsies will not affect your care or add any significant risk. Your endoscopic 
procedure will be the same whether or not you take part in the study. The doctor will discuss the results of 
your test either during or after the examination. 
 
Depending on the condition you are having tests for, you may be asked to complete a food and lifestyle 
questionnaire which should take about 20 min. This can often be completed during your hospital visit. If this 
is not possible, the form can be completed at home and posted back to us. Recordings of your height, 
weight, hip and waist circumference will also be made (if not already done on your clinic visit). 
 
After this, you can return home. If you attend follow-up clinic as per your routine treatment, we may ask you 
again for further samples (e.g. urine, stool or blood). You will not be required to make an additional visit to 
the hospital for this purpose. Below is a chart of what will happen. 
 
 
If you agree to participate, 
Sign CONSENT form 
 
 
 
Clinic visit – sample collection & completion of questionnaire as well as height/weight measurements 
 
 
 
For patients undergoing endoscopy – biopsy tissue sampling (optional) 
[If you are coming to hospital for an endoscopic examination then we will collect the samples and take 
measurements during this visit. You will not be required to attend a separate visit for this purpose to 
minimise inconvenience to yourself] 
 
 
 
Return Home 
 
  
 
 
C. Difficile – optional sub-study 
We are also looking specifically into Clostridium difficile, also known as C. difficile or C. diff and this is a 
bacteria that can infect the bowel and cause diarrhoea. This infection most commonly affects people who 
have recently been treated with antibiotics.  We want to be able to stratify risk of the ongoing disease and 
potentially guide therapy in this area. In order to do this we may ask your permission to take samples via an 
instrument which will be inserted directly into your rectum – this may be done anyway as part of your 
clinical assessment standard care. The procedure is known as mucosal sampling and is not dangerous. It 
is merely to sample the lining of the bowel. You do not have to take part if you do not wish. You will be 
asked to complete consent to this part of the study separately if you agree to take part.  
 
6. What do I have to do? 
 
You don’t need to do anything until you come into the hospital for an appointment. At this point, if you agree 
to participate, one of the the research team will discuss this with you and obtain your consent.  If you have 
any questions beforehand, please speak with us (details below).  
 
7. What are the possible disadvantages and risks of taking part? 
 
a) Bleeding very rarely occurs following biopsies and the risk of bleeding is small. (In one study, there was 
one case of bleeding noted after 5000 consecutive biopsies i.e. 0.02% risk). Our own experience in a 
previous study had no immediate complications following 4500 consecutive biopsies in 500 individuals  
b) Taking a blood sample can be a little uncomfortable and occasionally for some there is a little bruising.  
If follow-up is required, research team 
will contact you by post or phone and 
explain to you what the follow up may 
involve including sample collections. 
You will not be required to make any 
additional hospital visit to take part. 
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c) The additional biopsies required will add only 3-5 minutes to the procedure.  
d) In certain selected cases where an endoscopy is not planned we may ask for your permission to take 
samples via an instrument inserted into the rectum which is also referred to as mucosal sampling. This 
procedure is to assess the lining of the bowel and is not dangerous but may be potentially 
uncomfortable and may be part of your routine care.  
e) It is hoped that all necessary information can be obtained during the clinic or endoscopic visit and if not 
this will add no more than 20 min to your overall visit.  
 
8. What happens to the samples taken? 
 
Samples collected as part of this study will be stored for analysis. We will also request permission to store 
samples for future research studies. This is because in the future, newer techniques may become available 
which will allow us to perform more up to date testing. All of your samples will be stored anonymously 
which means that the results of the analysis cannot be traced directly back to you. However, significant 
clinical findings which relate directly to your care will be fed back to your overseeing consultant and to your 
GP. 
 
9. What are the possible benefits of taking part? 
 
Whilst taking part may not be particularly beneficial to you, we hope that the information we get from this 
study will help us understand more about how diet affects certain bacteria, genes and proteins in the 
normal bowel. In the future this may help us understand more about how certain diseases develop and 
perhaps even how to better prevent this through alteration in diet.  
 
10.   Will my taking part in this study be kept confidential? 
 
All the information we have about you from this study is strictly confidential.  This information will be kept 
securely while the study is taking place and only members of the research team will be able to access your 
information. They may also be looked at by representatives of regulatory authorities and by authorised 
people to check that the study is being carried out correctly. Any information about you that leaves the 
hospital will have your name, address and any other personal information removed so that you cannot be 
recognised. Your GP and your hospital consultant will be told that you are taking part in the study if you 
wish.  
 
11.  What if something goes wrong? 
 
In the unlikely event that something goes wrong, there are no special compensation arrangements.  If you 
are harmed due to someone’s negligence, then you may have grounds for a legal action but you may have 
to pay for it.  Regardless of this, if you wish to complain, or have any concerns about any aspect of the way 
you have been approached or treated during the course of this study, the normal National Health Service 
(NHS) complaints mechanisms will be available to you. 
 
12. Who is organising and funding the research? 
 
This study has been organised by UHCW NHS Trust in conjunction with the University of Warwick. The 
chief investigator is Professor R P Arasaradnam. None of the researchers will be paid in person nor will 
they receive any financial gain for doing this study. Funding in the form of Research Grants have been 
obtained from local charities, research networks and collaborative bids (commercial and non-commercial). 
 
13. Who has reviewed the study? 
 
The West Midlands – Coventry and Warwickshire Research Ethics Committee has reviewed and approved 
the study  
 
14. Contact for Further Information or Complaints 
 
Local Contact names and telephone numbers: 
Research Nurse..:  Ms. Subie Wurie, Ms. Leighanne Burns, Ms. Kirstie James 
Tel no…………....: 02476967724    
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Contact details….: Research & Development 
                              ADE30003, 3rd Floor Opposite Ward 30 
 
PALS (Patient Advice and Liaison Service) on freephone 0800 028 4203 or email: Feedback@uhcw.nhs.uk  
 
Study Chief Investigator:  
Professor R P Arasaradnam 
Department of Gastroenterology, 
University Hospital Coventry & Warwickshire, 
Clifford Bridge Rd, 
Coventry CV2 2DX 
 
Tel: 02476 966087 
Email: ramesh.arasaradnam@uhcw.nhs.uk  
 
Thank you for taking part in the study. 
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CONSENT FORM: FaMIsHED Study 
 
Study Title: Food and fermentation using 
metagenomics in health and disease  
 
Participant Study No: 
Participant Details: 
Chief Investigator.  
Prof Ramesh Arasaradnam 
Site: 
 
 
No Statement 
Please  
ONLY INTIAL 
(not tick) 
1 
I confirm that I have read the Participant Information Sheet (PIS) 
V8.0 dated 08.02.2017 for the above study. I have had the 
opportunity to consider the information, ask questions and have had 
these answered satisfactorily. 
 
2 
I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical 
care or legal rights being affected. 
 
3 
I agree to give the following samples for this study which will be 
stored for analysis (or) for future research studies 
INITIAL 
yes (or) no 
YES NO 
      a) Blood   
a) Urine   
b) Stool   
c) Breath   
d) Sputum   
e) Rectal mucosal swab   
f)   Tissue biopsy   
4 
Any procedures for obtaining samples and the related risks, if any, 
have been explained to me and I understand that this is for research 
purposes only. 
 
5 
I agree that my samples may be used by collaborators (academic or 
commercial) by application to the Arden Tissue Bank and my 
personal details will not be shared in any form or manner. 
 
6 
I understand that relevant sections of my medical notes and data 
collected during the study may be looked at by responsible 
individuals from regulatory authorities or from the NHS Trust, where 
it is relevant to my taking part in this research. I give permission for 
these individuals to have access to my records. 
 
 
7 I understand that the information collected about me will be used to  
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support research studies in the future, and may be shared 
anonymously with other researchers. 
 
8 
I agree to being contacted by a member of the research team by 
telephone or letter at a later date and that I am willing to answer 
questions related to symptoms and my general health. 
  
 
9 
I understand that I will not benefit financially if this research leads to 
the development of a new treatment or medical test. 
 
 
10 I agree to my General Practitioner (GP) being informed of my participation in this study. 
 
 
11 I agree to take part in the above study. 
 
 
 
 
Name of Participant                              Date                               Signature 
 
 
Name of Person Taking Consent            Date                                Signature 
 
 
 
 
 
 
 
 
 
 
 
 
When completed: 1 copy for the participant; 1 in their medical notes, and keep the original 
in the study site file. 
 
